# Extended Reality Interventions for Chronic Pain

March 2024



U.S. Department of Veterans Affairs

Veterans Health Administration Health Systems Research

**Recommended citation:** Goldsmith E, Anthony M, Landsteiner A, et al. Extended Reality Interventions for Chronic Pain: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Systems Research, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2024.



Evidence Synthesis Program

## **APPENDIX A. SEARCH STRATEGIES**

Search Date: 1946 to 05/01/23		Search Statement Results				
MEDLINE	1	exp Chronic pain/ OR Pain.tw.	753765			
	2	Intractable pain/ or ((chronic or persistent or intractable or refractory or sustain*) adj3 pain).ti,ab,kf.	100987			
	3	exp Back pain/ or exp Neck pain/ or exp Patellofemoral Pain Syndrome/ or exp Mastodynia/ or (carpal tunnel or epicondylitis or Dupuytren's or tenosynovitis or trigger finger or "costovertebral angle pain" or mastalgia).ti,ab,kf.	73784			
	4	Mastodynia/ or (mastodynia? or breast pain? or mammalgia?).ti,ab,kf.	1366			
	5	exp Musculoskeletal pain/ or exp Arthralgia/ or exp Metatarsalgia/ or (polyarthriti* or monoarthriti* or osteoarthriti* or arthriti*).mp.	361079			
	6	(neuralgia or neuropathy or phantom limb or Complex Regional Pain Syndrom* or CRPS).mp. or (morton neuroma or piriformis muscle syndrome or sciatica).ti,ab,kf.	127322			
	7	(headache or migrain*).ti,ab,kf.	110726			
	8	exp Facial Pain/ or exp Glossalgia/ or ("burning mouth syndrome" or tic douloureaux).tw.	11057			
	9	exp Abdominal pain/ or exp Pelvic Pain/ or exp Flank Pain/	44672			
	10	Cancer Pain/ or (cancer adj3 pain).ti,ab,kf.	14262			
	11	exp Nociceptive pain/ or exp Central Nervous System Sensitization/ or central sensiti#ation.tw.	5757			
	12	(somatic pain or tissue pain or nociceptive pain).ti,ab,kf.	2072			
	13	exp Myofascial Pain Syndromes/	6827			
	14	(myofascial trigger point pain or costen syndrome or temporomandibular joint dysfunction syndrome or tmj syndrome).ti,ab,kf.	273			
	15	(fibromyalgia or fibrositides or fibrositis or muscular rheumatism).mp.	13994			
	16	exp Muscle Spasticity/ or exp Paresis/ or (spasticity or hemiparesis).ti,ab,kf.	35498			
	17	Or/1-16	1304902			
	18	((Virtual or augmented or mixed) adj reality*).mp. or (VR or illusion* or ((Virtual or simulat* or immers* or 3D* or 3-D*) adj (environ* or techn*))).tw.	48953			
	19	exp Virtual reality exposure therapy/ or (Video gam* or exergam* or artificial intelligence or Wii or Nintendo or Kinect or Xbox or Playstation or Meta Quest or Oculus or HTC-Vive or HTC Vive or HP Reverb or Google Daydream or ((Head- mounted OR headmounted) adj display) or hippotherapy or (horse* adj2 simulat*) or cyberspace).mp.	71578			
	20	18 or 19	116722			
	21	17 and 20	3612			



22	Limit to English	3505
23	Limit 22 to (books or chapter or editorial or erratum or letter or note)	67
24	22 not 23	3458

Search Date: 1947 to 05/01/23		Search Statement	Results
Embase	1	exp Chronic pain/ OR Pain.tw.	1186047
	2	Intractable pain/ or ((chronic or persistent or intractable or refractory or sustain*) adj3 pain).ti,ab,kf.	150686
	3	exp Back pain/ or exp Neck pain/ or exp Patellofemoral Pain Syndrome/ or exp Mastodynia/ or (carpal tunnel or epicondylitis or Dupuytren's or tenosynovitis or trigger finger or "costovertebral angle pain" or mastalgia).ti,ab,kf.	197177
	4	Mastodynia/ or (mastodynia? or breast pain? or mammalgia?).ti,ab,kf.	5687
	5	exp Musculoskeletal pain/ or exp Arthralgia/ or exp Metatarsalgia/ or (polyarthriti* or monoarthriti* or osteoarthriti* or arthriti*).mp.	813297
	6	(neuralgia or neuropathy or phantom limb or Complex Regional Pain Syndrom* or CRPS).mp. or (morton neuroma or piriformis muscle syndrome or sciatica).ti,ab,kf.	298182
	7	(headache or migrain*).ti,ab,kf.	186866
	8	exp Facial Pain/ or exp Glossalgia/ or ("burning mouth syndrome" or tic douloureaux).tw.	14953
	9	exp Abdominal pain/ or exp Pelvic Pain/ or exp Flank Pain/	247032
	10	Cancer Pain/ or (cancer adj3 pain).ti,ab,kf.	34435
	11	exp Nociceptive pain/ or exp Central Nervous System Sensitization/ or central sensiti#ation.tw.	7995
	12	(somatic pain or tissue pain or nociceptive pain).ti,ab,kf.	3385
	13	exp Myofascial Pain Syndromes/	8889
	14	(myofascial trigger point pain or costen syndrome or temporomandibular joint dysfunction syndrome or tmj syndrome).ti,ab,kf.	347
	15	(fibromyalgia or fibrositides or fibrositis or muscular rheumatism).mp.	27737
	16	exp Muscle Spasticity/ or exp Paresis/ or (spasticity or hemiparesis).ti,ab,kf.	70069
	17	Or/1-16	2320301
	18	((Virtual or augmented or mixed) adj reality*).mp. or (VR or illusion* or ((Virtual or simulat* or immers* or 3D* or 3-D*) adj (environ* or techn*))).tw.	72207
	19	exp Virtual reality exposure therapy/ or (Video gam* or exergam* or artificial intelligence or Wii or Nintendo or Kinect or Xbox or Playstation or Meta Quest or Oculus or HTC-Vive or HTC Vive or HP Reverb or Google Daydream or ((Head-	86157



mounted OR headmounted) adj display) or hippotherapy or (horse\* adi2 simulat\*) or cyberspace).mp.

	(norse aujz sinulat ) or cyberspace).mp.	
20	18 or 19	152523
21	17 and 20	6428
22	Limit to English	6209
23	Limit 22 to (books or chapter or editorial or erratum or letter or note)	259
24	22 not 23	5950

Search Date: 1987 to 05/30/23		Search Statement	Results
PsycInfo	1	pain.tw.	99143
	2	chronic pain/ or back pain/ or myofascial pain/ or (patellofemoral syndrome or carpal tunnel or epicondylitis or Dupuytren or tenosynovitis or trigger finger).tw	19010
	3	(mastodynia or mammalgia or mastalgia).tw.	22
	4	Exp Arthritis/ or (arthralgia or metatarsalgia or arthriti* or polyarthriti* or monoarthriti* or osteoarthriti*).tw.	7939
-	5	exp Headache/ or headache.tw. or migraine.tw.	21361
	6	exp Neuralgia/ or exp Phantom Limbs/ or exp Neuropathy/ or (neuralgia or neuropathy or phantom limb or complex regional pain syndrom* or CRPS or morton neuroma or piriformis muscle syndrome or sciatica).tw	11356
	7	(Glossalgia or "burning mouth syndrome" or tic douloureaux).tw.	144
	8	"central nervous system sensitization".tw.	14
	9	exp Somatoform Pain Disorder/ or exp Myofascial Pain/ or tmj syndrome.tw.	1157
	10	exp Fibromyalgia/ or (fibromyalgia or fibrositides or fibrositis or muscular rheumatism).tw.	3799
	11	exp General Paresis/ or exp Hemiparesis/ or (muscle spasticity or hemiparesis).tw	2033
	12	Or/ 1-11	127765
	13	virtual reality/ or virtual environment/ or virtual reality exposure therapy/	11428
	14	computer games/ or (Video gam* or exergam* or artificial intelligence or Wii or Nintendo or Kinect or Xbox or Playstation or Meta Quest or Oculus or HTC-Vive or HTC Vive or HP Reverb or Google Daydream or hippotherapy or ("Head- mounted display" or "headmounted display") or horse* simulat*).tw. or cyberspace.tw.	21693
	15	13 or 14	31648
	16	12 and 15	608
	17	Limit to English	585



Search Date: 1971 to 05/25/23		Search Statement	Results
CINAHL	1	(MH "Chronic pain") OR (TI Pain OR AB Pain)	
	2	(MH "Back pain+") OR (MH "Neck pain") OR (MH "Musculoskeletal pain+") OR (MH "Muscle pain") OR (MH Arthralgia+) OR (MH Arthritis+) OR (MH "Knee pain") OR (MH "Patellofemoral Pain Syndrome") OR (MH "Elbow pain") OR (MH "Heel pain") OR (MH Metatarsalgia) OR (MH Tendinopathy+)	
	3	TI ("carpal tunnel" OR "tarsal tunnel" OR "Meralgia Paresthetica" OR epicondylitis OR Dupuytr* OR tenosynovitis OR "trigger finger" OR mastalgia# OR mastodynia# OR mammalgia# OR polyarthriti* OR monoarthriti* OR osteoarthriti* OR arthriti*) OR AB ("carpal tunnel" OR "tarsal tunnel" OR "Meralgia Paresthetica" OR epicondylitis OR Dupuytr* OR tenosynovitis OR "trigger finger" OR mastalgia# OR mastodynia# OR mammalgia# OR polyarthriti* OR monoarthriti* OR osteoarthriti* OR arthriti*)	
	4	(MH "Phantom pain") OR (MH "Neuralgia+") OR (MH "Referred pain") OR (MH "Complex Regional Pain Syndromes+") OR TI (neuralgia OR neuropathy OR "phantom limb" OR "Complex Regional Pain Syndrom*" OR CRPS OR "morton neuroma" OR "piriformis muscle syndrome" OR sciatica) OR AB (neuralgia OR neuropathy OR "phantom limb" OR "Complex Regional Pain Syndrom*" OR CRPS OR "morton neuroma" OR "piriformis muscle syndrome" OR sciatica)	
	5	(MH Headache+) OR TI( headache OR migrain*) OR AB (headache OR migrain*)	
	6	(MH "Facial Pain+") OR TI "burning mouth syndrome" OR AB "burning mouth syndrome" OR TI "tic douloureaux" OR AB "tic douloureaux"	
	7	(MH "Abdominal pain+") OR (MH "Pelvic Pain+") OR (MH "Cancer Pain") OR (MH "Nociceptive pain+") OR TI "central sensiti*" OR AB "central sensiti*"	
	8	(MH "Myofascial Pain Syndromes+") OR TI "myofascial trigger point" OR AB "myofascial trigger point"	
	9	MH "Temporomandibular Joint Syndrome" OR TI ("costen syndrome" OR "temporomandibular joint dysfunction" or TMJ) OR AB ("costen syndrome" OR "temporomandibular joint dysfunction" or TMJ)	
	10	MH fibromyalgia OR TI (fibromyalgia OR fibrositis OR "muscular rheumatism") OR AB (fibromyalgia OR fibrositis OR "muscular rheumatism")	
	11	(MH "Muscle Spasticity") OR TI (spasticity OR hemiparesis) or AB (spasticity OR hemiparesis)	
	12	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11	
-	13	(MH "Virtual reality+") OR (MH "Augmented reality") OR TI (((Virtual OR augmented OR mixed) W1 reality*) OR VR OR illusion* OR cyberspace) OR AB (((Virtual OR augmented OR mixed) W1 reality*) OR VR OR illusion* OR cyberspace) OR TI ((Virtual OR simulat* OR immers* OR 3D* OR 3-D*) W1	



	Total after deduplication	10,932
	Total	20,727
16	S12 AND S15	
15	S13 OR S14	
14	(MH "Virtual reality exposure therapy") OR (MH "Video games+") OR MH "Equine-assisted therapy" OR TI ("Video gam*" OR exergam* OR "artificial intelligence" OR Wii OR Nintendo OR Kinect OR Xbox OR Playstation OR "Meta Quest" OR Oculus OR HTC-Vive OR "HTC Vive" OR "HP Reverb" OR "Google Daydream" OR ((Head-mounted OR headmounted) W1 display) OR hippotherapy OR (horse* N2 simulat*)) OR AB ("Video gam*" OR exergam* OR "artificial intelligence" OR Wii OR Nintendo OR Kinect OR Xbox OR Playstation OR "Meta Quest" OR Oculus OR HTC-Vive OR "HTC Vive" OR "HP Reverb" OR "Google Daydream" OR ((Head-mounted OR headmounted) W1 display) OR hippotherapy OR (horse* N2 simulat*))	
	(environ* OR techn*)) OR AB ((Virtual OR simulat* OR immers* OR 3D* OR 3-D*) W1 (environ* OR techn*))	

### APPENDIX B. STUDIES EXCLUDED DURING FULL-TEXT SCREENING

- 1. Virtual reality system for the treatment of chronic pain and stroke rehabilitation. Journal of Pain & Palliative Care Pharmacotherapy 2008;**22**(1):83-84 Online First. *Ineligible study design*
- 2. HELPING VETS DEAL WITH CHRONIC PAIN: Virtual reality program provides real results. InMotion 2021;**31**(2):16-17 Online First. *Ineligible study design*
- Erratum: Effects of an 8-Week Virtual Reality Training Program on Pain, Fall Risk, and Quality of Life in Iderly Women with Chronic Low Back Pain: Double-Blind Randomized Clinical Trial (Games for Health Journal (2022) 11:2 (85-92) DOI: 10.1089/g4h.2021.0175). Games for Health Journal 2022;11(4):275 Online First. *Ineligible study design*
- 4. Adaikkammai S, Singhal M, Smita E, Sreenivas S, Abhishek Appaji M. Virtual Reality in Rehabilitating Amputees Suffering from Phantom Limb Pain. 2019 11th International Conference on Communication Systems and Networks, COMSNETS 2019 2019:801-06 Online First. *Ineligible study design*
- 5. Aivaliotis VI, Dlamini V, Callahan M, Kelly C, Nguyen LAB. 697 VIRTUAL REALITY MINDFULNESS THERAPY VS. VIRTUAL REALITY DISTRACTIVE THERAPY IN CHRONIC ABDOMINAL PAIN. Gastroenterology 2020;158(6 Supplement 1):S-145 Online First. Ineligible study design
- 6. Akbulut A, Aşçi G, Tarakçi E, Aydin MA, Zaim AH. A Wearable Device for Virtual Cyber Therapy of Phantom Limb Pain. 2018 International Conference on Artificial Intelligence and Data Processing, IDAP 2018 2019 Online First. *Ineligible study design*
- Akbulut A, Gungor F, Tarakci E, Cabuk A, Aydin MA. Immersive virtual reality games for rehabilitation of phantom limb pain. TIPTEKNO 2019 - Tip Teknolojileri Kongresi 2019 Online First. *Ineligible study design*
- 8. Alazba A, Al-Khalifa H, AlSobayel H. A proposed game for promoting physical activities among people with low back pain using virtual reality. ACM International Conference Proceeding Series 2018:141-44 Online First. *Ineligible study design*
- Alazba A, Al-Khalifa H, AlSobayel H. RabbitRun: An Immersive Virtual Reality Game for Promoting Physical Activities Among People with Low Back Pain †. Technologies 2019;7(1) Online First. *Ineligible population*
- Alnuman N, Jbara AA. Video Games and the Prevalence of Musculoskeletal Disorders in Young Adults. 2022 IEEE Zooming Innovation in Consumer Technologies Conference, ZINC 2022 2022:34-38 Online First. *Ineligible population*
- Alphonso AL, Monson BT, Zeher MJ, et al. Use of a virtual integrated environment in prosthetic limb development and phantom limb pain. Annual Review of CyberTherapy and Telemedicine 2012;10:305-09 Online First. *Ineligible study design*
- 12. Alves CM, Rezende AR, Marques IA, Silva DC, Paiva TS, Naves ELM. Serious Games and Virtual Reality in the Treatment of Chronic Stroke: Both Sides Rehabilitation. IFMBE Proceedings 2022;83:239-44 Online First. *Ineligible population*
- Ambron E, Buxbaum L, Kuchenbecker K, Miller A, Coslett B. Virtual reality treatment for phantom limb pain. Neurorehabilitation and Neural Repair 2019;33(12):1083 Online First. *Ineligible study design*



- 14. Ambron E, Buxbaum LJ, Miller A, Stoll H, Kuchenbecker KJ, Coslett HB. Virtual Reality Treatment Displaying the Missing Leg Improves Phantom Limb Pain: A Small Clinical Trial. Neurorehabilitation and neural repair 2021;35(12):1100-11 Online First. *Ineligible study design*
- 15. Amin AM. Effectiveness of mobile virtual reality as a means for pain distraction. 2016 Online First. *Ineligible population*
- 16. Anam M, Sizemore K, Mansour H, et al. (309) Virtual Reality Walking for Neuropathic Pain in Spinal Cord Injury: Preliminary Efficacy Findings. Journal of Pain 2019;20:S51-S51 Online First. *Ineligible study design*
- Anwar N, Karimi H, Ahmad A, et al. Virtual Reality Training Using Nintendo Wii Games for Patients With Stroke: Randomized Controlled Trial. JMIR serious games 2022;10(2):e29830 Online First. *Ineligible population*
- 18. Arnoni JLB, Kleiner AFR, Lima CRG, De Campos AC, Rocha NACF. Nonimmersive Virtual Reality as Complementary Rehabilitation on Functional Mobility and Gait in Cerebral Palsy: A Randomized Controlled Clinical Trial. Games for Health Journal 2021;10(4):254-63 Online First. *Ineligible population*
- 19. Artifon M, Adachi L, Schestatsky P. Proceedings #39: Effects of tDCS alone and combined with virtual reality in clinical practice. Brain Stimulation 2019;**12**(2):e109-e10 Online First. *Not published in English*
- 20. Bahirat K, Annaswamy T, Prabhakaran B. Mr.MAPP: Mixed reality for MAnaging phantom pain. MM 2017 - Proceedings of the 2017 ACM Multimedia Conference 2017:1558-66 Online First. *Ineligible study design*
- 21. Bahirat K, Raval G, Chung YY, et al. Using Mr. MAPp for lower limb phantom pain management. MM 2019 - Proceedings of the 27th ACM International Conference on Multimedia 2019:1071-75 Online First. *Ineligible study design*
- 22. Baltaci G, Harput G, Haksever B, Ulusoy B, Ozer H. Comparison between Nintendo Wii Fit and conventional rehabilitation on functional performance outcomes after hamstring anterior cruciate ligament reconstruction: prospective, randomized, controlled, double-blind clinical trial. Knee surgery, sports traumatology, arthroscopy 2013;21:880-87 Online First. *No eligible outcomes provided*
- 23. Bani Mohammad E, Ahmad M. Virtual reality as a distraction technique for pain and anxiety among patients with breast cancer: A randomized control trial. Palliative & supportive care 2019;17(1):29-34 Online First. *Ineligible setting or follow-up*
- 24. Baqai A, Memon K, Memon AR, Shah SMZA. Interactive Physiotherapy: An Application Based on Virtual Reality and Bio-feedback. Wireless Personal Communications 2019;**106**(4):1719-41 Online First. *Ineligible study design*
- 25. Bartlett J, Fisher E, Liikkanen S, Turunen J, Skog M, Eccleston C. The Design and Development of an Embodied Semi-Autonomous Mentoring Intelligence (SAMI) for Use in Virtual Reality Interventions, Operationalized for the Self-Management of Chronic Pain. Frontiers in Virtual Reality 2022;**3** Online First. *Ineligible study design*
- 26. Basha MA, Aboelnour NH, Alsharidah AS, Kamel FH. Effect of exercise mode on physical function and quality of life in breast cancer-related lymphedema: a randomized trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022;**30**(3):2101-10 Online First. *Ineligible population*
- 27. Behar C, Lustick M, Foreman MH, Webb J, Engsberg JR. Personalized virtual reality for upper extremity rehabilitation: Moving from the clinic to a home exercise program. Journal of



Intellectual Disability - Diagnosis and Treatment 2016;4(3):160-69 Online First. *Ineligible population* 

- 28. Beltran-Alacreu H, Navarro-Fernandez G, Godia-Lledo D, et al. A Serious Game for Performing Task-Oriented Cervical Exercises Among Older Adult Patients With Chronic Neck Pain: Development, Suitability, and Crossover Pilot Study. JMIR serious games 2022;10(1):e31404 Online First. *Ineligible study design*
- Benham S, Kang M, Grampurohit N. Immersive Virtual Reality for the Management of Pain in Community-Dwelling Older Adults. OTJR : occupation, participation and health 2019;39(2):90-96 Online First. *Ineligible study design*
- 30. Ber R, VanOosterhout S, Van Loo L, et al. TCT-261 Impact of Virtual Reality on Pre-Procedural Anxiety Prior to Heart Catheterization: The VR-THEIA Study. Journal of the American College of Cardiology 2022;**80**(12 Supplement):B103-B04 Online First. *Ineligible population*
- 31. Bogdanovych A, Chuan A. The Island of Pain: A Virtual Reality Experience for Patients with Chronic Pain. SIGGRAPH Asia 2020 XR, SA 2020 2020 Online First. *Ineligible study design*
- 32. Bolte B, e Lussanet M, Lappe M. Virtual reality system for the enhancement of mobility in patients with chronic back pain. Technology, rehabilitation and empowerment of people with special needs. 2015:47-59 Online First. *Ineligible study design*
- 33. Botella C, Garcia-Palacios A, Vizcaino Y, Herrero R, Banos RM, Belmonte MA. Virtual reality in the treatment of fibromyalgia: a pilot study. Cyberpsychology, behavior and social networking 2013;16(3):215-23 Online First. *Ineligible population*
- 34. Bottiroli S, Matamala-Gomez M, Allena M, et al. The virtual Enfacement Illusion on pain perception in patients suffering from chronic migraine: Preliminary data from a randomized controlled trial. Cephalalgia 2022;**42**(1 Supplement):47 Online First. *Ineligible study design*
- 35. Bratosin IA, Pavaloiu IB, Goga N, Luca AI. Virtual Reality Application for Pain Management: User Requirements. International Journal of Advanced Computer Science and Applications 2022;13(4):351-56 Online First. *Ineligible population*
- 36. Bratosin IA, Pavaloiu IB, Vasilateanu A, Gavajiuc D, Dragoi G, Goga N. Pain Relief using Virtual Reality. Proceedings of the 11th International Conference on Electronics, Computers and Artificial Intelligence, ECAI 2019 2019 Online First. *Ineligible study design*
- Buttress S, Granat M, Barratt A, Roy B. The use of gamified virtual physiotherapy as an effective treatment for patients with shoulder problems. Physiotherapy (United Kingdom) 2019;105(Supplement 1):e162-e63 Online First. *Ineligible study design*
- 38. Cacau LdAP, Oliveira GU, Maynard LG, et al. The use of the virtual reality as intervention tool in the postoperative of cardiac surgery. Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular 2013;28(2):281-9 Online First. *Ineligible setting or follow-up*
- 39. Carrougher GJ, Hoffman HG, Nakamura D, et al. The effect of virtual reality on pain and range of motion in adults with burn injuries. Journal of burn care & research : official publication of the American Burn Association 2009;**30**(5):785-91 Online First. *Ineligible population*
- 40. Cawthorne D, March L, Parker D, Coolican M, Negus J. TKR-power-patient outcomes using wii enhanced rehabilitation after a total knee replacement. Physiotherapy (United Kingdom) 2015;101(SUPPL. 1):eS204-eS05 Online First. *Ineligible study design*
- 41. Chandler JM, Taylor JS, Portelli KI, et al. Small surgeries, big smiles: Reducing sedation through virtual reality. Journal of Laparoendoscopic and Advanced Surgical Techniques 2019;29(6):A64 Online First. *Ineligible population*



- 42. Chau B, Phelan I, Ta P, et al. Immersive Virtual Reality for Pain Relief in Upper Limb Complex Regional Pain Syndrome: A Pilot Study. Innovations in clinical neuroscience 2020;**17**(4-6):47-52 Online First. *Ineligible population*
- 43. Chavez T. (410) Therapeutic Virtual Reality in Pain Management. Journal of Pain 2019;**20**:S74-S74 Online First. *Ineligible study design*
- 44. Chen C-C. Multimedia virtualized environment for shoulder pain rehabilitation. Journal of physical therapy science 2016;**28**(4):1349-54 Online First. *No eligible outcomes provided*
- 45. Christensen SWM, Almsborg M H, Vain M TS, Vaegter HB. The Effect of Virtual Reality on Cold Pain Sensitivity in Patients with Fibromyalgia and Pain-Free Individuals: A Randomized Crossover Study. Games for health journal 2022 Online First. *No eligible outcomes provided*
- 46. Christiansen CL, Bade MJ, Davidson BS, Dayton MR, Stevens-Lapsley JE. Effects of weightbearing biofeedback training on functional movement patterns following total knee arthroplasty: a randomized controlled trial. journal of orthopaedic & sports physical therapy 2015;45(9):647-55 Online First. *Ineligible intervention*
- 47. Chughtai M, Kelly JJ, Newman JM, et al. The Role of Virtual Rehabilitation in Total and Unicompartmental Knee Arthroplasty. The journal of knee surgery 2019;**32**(1):105-10 Online First. *Ineligible study design*
- Clavelin G, Bouhier M, Tseng WJ, Gugenheimer J. Exploring the Perception of Pain in Virtual Reality through Perceptual Manipulations. Conference on Human Factors in Computing Systems - Proceedings 2023 Online First. *Ineligible population*
- 49. Cuneo A, Yang R, Wang K, et al. Utility of a Novel, Combined Biofeedback-Virtual Reality Tool as Add-on Treatment for Chronic Migraine. Neurology 2022;**98**(18 SUPPL) Online First. *Ineligible study design*
- D. M P, L. A M, R. B W, L. J H. Effect of Virtual Reality Immersion on Phantom Limb Pain and Phantom Limb Sensation...45th Academy Annual Meeting and Scientific Symposium, March 6– 9, 2019, Orlando, Florida. Journal of Prosthetics & Orthotics (JPO) 2019;**31**:6-6 Online First. *Ineligible study design*
- 51. Dagenais M, Brun C, Ohayon A, Mercier C. Virtual Reality in Fibromyalgia: Does Altering Visual Feedback Impact on Pain and Movement During Reaching? Frontiers in Virtual Reality 2021;2 Online First. *Ineligible study design*
- 52. Dailey F, Tashjian VC, Mosadeghi S, et al. The clinical utility of virtual reality in inpatient pain management among patients with gastrointestinal disorders. American Journal of Gastroenterology 2016;**111**(Supplement 1):S464-S65 Online First. *Ineligible population*
- 53. Daste C, Foissac F, Abdoul H, Rannou F, Poiraudeau S, Nguyen C. Patient acceptable symptom state for patient-reported outcomes in 2 populations of patients with non-specific chronic low back pain: A secondary analysis of 2 randomized trials. Annals of Physical and Rehabilitation Medicine 2018 Online First. *Ineligible study design*
- 54. Demeter N, Josman N, Eisenberg E, Pud D. Who can benefit from virtual reality to reduce experimental pain? A crossover study in healthy subjects. European journal of pain (London, England) 2015;**19**(10):1467-75 Online First. *Ineligible population*
- 55. Depauw L, Bosteels A, Maes S, Sermeus L, Saldien V. Virtual reality hypnosis for postoperative pain after total knee arthroplasty. Acta Anaesthesiologica Belgica 2020;**71**:73-77 Online First. *Ineligible study design*



- 56. Deshpande AK, Bhatt I, Rojanaworarit C. Virtual reality for tinnitus management: a randomized controlled trial. International journal of audiology 2022;**61**(10):868-75 Online First. *Ineligible population*
- 57. Diaz-Orueta U, Alvarado S, Gutierrez D, Climent G, Banterla F. "Isla Calma", a Novel Virtual Reality Environment for Pain and Anxiety Distraction: Report on Usability, Acceptability, and Subjective Experience. Games for health journal 2012;1(5):353-61 Online First. *Ineligible study design*
- 58. DiMeola KA, Haynes J, Barone M, et al. A Pilot Investigation of Nonpharmacological Pain Management Intervention Groups in Methadone Maintenance Treatment. Journal of addiction medicine 2022;16(2):229-34 Online First. *No eligible outcomes provided*
- 59. Dingli A, Bondin L. Realtime adaptive virtual reality for pain reduction. IEEE Conference on Computatonal Intelligence and Games, CIG 2019;**2019-August** Online First. *Ineligible study design*
- 60. Donegan T, Ryan BE, Swidrak J, Sanchez-Vives MV. Immersive Virtual Reality for Clinical Pain: Considerations for Effective Therapy. Frontiers in Virtual Reality 2020;1 Online First. *Ineligible study design*
- 61. Dulau E, Botha-Ravyse CR, Luimula M. Virtual reality for physical rehabilitation: A Pilot study How will virtual reality change physical therapy? 10th IEEE International Conference on Cognitive Infocommunications, CogInfoCom 2019 - Proceedings 2019:277-82 Online First. *Ineligible population*
- 62. e Carvalho MS, Carvalho LC, Alves RdS, et al. Analysis of the Muscular Activity, Peak Torque in the Lower Limbs, and Static Balance after Virtual Rehabilitation in Women with Fibromyalgia: A Randomized Controlled Study. Games for health journal 2021;**10**(3):190-97 Online First. *No eligible outcomes provided*
- 63. e Oliveira PF, Alves RdS, Iunes DH, et al. Effect of Exergaming on Muscle Strength, Pain, and Functionality of Shoulders in Cancer Patients. Games for health journal 2020;**9**(4):297-303 Online First. *Ineligible study design*
- 64. e Tommaso M, Ricci K, Laneve L, Savino N, Antonaci V, Livrea P. Virtual visual effect of hospital waiting room on pain modulation in healthy subjects and patients with chronic migraine. Pain research and treatment 2013;**2013**:515730 Online First. *Ineligible setting or follow-up*
- 65. e Villiers E, Stone T, Wang N-W, Sarangi V, Pelah A, Shenker N. Virtual Environment Rehabilitation for Patients with Motor Neglect Trial (VERMONT): A Single-Center Randomized Controlled Feasibility Trial. Brain sciences 2021;**11**(4) Online First. *Ineligible study design*
- 66. Ebrahimi N, Rojhani-Shirazi Z, Yoosefinejad AK, Nami M. The effects of virtual reality training on clinical indices and brain mapping of women with patellofemoral pain: a randomized clinical trial. BMC musculoskeletal disorders 2021;**22**(1):900 Online First. *Ineligible study design*
- 67. Elhafez HM, Elmageed SNA, Ali EA. Effect of Interactive Virtual Reality Device on Cervical Pain and Neck Function in Forward Head Posture. Egyptian Journal of Hospital Medicine 2022;**89**(1):6024-29 Online First. *Ineligible population*
- 68. Elor A, Teodorescu M, Kurniawan S. Project Star Catcher: A novel immersive virtual reality experience for upper limb rehabilitation. ACM Transactions on Accessible Computing 2018;11(4) Online First. *Ineligible population*
- 69. Erdoğan K, Ceylan R, Albayrak Gezer İ. The use of augmented reality in the teaching and training of basic exercises involved in the non-surgical treatment of neck pain. Virtual Reality 2023;**27**(1):481-92 Online First. *No eligible outcomes provided*



- 70. Faraj MM, Lipanski NM, Morales A, et al. A Virtual Reality Meditative Intervention Modulates Pain and the Pain Neuromatrix in Patients with Opioid Use Disorder. Pain medicine (Malden, Mass.) 2021;22(11):2739-53 Online First. *Ineligible population*
- 71. Fascio E, Vitale JA, Sirtori P, Peretti G, Banfi G, Mangiavini L. Early Virtual-Reality-Based Home Rehabilitation after Total Hip Arthroplasty: A Randomized Controlled Trial. Journal of Clinical Medicine 2022;**11**(7):1766 Online First. *Ineligible setting or follow-up*
- 72. Feintuch U, Tuchner M, Lorber-Haddad A, Meiner Z, Shiri S. VirHab A virtual reality system for treatment of chronic pain and disability. 2009 Virtual Rehabilitation International Conference, VR 2009 2009:83-86 Online First. Ineligible *study design*
- 73. Ficklscherer A, Stapf J, Meissner KM, et al. Testing the feasibility and safety of the Nintendo Wii gaming console in orthopedic rehabilitation: a pilot randomized controlled study. Archives of Medical Science 2016;**12**(6):1273-78 Online First. *Ineligible population*
- 74. Fonseca M, Cardoso H, Ferreira N, Loureiro T, Gomes I, Quaresma C. VR4Neuropain: Interactive rehabilitation system. BIODEVICES 2019 - 12th International Conference on Biomedical Electronics and Devices, Proceedings; Part of 12th International Joint Conference on Biomedical Engineering Systems and Technologies, BIOSTEC 2019 2019:285-90 Online First. *Ineligible study design*
- 75. Ford S. Video game exercises 'can help treat chronic lower back pain'. Nursing Times 2018;**114**(9):148-48 Online First. *Ineligible study design*
- 76. Fowler CA, Ballistrea LM, Mazzone KE, et al. Virtual Reality as a Therapy Adjunct for Fear of Movement in Veterans With Chronic Pain: Single-Arm Feasibility Study. JMIR formative research 2019;**3**(4):e11266 Online First. *Ineligible study design*
- 77. Freedman S, Hoffman H. Interrupting traumatic memories: An emergency room virtual reality intervention for pain reduction and the prevention of PTSD. Journal of Cyber Therapy and Rehabilitation 2016;**9**(1):39 Online First. *Ineligible study design*
- 78. Fritz RC, Chaudhari AS, Boutin RD. Preoperative MRI of Articular Cartilage in the Knee: A Practical Approach. Journal of Knee Surgery 2020;**33**(11):1088-99 Online First. *Ineligible intervention*
- 79. Fung V, Ho A, Shaffer J, Chung E, Gomez M. Use of Nintendo Wii Fit TM in the rehabilitation of outpatients following total knee replacement: a preliminary randomised controlled trial. Physiotherapy 2012;98(3):183-8 Online First. *Ineligible setting or follow-up*
- 80. Fung V, Ho A, Shaffer J, Gomez M. The utilization of nintendo wii fit in the rehabilitation of outpatients following total knee replacements: Preliminary results of a randomized controlled trial. Archives of Physical Medicine and Rehabilitation 2010;**91**(10):e37 Online First. *Ineligible study design*
- 81. Fung V, Shaffer J, Chung E, Ho A, Gomez M. The utilization of nintendo wii fittm in the rehabilitation of outpatients following total knee replacements-a randomized controlled trial. Physiotherapy (United Kingdom) 2011;97(SUPPL. 1):eS419 Online First. *Ineligible population*
- 82. Gad R, Wilson M. Can we safely manage pain using virtual reality (VR)? Pain Management Nursing 2023;**24**(3):243-45 Online First. *Ineligible study design*
- 83. Gauthier LV, Kane C, Borstad A, et al. Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): protocol for a multi-center comparative effectiveness trial of in-home gamified constraint-induced movement therapy for rehabilitation of chronic upper extremity hemiparesis. BMC neurology 2017;17(1):109 Online First. *Ineligible study design*

- 84. Gazerani P. Virtual reality for pain control Virtual or real? European Neurological Review 2016;**12**(2) Online First. *Ineligible study design*
- 85. Geman O, Chiuchisan I, Vicoveanu D. Serious Games used in Rehabilitation of Patients with Osteoarthritis. 2021 9th E-Health and Bioengineering Conference, EHB 2021 2021 Online First. *Ineligible study design*
- 86. Giap B, Xavier M, Malekirad J, Giap HB. Virtual Reality Therapy Can Improve Fatigue and Cognitive Function after Radiation and Chemotherapy. International Journal of Radiation Oncology Biology Physics 2019;105(1 Supplement):E585 Online First. *Ineligible study design*
- 87. Glavare M, Stalnacke B-M, Hager CK, Lofgren M. Virtual Reality Exercises in an Interdisciplinary Rehabilitation Programme for Persons with Chronic Neck Pain: a Feasibility Study. Journal of rehabilitation medicine. Clinical communications 2021;4:1000067 Online First. *Ineligible study design*
- 88. Gray E, Erickson M, Bindler R, Eti DU, Wilson M. Experiencing COMFORT: Perceptions of Virtually-delivered Nonpharmacologic Therapies in Adults Prescribed Opioids for Chronic Pain. Pain Management Nursing 2023 Online First. *Ineligible study design*
- 89. Gray ML, Goldrich DY, McKee S, et al. Virtual Reality as Distraction Analgesia for Office-Based Procedures: A Randomized Crossover-Controlled Trial. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2021;164(3):580-88 Online First. *Ineligible setting or follow-up*
- 90. Gromala D, Barnes SJ, Song M, et al. Immersive VR: A non-pharmacological analgesic for chronic pain? Conference on Human Factors in Computing Systems - Proceedings 2011:1171-76 Online First. *Ineligible study design*
- 91. Gromala D, Tong X, Choo A, Karamnejad M, Shaw CD. The virtual meditative walk: Virtual reality therapy for chronic pain management. Conference on Human Factors in Computing Systems Proceedings 2015;2015-April:521-24 Online First. *Ineligible study design*
- 92. Groninger H, Stewart D, Fisher JM, Tefera E, Cowgill J, Mete M. Virtual reality for pain management in advanced heart failure: A randomized controlled study. Palliative medicine 2021;35(10):2008-16 Online First. *Ineligible population*
- 93. Groninger H, Stewart D, Wesley D, Cowgill J, Mete M. Virtual reality for management of cancer pain: Study rationale and design. Contemporary clinical trials communications 2022;26:100895 Online First. *Ineligible study design*
- 94. Gu Y, Yao Q, Xu Y, Zhang H, Wei P, Wang L. A Clinical Application Study of Mixed Reality Technology Assisted Lumbar Pedicle Screws Implantation. Medical science monitor : international medical journal of experimental and clinical research 2020;26:e924982 Online First. *Ineligible intervention*
- 95. Guarino D, La Paglia F, Daino M, et al. Chronic pain treatment through virtual reality. Annual Review of CyberTherapy and Telemedicine 2017;15:181-84 Online First. *Not published in English*
- 96. Guerra-Armas J, Flores-Cortes M, Pineda-Galan C, Luque-Suarez A, La Touche R. Role of Immersive Virtual Reality in Motor Behaviour Decision-Making in Chronic Pain Patients. Brain Sciences 2023;13(4) Online First. *Ineligible study design*
- 97. Gulsen CPTM, Soke FPTP, Eldemir KPTM, et al. Effect of fully immersive virtual reality treatment combined with exercise in fibromyalgia patients: a randomized controlled trial. Assistive technology : the official journal of RESNA 2022;**34**(3):256-63 Online First. *Ineligible population*



- 98. Gunduz AG, Soke F, Aydin Y, et al. An investigation of effects of immersive virtual reality combined with exercise training in fibromyalgia patients: A pilot study. Fizyoterapi Rehabilitasyon 2018;29(2):S12 Online First. *Ineligible study design*
- 99. Gutierrez-Maldonado J, Gutierrez-Martinez O, Cabas-Hoyos K. Interactive and passive virtual reality distraction: effects on presence and pain intensity. Studies in health technology and informatics 2011;**167**:69-73 Online First. *Ineligible population*
- 100. Hadamus A, Bialoszewski D, Blazkiewicz M, et al. Assessment of the Effectiveness of Rehabilitation after Total Knee Replacement Surgery Using Sample Entropy and Classical Measures of Body Balance. Entropy (Basel, Switzerland) 2021;23(2) Online First. No eligible outcomes provided
- 101. Hadamus A, Blazkiewicz M, Wydra KT, et al. Effectiveness of Early Rehabilitation with Exergaming in Virtual Reality on Gait in Patients after Total Knee Replacement. Journal of clinical medicine 2022;**11**(17) Online First. *No eligible outcomes provided*
- 102. Haffar A, Bryan S, Harwood M, Lonner JH. Patient Resilience Has Moderate Correlation With Functional Outcomes, but Not Satisfaction, After Primary Unilateral Total Knee Arthroplasty. Arthroplasty today 2021;**10**:123-27 Online First. *Ineligible intervention*
- 103. Haisley KR, Straw OJ, Muller DT, et al. Feasibility of implementing a virtual reality program as an adjuvant tool for peri-operative pain control; Results of a randomized controlled trial in minimally invasive foregut surgery. Complementary therapies in medicine 2020;49:102356 Online First. *Ineligible population*
- 104. Hammond A, O'Brien R, Woodbridge S, et al. Job retention vocational rehabilitation for employed people with inflammatory arthritis (WORK-IA): a feasibility randomized controlled trial. BMC musculoskeletal disorders 2017;**18**(1):315 Online First. *Ineligible intervention*
- 105. Hammond A, Prior Y, O'Brien R, Woodbridge S, Radford K. Work rehabilitation in inflammatory arthritis: A pilot randomised controlled trial. Annals of the Rheumatic Diseases 2014;73(SUPPL. 2) Online First. *Ineligible study design*
- 106. Hansford KJ, Baker DH, McKenzie KJ, Preston CEJ. Distinct Neural Signatures of Multimodal Resizing Illusions: Implications for Chronic Pain Treatment. bioRxiv 2023 Online First. *No eligible outcomes provided*
- 107. Hemphill S, Rodriguez S, Wang E, et al. Virtual Reality Augments Movement during Physical Therapy. American Journal of Physical Medicine and Rehabilitation 2022;**101**(3):229-36 Online First. *Ineligible population*
- 108. Hennessy R, Rumble D, Sprigner C, et al. (380) Preliminary Feasibility of a Graded, Locomotor-Enabled, Whole-Body Virtual Reality Intervention for Individuals with Chronic Low Back Pain. Journal of Pain 2019;20:S69-S69 Online First. *Ineligible study design*
- 109. Hennessy RW, Rumble D, Christian M, Brown DA, Trost Z. A Graded Exposure, Locomotion-Enabled Virtual Reality App During Walking and Reaching for Individuals With Chronic Low Back Pain: Cohort Gaming Design. JMIR serious games 2020;8(3):e17799 Online First. Ineligible population
- 110. Henriksen B, Nielsen R, Kraus M, Geng B. A virtual reality system for treatment of phantom limb pain using game training and tactile feedback. ACM International Conference Proceeding Series 2017 Online First. *Ineligible study design*
- 111. Henriksen B, Nielsen RN, Kraus M, Geng B. Comparison of movements in a virtual reality mirror box therapy for treatment of lower limb phantom pain. VISIGRAPP 2018 Proceedings

of the 13th International Joint Conference on Computer Vision, Imaging and Computer Graphics Theory and Applications 2018;1:167-74 Online First. *Ineligible study design* 

- 112. Herrero R, Garcia-Palacios A, Castilla D, Molinari G, Botella C. Virtual reality for the induction of positive emotions in the treatment of fibromyalgia: a pilot study over acceptability, satisfaction, and the effect of virtual reality on mood. Cyberpsychology, behavior and social networking 2014;**17**(6):379-84 Online First. *Ineligible study design*
- 113. Hoffman HG, Fontenot MR, Garcia-Palacios A, et al. Adding tactile feedback increases avatar ownership and makes virtual reality more effective at reducing pain in a randomized crossover study. Scientific Reports 2023;13(1) Online First. *Ineligible population*
- 114. Holly J, Bridgewater C, Lambert AM. The use of virtual reality as a treatment medium for autonomic dysfunction across three diagnostic groups: Case studies. International Conference on Virtual Rehabilitation, ICVR 2017;2017-June Online First. *Ineligible study design*
- 115. Houdayer E, Alemanno F, Emedoli D, Locatelli M, Iannaccone S. Restoring "body image" in chronic pain: An innovative application of virtual reality. Neurorehabilitation and Neural Repair 2018;**32**(4-5):354 Online First. *Ineligible study design*
- 116. Hsiao PW, Kong LQ, Ye YL. Interactive game experience: a preliminary investigation of the impact of virtual reality on exercise rehabilitation behaviors. Interactive Learning Environments 2023 Online First. *Ineligible population*
- 117. Hsu JK, Thibodeau R, Wong SJ, Zukiwsky D, Cecile S, Walton DM. A "Wii" bit of fun: the effects of adding Nintendo Wii( R) Bowling to a standard exercise regimen for residents of long-term care with upper extremity dysfunction. Physiotherapy theory and practice 2011;27(3):185-93 Online First. *Ineligible population*
- 118. Hugli AS, Ernst MJ, Kool J, et al. Adherence to home exercises in non-specific low back pain. A randomised controlled pilot trial. Journal of bodywork and movement therapies 2015;19(1):177-85 Online First. *No eligible outcomes provided*
- 119. Hung ES-W, Chen S-C, Chang F-C, Shiao Y, Peng C-W, Lai C-H. Effects of Interactive Video Game-Based Exercise on Balance in Diabetic Patients with Peripheral Neuropathy: An Open-Level, Crossover Pilot Study. Evidence-based complementary and alternative medicine : eCAM 2019;2019:4540709 Online First. *No eligible outcomes provided*
- 120. Igna R, Stefan S, Onac I, Onac I, Ungur R-A, Szentagotai Tatar A. Mindfulness-based cognitive-behavior therapy (MCBT versus virtual reality (VR) enhanced CBT, versus treatment as usual for chronic back pain. A clinical trial. Journal of Evidence-Based Psychotherapies 2014;14(2):229-47 Online First. *Ineligible study design*
- 121. Inoue R, Sumitani M, Otake Y, et al. The effect of our physical training equipment presenting exercise instructions in the virtual reality space for chronic musculoskeletal pain. Pain Practice 2020;20(SUPPL 1):88 Online First. *Ineligible study design*
- 122. Jachak S, Phansopkar P. Effect of Oculus Guided Physical Therapy in adjunct to Conventional Therapy in Knee Osteoarthritis Patients. Journal of Medical Pharmaceutical and Allied Sciences 2022;11(4):5184-89 Online First. *Ineligible study design*
- 123. Janhunen M, Lopponen A, Walker S, et al. Movement characteristics during customized exergames after total knee replacement in older adults. Frontiers in sports and active living 2022;4:915210 Online First. *Ineligible population*
- 124. Jansen-Kosterink SM, Huis In 't Veld RMHA, Schonauer C, Kaufmann H, Hermens HJ, Vollenbroek-Hutten MMR. A Serious Exergame for Patients Suffering from Chronic

Musculoskeletal Back and Neck Pain: A Pilot Study. Games for health journal 2013;**2**(5):299-307 Online First. *Ineligible setting or follow-up* 

- 125. Jin W, Choo A, Gromala D, Shaw C, Squire P. A Virtual Reality Game for Chronic Pain Management: A Randomized, Controlled Clinical Study. Studies in health technology and informatics 2016;**220**:154-60 Online First. *Ineligible setting or follow-up*
- 126. Johnson L, Bird M-L, Muthalib M, Teo W-P. Innovative STRoke Interactive Virtual thErapy (STRIVE) online platform for community-dwelling stroke survivors: a randomised controlled trial protocol. BMJ open 2018;**8**(1):e018388 Online First. *Ineligible study design*
- 127. Jones T, Moore T, Rose H, Choo J. (512) The impact of virtual reality on chronic pain. Journal of Pain 2016;**17**:S102-S03 Online First. *Ineligible study design*
- 128. Joo SY, Cho YS, Lee SY, Seok H, Seo CH. Effects of Virtual Reality-Based Rehabilitation on Burned Hands: A Prospective, Randomized, Single-Blind Study. Journal of clinical medicine 2020;9(3) Online First. *Ineligible study design*
- 129. Junior VADS, Santos MdS, Ribeiro NMdS, Maldonado IL. Combining Proprioceptive Neuromuscular Facilitation and Virtual Reality for Improving Sensorimotor Function in Stroke Survivors: A Randomized Clinical Trial. Journal of central nervous system disease 2019;11:1179573519863826 Online First. *Ineligible population*
- 130. Kamdar M, Centi AJ, Agboola S, et al. A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain. Journal of Clinical Oncology 2019;**37**(Supplement 15) Online First. *Ineligible study design*
- 131. Kapsigay B, Sari Z, Kavlak B, Aras I, Tanhan A. HPR effects of virtual rehabilitation on shoulder periarthritis. Annals of the Rheumatic Diseases 2017;76(Supplement 2):1496 Online First. *Ineligible study design*
- 132. Karakoc ZB, Kuru Colak T, Kapsigay B, Sari Z, Polat MG. HPR the effcet of adding Wii Fit games to traditional rehabilitation on pain, quality of life and functionality after ACL reconstruction. Annals of the Rheumatic Diseases 2017;**76**(Supplement 2):1537 Online First. *Ineligible study design*
- 133. Kazis LE, Nethercot VA, Ren XS, Lee A, Selim A, Miller DR. Medication effectiveness studies in the United States Veterans Administration health care system: A model for large integrated delivery systems. Drug Development Research 2006;**67**(3):217-26 Online First. *Ineligible intervention*
- 134. Keefe FJ, Huling DA, Coggins MJ, et al. Virtual reality for persistent pain: a new direction for behavioral pain management. Pain 2012;**153**(11):2163-66 Online First. *Ineligible study design*
- 135. Kilbride C, Scott D, Butcher T, et al. Rehabilitation via home based gaming exercise for the upper-limb post stroke (RHOMBUS): results of an intervention feasibility trial. Physiotherapy (United Kingdom) 2020;**107**(Supplement 1):e25 Online First. *Ineligible population*
- 136. Kilbride C, Scott DJM, Butcher T, et al. Safety, feasibility, acceptability and preliminary effects of the Neurofenix platform for Rehabilitation via HOMe Based gaming exercise for the Upperlimb post Stroke (RHOMBUS): results of a feasibility intervention study. BMJ open 2022;12(2):e052555 Online First. *Ineligible study design*
- 137. Kim S-K, HwangBo G. The effects of horse-riding simulator exercise on balance in elderly with knee osteoarthritis. Journal of physical therapy science 2017;**29**(3):387-89 Online First. *No eligible outcomes provided*



- 138. Kim S-K, Kim S-G, HwangBo G. The effect of horse-riding simulator exercise on the gait, muscle strength and muscle activation in elderly people with knee osteoarthritis. Journal of physical therapy science 2017;**29**(4):693-96 Online First. *Ineligible study design*
- 139. Kim TY, Lee JH, Oh S, Kim SM, Yoon BC. Effect of simulated horseback-riding and sling exercise for patients with low back pain. Archives of Physical Medicine and Rehabilitation 2017;**98**(12):e175-e76 Online First. *Ineligible study design*
- 140. King A, Leggiero N, Acquaye A, et al. Use of virtual reality environments to improve self-reported distress, mood disturbance and overall symptom burden using correlative stress biomarkers in primary brain tumor (PBT) patients. Neuro-Oncology 2019;21(Supplement 6):vi219 Online First. *Ineligible study design*
- 141. Kiper P, Przysiezna E, Cieslik B, et al. Effects of Immersive Virtual Therapy as a Method Supporting Recovery of Depressive Symptoms in Post-Stroke Rehabilitation: Randomized Controlled Trial. Clinical interventions in aging 2022;17:1673-85 Online First. *Ineligible population*
- 142. Koo KI, Park DK, Youm YS, Cho SD, Hwang CH. Enhanced Reality Showing Long-Lasting Analgesia after Total Knee Arthroplasty: Prospective, Randomized Clinical Trial. Scientific Reports 2018;8(1) Online First. *Ineligible setting or follow-up*
- 143. Kragting M, Schuiling SF, Voogt L, Pool-Goudzwaard AL, Coppieters MW. Using visual feedback manipulation in virtual reality to influence pain-free range of motion in people with non-specific neck pain. Pain practice : the official journal of World Institute of Pain 2020 Online First. *Ineligible study design*
- 144. Krause K, Guertler D, Moehring A, et al. Association between Alcohol Consumption and Health-Related Quality of Life among Hospital and Ambulatory Care Patients with Past Year Depressive Symptoms. International journal of environmental research and public health 2022;**19**(22) Online First. *Ineligible intervention*
- 145. Krogg W, Golovyan D, Abshire L, et al. Development of a virtual reality environment to provide cognitive stimulation: A novel tool to reduce pain, anxiety, and delirium in critically ill patients. American Journal of Respiratory and Critical Care Medicine 2018;197(MeetingAbstracts) Online First. *Ineligible study design*
- 146. Kumru H, Soler D, Vidal J, et al. The effects of transcranial direct current stimulation with visual illusion in neuropathic pain due to spinal cord injury: an evoked potentials and quantitative thermal testing study. European journal of pain (London, England) 2013;17(1):55-66 Online First. *Ineligible study design*
- 147. Lehrl S, Gusinde J, Schulz-Drost S, et al. Advancement of physical process by mental activation: a prospective controlled study. Journal of Rehabilitation Research & Development 2012;**49**(8) Online First. *Ineligible intervention*
- 148. Lew D, Bancila L, Wang K, et al. Virtual Reality Can Reduce Pain and Opioid Use in Sphincter of Oddi Dysfunction (SOD) Type III: A Prospective Pilot Study. American Journal of Gastroenterology 2020;**115**(SUPPL):S39-S40 Online First. *Ineligible study design*
- 149. Li L. Effect of Remote Control Augmented Reality Multimedia Technology for Postoperative Rehabilitation of Knee Joint Injury. Computational and mathematical methods in medicine 2022;2022:9320063 Online First. *Ineligible setting or follow-up*
- 150. Lier EJ, Oosterman JM, Assmann R, e Vries M, van Goor H. The effect of Virtual Reality on evoked potentials following painful electrical stimuli and subjective pain. Scientific reports 2020;10(1):9067 Online First. *Ineligible population*



- 151. Liu K, Madrigal E, Chung JS, et al. Preliminary Study of Virtual-reality-guided Meditation for Veterans with Stress and Chronic Pain. Alternative therapies in health and medicine 2021 Online First. *Ineligible study design*
- 152. Llorens R, Noe E, Colomer C, Alcaniz M. Effectiveness, usability, and cost-benefit of a virtual reality-based telerehabilitation program for balance recovery after stroke: a randomized controlled trial. Archives of physical medicine and rehabilitation 2015;**96**(3):418-25.e2 Online First. *Ineligible population*
- 153. Luque-Moreno C, Cano-Bravo F, Kiper P, et al. Reinforced Feedback in Virtual Environment for Plantar Flexor Poststroke Spasticity Reduction and Gait Function Improvement. BioMed research international 2019;**2019**:6295263 Online First. *Ineligible population*
- 154. MacIntyre E, Sigerseth M, Larsen TF, et al. Get your head in the game: a replicated single-caseexperimental-design evaluating the effect of a novel virtual reality intervention in people with chronic low back pain. The journal of pain 2023 Online First. *Ineligible study design*
- 155. Malik M, Shaw M, Palmeri M, Charvet L. Virtual reality as an intervention for chronic pain in multiple sclerosis. Neurology 2021;**96**(15 SUPPL 1) Online First. *Ineligible study design*
- 156. Manlapaz DG, Escuadra CT, Regino JM, et al. Effectiveness of exergaming, Tai Chi, and physical therapy in improving dynamic balance and enjoyment of older adults with knee osteoarthritis. Osteoarthritis and Cartilage 2020;**28**(Supplement 1):S166-S67 Online First. *Ineligible study design*
- 157. Marc A, Henry F, Duault E. The virtual reality headset, an alternative to pain and anxiety. Oxymag 2022;**35**(183):21-23 Online First. *Ineligible study design*
- 158. Marcuzzi A, Bach K, Nordstoga AL, et al. Individually tailored self-management app-based intervention (selfBACK) versus a self-management web-based intervention (e-Help) or usual care in people with low back and neck pain referred to secondary care: protocol for a multiarm randomised clinical trial. BMJ open 2021;**11**(9):e047921 Online First. *Ineligible study design*
- 159. Marsh J, Pettifer S, Richardson C, Kulkarni J. Experiences of treating phantom limb pain using immersive virtual reality. ACM SIGGRAPH 2019 Talks, SIGGRAPH 2019 2019 Online First. *Ineligible study design*
- 160. Marshall AN, Hertel J, Hart JM, Russell S, Saliba SA. Visual Biofeedback and Changes in Lower Extremity Kinematics in Individuals With Medial Knee Displacement. Journal of athletic training 2020;55(3):255-64 Online First. *Ineligible population*
- 161. Martínez D, Zavala J. Functional results when adding Microsoft Kinect® in the physiotherapeutic rehabilitation of patients with total knee arthroplasty. Fisioterapia 2020;42(6):295-300 Online First. *Ineligible study design*
- 162. Matamala-Gomez M, Diaz Gonzalez AM, Slater M, Sanchez-Vives MV. Decreasing Pain Ratings in Chronic Arm Pain Through Changing a Virtual Body: Different Strategies for Different Pain Types. The journal of pain 2019;20(6):685-97 Online First. *Ineligible study design*
- 163. Matheve T, Bogaerts K, Timmermans A. Virtual reality distraction induces hypoalgesia in patients with chronic low back pain: a randomized controlled trial. Journal of neuroengineering and rehabilitation 2020;17(1):55 Online First. *Ineligible setting or follow-up*
- 164. Matsangidou M, P. Kassianos A, Papaioannou D, et al. Virtual Painkillers: Designing Accessible Virtual Reality Experiences for Helping Cancer Patients Manage Pain at Home. Conference on Human Factors in Computing Systems - Proceedings 2022 Online First. No eligible outcomes provided



- 165. Mbada C, Oni A, Makinde M, Fasuyi F, Adegbemigun O, Awotidebe T. Does Virtual Reality Type Matter on Clinical Outcomes of Patients with Long-term Non-Specific Low-Back Pain? Archives of Physical Medicine and Rehabilitation 2019;**100**(12):e174 Online First. *Ineligible study design*
- 166. McDonald DD, Gifford T, Walsh S. Effect of a Virtual Pain Coach on Older Adults' Pain Communication: A Pilot Study. Pain Management Nursing 2011;12(1):50-56 Online First. *Ineligible intervention*
- 167. McFarland M, Zelaya N, Hossain G, Hicks D, McLauchlan L. Pain Mitigation through Virtual Reality Applications. 2019 22nd IEEE International Symposium on Measurement and Control in Robotics: Robotics for the Benefit of Humanity, ISMCR 2019 2019 Online First. *Ineligible study design*
- 168. Meinke A, Peters R, Knols RH, Swanenburg J, Karlen W. Feedback on Trunk Movements From an Electronic Game to Improve Postural Balance in People With Nonspecific Low Back Pain: Pilot Randomized Controlled Trial. JMIR serious games 2022;10(2):e31685 Online First. Ineligible population
- 169. Menek B, Tarakci D, Tarakci E, Menek MY. Investigation on the Efficiency of the Closed Kinetic Chain and Video-Based Game Exercise Programs in the Rotator Cuff Rupture: A Randomized Trial. Games for health journal 2022;11(5):298-306 Online First. *Ineligible setting* or follow-up
- 170. Mercier C, Roosink M, McFadyen BJ, Hebert LJ, Jackson PL, Bouyer LJ. Assessing the perception of movements in subjects with chronic pain using altered virtual feedback. Annals of Physical and Rehabilitation Medicine 2015;**58**(SUPPL. 1):e94 Online First. *Ineligible study design*
- 171. Merliot-Gailhoustet L, Raimbert C, Garnier O, et al. Discomfort improvement for critically ill patients using electronic relaxation devices: results of the cross-over randomized controlled trial E-CHOISIR (Electronic-CHOIce of a System for Intensive care Relaxation). Critical care (London, England) 2022;26(1):263 Online First. *Ineligible population*
- 172. Merlot B, Dispersyn G, Husson Z, et al. Pain Reduction With an Immersive Digital Therapeutic Tool in Women Living With Endometriosis-Related Pelvic Pain: Randomized Controlled Trial. Journal of medical Internet research 2022;24(9):e39531 Online First. *Ineligible setting or follow-up*
- 173. Mihajlovic Z, Popovic S, Brkic K, Cosic K. A system for head-neck rehabilitation exercises based on serious gaming and virtual reality. Multimedia Tools and Applications 2018;77(15):19113-37 Online First. *Ineligible study design*
- 174. Morkisch N, Jettkowski K, Dos Santos LF, Dohle C. Modelling of therapeutic action during mirror therapy. Current Directions in Biomedical Engineering 2017;**3**(1):45-48 Online First. *Ineligible study design*
- 175. Morris NA, Wang Y, Felix RB, et al. Adjunctive virtual reality pain relief after traumatic injury: a proof-of-concept within-person randomized trial. Pain 2023 Online First. *Ineligible setting or follow-up*
- 176. Mortensen J, Kristensen LQ, Brooks EP, Brooks AL. Women with fibromyalgia's experience with three motion-controlled video game consoles and indicators of symptom severity and performance of activities of daily living. Disability and rehabilitation. Assistive technology 2015;**10**(1):61-6 Online First. *Ineligible study design*
- 177. Mouraux D, Brassinne E, Sobczak S, et al. 3D augmented reality mirror visual feedback therapy applied to the treatment of persistent, unilateral upper extremity neuropathic pain: a preliminary



study. The Journal of manual & manipulative therapy 2017;**25**(3):137-43 Online First. *Ineligible study design* 

- 178. Mukherjee M, Bedekar N, Sancheti PK, Shyam A. Immediate and short-term effect of virtual reality training on pain, range of motion, and kinesiophobia in patients with cervical spondylosis. Indian Journal of Physical Therapy and Research 2020;**2**(1):55 Online First. *Ineligible population*
- 179. Najafi B, Grewal G, Sayeed R, et al. Early detection of peripheral neuropathy using virtual obstacle crossing. Diabetes 2012;61(SUPPL. 1):A162 Online First. *Ineligible intervention*
- 180. Nakad L, Rakel B. (271) Attitudes of Older Adults with Chronic Musculoskeletal Pain towards Immersive Virtual Reality. Journal of Pain 2019;20:S42-S42 Online First. No eligible outcomes provided
- 181. Nambi G, Abdelbasset WK, Alqahatani BA. Radiological (Magnetic Resonance Image and Ultrasound) and biochemical effects of virtual reality training on balance training in football players with chronic low back pain: A randomized controlled study. Journal of back and musculoskeletal rehabilitation 2021;**34**(2):269-77 Online First. *No eligible outcomes provided*
- 182. Nguyen LAB, Adler EP, Rodriguez S, et al. VIRTUAL REALITY MINDFULNESS THERAPY REDUCES PAIN AND ANXIETY IN PATIENTS WITH CHRONIC ABDOMINAL PAIN. Gastroenterology 2019;156(6 Supplement 1):S-1062 Online First. Ineligible study design
- 183. Ortiz-Catalan M, Gumundsdottir RA, Kristoffersen MB, et al. Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England) 2016;**388**(10062):2885-94 Online First. *Ineligible study design*
- 184. Ozkul C, Kilinc M, Yildirim SA, Topcuoglu EY, Akyuz M. Effects of visual illusion and transcutaneous electrical nerve stimulation on neuropathic pain in patients with spinal cord injury: A randomised controlled cross-over trial. Journal of back and musculoskeletal rehabilitation 2015;**28**(4):709-19 Online First. *Ineligible intervention*
- 185. Palmeri M, Shaw M, Dobbs B, et al. Abstract #144: Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed with Neurological Disorders. Brain Stimulation 2019;12(2):e49 Online First. *Ineligible population*
- 186. Pamment J, Aspell JE. Putting pain out of mind with an 'out of body' illusion. European journal of pain (London, England) 2017;**21**(2):334-42 Online First. *Ineligible study design*
- 187. Park H-Y, Nam KE, Lim J-Y, Yeo SM, In Lee J, Hwang JH. Real-time interactive digital healthcare system for post-operative breast cancer patients: study protocol for a randomized controlled trial. Trials 2021;**22**(1):549 Online First. *Ineligible study design*
- 188. Park H-Y, Nam KE, Lim J-Y, Yeo SM, Lee JI, Hwang JH. Real-Time Interactive Digital Health Care System for Postoperative Breast Cancer Patients: A Randomized Controlled Trial. Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2022 Online First. *Ineligible population*
- 189. Park J-H, Lee S-H, Ko D-S. The Effects of the Nintendo Wii Exercise Program on Chronic Work-related Low Back Pain in Industrial Workers. Journal of physical therapy science 2013;25(8):985-8 Online First. *Ineligible study design*
- 190. Patel P, Ivanov D, Bhatt S, et al. Low-Cost Virtual Reality Headsets Reduce Perceived Pain in Healthy Adults: A Multicenter Randomized Crossover Trial. Games for health journal 2020;9(2):129-36 Online First. *Ineligible population*



- 191. Patricio NA, Vidal DG, Pinto EB, Sa KN, Baptista AF. Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial. Journal of neurovirology 2020;**26**(5):676-86 Online First. *Ineligible study design*
- 192. Patterson DR, Hoffman HG, Palacios AG, Jensen MJ. Analgesic effects of posthypnotic suggestions and virtual reality distraction on thermal pain. Journal of abnormal psychology 2006;**115**(4):834-41 Online First. *Ineligible population*
- 193. Patterson DR, Soltani M, Teeley A, Morse D, Wiechman SA, Gibran NS. Hypnosis delivered through immersive virtual reality for wound care: A randomized, controlled study. Journal of Burn Care and Research 2012;**33**(2 SUPPL. 1):S70 Online First. *Ineligible study design*
- 194. Payne O, Smith V, Rolnik DL, et al. Virtual reality and its use in post-operative pain following laparoscopy: a feasibility study. Scientific reports 2022;**12**(1):13137 Online First. *Ineligible study design*
- 195. Pekyavas NO, Ergun N. Effects of different exercise and kinesiotaping application on pain, flexibility, strength and range of motion in patients with subacromial impingement syndrome. Fizyoterapi Rehabilitasyon 2014;**25**(1 SUPPL. 1):S31 Online First. *Ineligible study design*
- 196. Pekyavas NO, Ergun N. Comparison of virtual reality exergaming and home exercise programs in patients with subacromial impingement syndrome and scapular dyskinesis: Short term effect. Acta orthopaedica et traumatologica turcica 2017;**51**(3):238-42 Online First. *Ineligible population*
- 197. Perales FJ, Riera L, Ramis S, Guerrero A. Evaluation of a VR system for Pain Management using binaural acoustic stimulation. Multimedia Tools and Applications 2019;**78**(23):32869-90 Online First. *Ineligible study design*
- 198. Perez-Marcos D, Chevalley O, Schmidlin T, et al. Increasing upper limb training intensity in chronic stroke using embodied virtual reality: a pilot study. Journal of neuroengineering and rehabilitation 2017;**14**(1):119 Online First. *Ineligible study design*
- 199. Perna-Forrest L, Minton O. THE POTENTIAL FOR VIRTUAL REALITY THERAPY IN PALLIATIVE CARE PRELIMINARY FINDINGS. BMJ Supportive and Palliative Care 2019;9(Supplement 1):A63 Online First. *Ineligible study design*
- 200. Perry BN, Armiger RS, Wolde M, et al. Clinical Trial of the Virtual Integration Environment to Treat Phantom Limb Pain With Upper Extremity Amputation. Frontiers in neurology 2018;9:770 Online First. *Ineligible study design*
- 201. Perry BN, Mercier C, Pettifer SR, Cole J, Tsao JW. Virtual reality therapies for phantom limb pain. 2014;**18**(7):897-99 Online First. *Ineligible study design*
- 202. Peterson BN, Hitching R, Howard L, et al. Immersive Virtual Reality: A Safe, Scalable, Nonopioid Analgesic for Military and Veteran Patients. Frontiers in Virtual Reality 2021;2 Online First. *Ineligible study design*
- 203. Pettifer S, Howard T, Blundell B, Edwards D, Lieberman I. An immersive virtual environment for Phantom Limb Pain rehabilitation. GRAPP 2012 IVAPP 2012 - Proceedings of the International Conference on Computer Graphics Theory and Applications and International Conference on Information Visualization Theory and Applications 2012:426-33 Online First. *Ineligible study design*
- 204. Phelan I. How Virtual Reality Can Reduce Pain and Aid Rehabilitation. ITNOW 2022;**64**(3):22-23 Online First. *Ineligible study design*

- 205. Piccoli A, Samuels G, Mirakaj A, et al. Immersive Virtual Reality for individuals with spinal cord injuries. 2017 IEEE Long Island Systems, Applications and Technology Conference, LISAT 2017 2017 Online First. *Ineligible population*
- 206. Polat M, Kahveci A, Gunendi Z, Karatas GK. The effect of virtual reality exercises on pain, functionality, cardiopulmonary capacity and quality of life in fibromyalgia syndrome: A randomized, single-blind, controlled study. Annals of the Rheumatic Diseases 2019;78(Supplement 2):526 Online First. *Ineligible study design*
- 207. Popert S, Magar K. EXPANDING THE REACH OF VIRTUAL REALITY FOR PALLIATIVE PATIENTS. BMJ Supportive and Palliative Care 2021;11(Supplement 2):A59 Online First. *Ineligible study design*
- 208. Pournajaf S, Goffredo M, Pellicciari L, et al. Effect of balance training using virtual realitybased serious games in individuals with total knee replacement: A randomized controlled trial. Annals of physical and rehabilitation medicine 2022;**65**(6):101609 Online First. *Ineligible setting or follow-up*
- 209. Powell W, Stevens B, Simmonds M. Annual review of cybertherapy and telemedicine 2009. Treadmill interface for virtual reality vs. overground walking: a comparison of gait in individuals with and without pain. Studies in Health Technology & Informatics 2009;144:198-203 Online First. *Ineligible intervention*
- 210. Pozeg P, Palluel E, Ronchi R, et al. Virtual reality improves embodiment and neuropathic pain caused by spinal cord injury. Neurology 2017;**89**(18):1894-903 Online First. *No eligible outcomes provided*
- 211. Prabhu VG, Stanley LM, Linder C, Morgan R. Analyzing the Efficacy of a Restorative Virtual Reality Environment using HRV Biofeedback for Pain and Anxiety Management. Proceedings of the 2020 IEEE International Conference on Human-Machine Systems, ICHMS 2020 2020 Online First. *Ineligible population*
- 212. Prahm C, Bressler M, Eckstein K, Kuzuoka H, Daigeler A, Kolbenschlag J. Developing a wearable Augmented Reality for treating phantom limb pain using the Microsoft Hololens 2. ACM International Conference Proceeding Series 2022:309-12 Online First. *Ineligible study design*
- 213. Preatoni G, Bracher NM, Raspopovic S. Towards a future VR-TENS multimodal platform to treat neuropathic pain. International IEEE/EMBS Conference on Neural Engineering, NER 2021;2021-May:1105-08 Online First. *Ineligible population*
- 214. Preston C, Gilpin HR, Newport R. An exploratory investigation into the longevity of pain reduction following multisensory illusions designed to alter body perception. Musculoskeletal science & practice 2020;45:102080 Online First. *Ineligible intervention*
- 215. Putrino D, Tabacof L, Breyman E, et al. Pain Reduction after Short Exposure to Virtual Reality Environments in People with Spinal Cord Injury. International journal of environmental research and public health 2021;**18**(17) Online First. *Ineligible study design*
- 216. Rahbar M, Salekzamani Y, Jahanjou F, Eslamian F, Niroumand A, Dolatkhah N. Effect of hippotherapy simulator on pain, disability and range of motion of the spinal column in subjects with mechanical low back pain: A randomized single-blind clinical trial. Journal of back and musculoskeletal rehabilitation 2018;**31**(6):1183-92 Online First. *Ineligible population*
- 217. Ramsayer B, Honold M, Beck K, Kraus M, Kramer M, Dehner C. Cervicocephalic kinaesthesia in subjects with and without peripherally induced pain. Journal of Musculoskeletal Pain 2013;21(4):327-33 Online First. *Ineligible intervention*



- 218. Rawlins CR, Veigulis Z, Hebert C, Curtin C, Osborne TF. Effect of Immersive Virtual Reality on Pain and Anxiety at a Veterans Affairs Health Care Facility. Frontiers in Virtual Reality 2021;**2** Online First. *Ineligible study design*
- 219. Reinersmann A, Landwehrt J, Krumova EK, et al. The rubber hand illusion in complex regional pain syndrome: preserved ability to integrate a rubber hand indicates intact multisensory integration. Pain 2013;**154**(9):1519-27 Online First. *Ineligible study design*
- 220. Richardson EJ, McKinley EC, Rahman AKMF, Klebine P, Redden DT, Richards JS. Effects of virtual walking on spinal cord injury-related neuropathic pain: A randomized, controlled trial. Rehabilitation psychology 2019;64(1):13-24 Online First. *Ineligible setting or follow-up*
- 221. Risso G, Preatoni G, Valle G, Marazzi M, Bracher NM, Raspopovic S. Multisensory stimulation decreases phantom limb distortions and is optimally integrated. iScience 2022;25(4):104129 Online First. *Ineligible population*
- 222. Rivera I, Billington J, Lloyd D. Can virtual reality reduce the perception of pain? Journal of Cyber Therapy and Rehabilitation 2017;**10**(1):51 Online First. *Ineligible study design*
- 223. Rizzo J-R, Thai P, Li EJ, et al. Structured Wii protocol for rehabilitation of shoulder impingement syndrome: A pilot study. Annals of physical and rehabilitation medicine 2017;**60**(6):363-70 Online First. *Ineligible study design*
- 224. Rodriguez MC, Aruanno B, Bordegoni M, Rossini M, Molteni F. Immersive virtual reality system for treatment of phantom limb pain (plp). Proceedings of the ASME Design Engineering Technical Conference 2017;1 Online First. *Ineligible population*
- 225. Rodriguez S, Badia SB, Cameirao MD, et al. Effects of virtual reality upper limb based training (rehabilitation gaming system) on spasticity, shoulder pain depression after stroke. PM and R 2011;3(10 SUPPL. 1):S160 Online First. *Ineligible study design*
- 226. Rodriguez-Mansilla J, Mejias-Gil A, Garrido-Ardila EM, Jimenez-Palomares M, Montanero-Fernandez J, Gonzalez-Lopez-Arza MV. Effects of Non-Pharmacological Treatment on Pain, Flexibility, Balance and Quality of Life in Women with Fibromyalgia: A Randomised Clinical Trial. Journal of clinical medicine 2021;**10**(17) Online First. *Ineligible intervention*
- 227. Rothbaum AO, Tannenbaum LR, Zimand E, Rothbaum BO. A pilot randomized controlled trial of virtual reality delivered relaxation for chronic low back pain. Virtual Reality 2023 Online First. *Ineligible study design*
- 228. Saadon-Grosman N, Arzy S. Virtual reality may relieve pain in patients with spinal cord injury. Neurology 2017;**89**(18):e227-e30 Online First. Ineligible *study design*
- 229. Saito K, Miyaki T, Rekimoto J. The method of reducing phantom limb pain using optical seethrough head mounted display. 26th IEEE Conference on Virtual Reality and 3D User Interfaces, VR 2019 - Proceedings 2019:1560-62 Online First. *Ineligible study design*
- 230. Saito K, Okada A, Matsumura Y, Rekimoto J. Remote Treatment System of Phantom Limb Pain by Displaying Body Movement in Shared VR Space. ACM International Conference Proceeding Series 2020 Online First. *Ineligible study design*
- 231. Sandal LF, Stochkendahl MJ, Svendsen MJ, et al. An App-Delivered Self-Management Program for People With Low Back Pain: Protocol for the selfBACK Randomized Controlled Trial. JMIR research protocols 2019;8(12):e14720 Online First. *Ineligible study design*
- 232. Sargut M, Schorn S, Novotny A, et al. The effect of Virtual Reality (VR) on anxiety and pain in patients undergoing port implantation Preliminary results of a feasibility study. Current Directions in Biomedical Engineering 2022;8(1):97-100 Online First. *Ineligible population*



- 233. Sarig Bahat H, Weiss PLT, Laufer Y. Characteristics of cervical motion affected by neck pain, as assessed in a virtual environment. Physiotherapy (United Kingdom) 2011;97(SUPPL. 1):eS1097-eS98 Online First. *Ineligible study design*
- 234. Sarig-Bahat H, Takasaki H, Chen X, Betor Y, Treleaven J. Cervical kinematic training with and without an interactive virtual reality device for chronic neck pain-a pilot randomized clinical trial. Physiotherapy (United Kingdom) 2015;101(SUPPL. 1):eS1535-eS36 Online First. *Ineligible study design*
- 235. Schneider SM, Hood LE. Virtual reality: a distraction intervention for chemotherapy. Oncology nursing forum 2007;**34**(1):39 Online First. *Ineligible population*
- 236. Schroeder D, Korsakov F, Jolton J, Keefe FJ, Haley A, Keefe DF. Creating widely accessible spatial interfaces: mobile VR for managing persistent pain. IEEE computer graphics and applications 2013;**33**(3):82-9 Online First. *Ineligible study design*
- 237. Schwartz I, Safran O, Karniel N, et al. Positive Effect of Manipulated Virtual Kinematic Intervention in Individuals with Traumatic Stiff Shoulder: A Pilot Study. Journal of clinical medicine 2022;11(13) Online First. *Ineligible study design*
- 238. Seo M, Jeon S, Kim B, Ryu J, Lee K. Pain perception and visual feedback in virtual reality. IBRO Reports 2019;6(Supplement):S323 Online First. *Ineligible study design*
- 239. Shahid Khan MU, Hussain HG, Farooq M, et al. The potential of virtual reality for rehabilitation intervention in females with breast cancer. International Journal of Surgery 2022;106 Online First. *Ineligible study design*
- 240. Shahrbanian S. Virtual reality training or physical activity? Which one is more effective in reducing pain among persons with multiple sclerosis? A randomized controlled trial. Multiple Sclerosis Journal 2017;**23**(3 Supplement 1):959-60 Online First. *Ineligible study design*
- 241. Shahrbanian S, Simmonds MJ. Effects of different virtual reality environments on experimental pain rating in post-stroke individuals with and without pain in comparison to pain free healthy individuals. Annual Review of CyberTherapy and Telemedicine 2008;**6**:53-59 Online First. *Ineligible study design*
- 242. Shanbehzadeh M, Orooji A, Kazemi-Arpanahi H. Comparing of data mining techniques for predicting in-hospital mortality among patients with covid-19. Journal of Biostatistics and Epidemiology 2021;7(2):154-69 Online First. *Ineligible population*
- 243. Shaw M, Palmeri M, Krupp L, Charvet L. Acute and lasting benefits of a virtual reality in multiple sclerosis. Neurology 2019;**92**(15 Supplement 1) Online First. *Ineligible population*
- 244. Sherrard C, Parker D, Negus J, McIntosh B. The effects of a Wii Fit-based balance program on knee pain and function in patellofemoral pain sufferers. Journal of Science and Medicine in Sport 2010;**13**(SUPPL. 1):e6-e7 Online First. *Ineligible study design*
- 245. Silva Ribeiro NM, Ferraz DD, Pedreira E, et al. Virtual rehabilitation via Nintendo Wii R and conventional physical therapy effectively treat post-stroke hemiparetic patients. Topics in stroke rehabilitation 2015;**22**(4):299-305 Online First. *Ineligible population*
- 246. Smith V, Warty RR, Kashyap R, et al. A randomised controlled trial to assess the feasibility of utilising virtual reality to facilitate analgesia during external cephalic version. Scientific reports 2020;**10**(1):3141 Online First. *Ineligible population*
- 247. Sobie T. Virtual reality bonestm and feldenkraismovements compared to core stabilization biofeedback and motor control exercises: Comparative effects on chronic nonspecific low back pain in an outpatient clinical setting: A dissertation study and randomized controlled trial. Global Advances in Health and Medicine 2020;9:104-05 Online First. *Ineligible study design*



- 248. Solca M, Ronchi R, Bello-Ruiz J, et al. Heartbeat-enhanced immersive virtual reality to treat complex regional pain syndrome. Neurology 2018;**91**(5):e479-e89 Online First. *Ineligible study design*
- 249. Soler D, Kumru H, Vidal J, et al. Transcranial direct current stimulation (TDCS) and virtual reality (VR) techniques for treatment neuropathic central pain in spinal cord injury (NP-SCI). European Journal of Pain Supplements 2010;4(1):105-06 Online First. *Ineligible study design*
- 250. Soler D, Morina D, Kumru H, Vidal J, Navarro X. Transcranial Direct Current Stimulation and Visual Illusion Effect According to Sensory Phenotypes in Patients With Spinal Cord Injury and Neuropathic Pain. The journal of pain 2021;**22**(1):86-96 Online First. *Ineligible study design*
- 251. Soler MD, Kumru H, Pelayo R, et al. Effectiveness of transcranial direct current stimulation and visual illusion on neuropathic pain in spinal cord injury. Brain : a journal of neurology 2010;133(9):2565-77 Online First. *Ineligible intervention*
- 252. Stamm O, Dahms R, Reithinger N, Rus A, Muller-Werdan U. Virtual reality exergame for supplementing multimodal pain therapy in older adults with chronic back pain: a randomized controlled pilot study. Virtual reality 2022;**26**(4):1291-305 Online First. *Ineligible population*
- 253. Stanmore EK, Mavroeidi A, e Jong LD, et al. The effectiveness and cost-effectiveness of strength and balance Exergames to reduce falls risk for people aged 55 years and older in UK assisted living facilities: a multi-centre, cluster randomised controlled trial. BMC medicine 2019;17(1):49 Online First. *Ineligible population*
- 254. Tasci Z, Cirak Y, Elbasi N, Tutuneken YE, Pamukcu B, Asalioglu A. The effects of virtual reality on pulmonary functions, functional level and pain in the early period after open heart surgery. European Respiratory Journal 2020;**56**(Supplement 64) Online First. *Ineligible population*
- 255. Tefertiller C, Ketchum JM, Bartelt P, Peckham M, Hays K. Feasibility of virtual reality and treadmill training in traumatic brain injury: a randomized controlled pilot trial. Brain Injury 2022;**36**(7):898-908 Online First. *Ineligible population*
- 256. Teremetz M, Garcia Alvarez A, Hanneton S, et al. Improving upper-limb and trunk kinematics by interactive gaming in individuals with chronic stroke: A single-blinded RCT. Annals of physical and rehabilitation medicine 2022;65(3):101622 Online First. *No eligible outcomes provided*
- 257. Tran Y, Austin P, Lo C, et al. An Exploratory EEG Analysis on the Effects of Virtual Reality in People with Neuropathic Pain Following Spinal Cord Injury. Sensors (Basel, Switzerland) 2022;22(7) Online First. *Ineligible population*
- 258. Trost Z, Nowlin L, Guck A, Madi D, Davis M. Exploring the role of pain-related fear and catastrophizing in response to a virtual reality gaming intervention for chronic low back pain. Journal of Pain 2015;**16**(4 SUPPL. 1):S98 Online First. *Ineligible study design*
- 259. Trujillo M, Crossland D, Alvarez A, Petros J. Virtual embodiment influences dynamic range of motion in chronic shoulder pain patients. Neuromodulation 2020;23(3):e179 Online First. *Ineligible study design*
- 260. Tuck N, Pollard C, Good C, et al. Active Virtual Reality for Chronic Primary Pain: Mixed Methods Randomized Pilot Study. JMIR formative research 2022;**6**(7):e38366 Online First. *Ineligible study design*
- 261. Ucero-Lozano R, Perez-Llanes R, Lopez-Pina JA, Cuesta-Barriuso R. Approach to Knee Arthropathy through 180-Degree Immersive VR Movement Visualization in Adult Patients with

Severe Hemophilia: A Pilot Study. Journal of clinical medicine 2022;**11**(20) Online First. *Ineligible population* 

- 262. Ucero-Lozano R, Perez-Llanes R, Lopez-Pina JA, Cuesta-Barriuso R. Effectiveness of Motion Visualization Through Immersive Video in Patients With Hemophilic Arthropathy Of The Ankle. Archives of Physical Medicine and Rehabilitation 2022;103(12):e167 Online First. Ineligible study design
- 263. Ucero-Lozano R, Perez-Llanes R, Lopez-Pina JA, Cuesta-Barriuso R. IMMERSIVE VR VISUALIZATION to IMPROVE QUALITY of LIFE in PATIENTS with HEMOPHILIC ANKLE ARTHROPATHY. Haemophilia 2022;**28**(SUPPL 1):23-24 Online First. *Ineligible study design*
- 264. Ucero-Lozano R, Perez-Llanes R, Lopez-Pina JA, Cuesta-Barriuso R. 180-degree immersive VR motion visualization in the treatment of haemophilic ankle arthropathy. Haemophilia : the official journal of the World Federation of Hemophilia 2023;**29**(1):282-89 Online First. *Ineligible study design*
- 265. Vázques JLM, Golsong JB, Wiederhold MD. Cybertherapy in medicine Clinical applications to reduce pain and anxiety. Journal of Cyber Therapy and Rehabilitation 2013;6(1):28-29 Online First. *Ineligible study design*
- 266. Venuturupalli RS, Chu T, Vicari M, Kumar A, Fortune N, Spielberg B. Virtual Reality-Based Biofeedback and Guided Meditation in Rheumatology: A Pilot Study. ACR open rheumatology 2019;1(10):667-75 Online First. *Ineligible setting or follow-up*
- 267. Vilalta-Abella F, Gutierrez-Maldonado J, Pla-Sanjuanelo J. Development Of A Virtual Environment Based On The Perceived Characteristics Of Pain In Patients With Fibromyalgia. Studies in health technology and informatics 2015;219:158-62 Online First. *Ineligible study design*
- 268. Villiger M, Bohli D, Kiper D, et al. Virtual reality training for the rehabilitation of lower limb motor dysfunction and neuropathic pain after spinal cord injury. Neurorehabilitation and Neural Repair 2012;26(4):398 Online First. *Ineligible study design*
- 269. Vugts MA, Zedlitz AM, Joosen MC, Vrijhoef HJ. Serious Gaming During Multidisciplinary Rehabilitation for Patients With Chronic Pain or Fatigue Symptoms: Mixed Methods Design of a Realist Process Evaluation. Journal of medical Internet research 2020;**22**(3):e14766 Online First. *Ineligible study design*
- 270. Vugts MAP, Joosen MCW, Mert A, Zedlitz A, Vrijhoef HJM. Serious gaming during multidisciplinary rehabilitation for patients with complex chronic pain or fatigue complaints: study protocol for a controlled trial and process evaluation. BMJ open 2017;7(6):e016394 Online First. *Ineligible study design*
- 271. Wake N, Sano Y, Oya R, Sumitani M, Kumagaya SI, Kuniyoshi Y. Multimodal virtual reality platform for the rehabilitation of phantom limb pain. International IEEE/EMBS Conference on Neural Engineering, NER 2015;**2015-July**:787-90 Online First. *Ineligible study design*
- 272. Walter S, Traue HC. Differential effects in the intervention with different forms of virtual reality in the psychological pain treatment. Verhaltenstherapie und Verhaltensmedizin 2015;36(1):66-68 Online First. Not published in English
- 273. Wang J, Anslow C, Robinson B, McCallum S. Extended reality for chronic pain relief. Proceedings of the ACM Symposium on Virtual Reality Software and Technology, VRST 2019 Online First. *Ineligible study design*

- 274. Wiederhold BK, Gao K, Kong L, Wiederhold MD. Mobile devices as adjunctive pain management tools. Cyberpsychology, behavior and social networking 2014;**17**(6):385-9 Online First. *Ineligible study design*
- 275. Wiederhold BK, Miller IT, Wiederhold MD. Using Virtual Reality to Mobilize Health Care: Mobile Virtual Reality Technology for Attenuation of Anxiety and Pain. IEEE Consumer Electronics Magazine 2018;7(1):106-09 Online First. *Ineligible study design*
- 276. Wiederhold BK, Riva G, Wiederhold MD. How can virtual reality interventions help reduce prescription opioid drug misuse? Cyberpsychology, Behavior, and Social Networking 2014;17(6):331-32 Online First. *Ineligible study design*
- 277. Wilson AS, Ramesh A, Carruthers D, connor J. A prototype virtual reality rehabilitation game for complex regional pain syndrome. Proceedings of the European Conference on Games-based Learning 2018;**2018-October**:745-53 Online First. *Ineligible population*
- 278. Winkler SL, Kairalla JA, Cooper R, et al. Comparison of functional benefits of selfmanagement training for amputees under virtual world and e-learning conditions. Journal of Alternative Medicine Research 2018;**10**(1):65-72 Online First. *Ineligible intervention*
- 279. Won AS, Barreau AC, Gaertner M, et al. Assessing the Feasibility of an Open-Source Virtual Reality Mirror Visual Feedback Module for Complex Regional Pain Syndrome: Pilot Usability Study. Journal of medical Internet research 2021;**23**(5):e16536 Online First. *Ineligible study design*
- 280. Wood DP, Wiederhold MD, Spira J, Scholl D, Pyne J, Wiederhold BK. Cybertherapy for combat related posttraumatic stress disorder, pain management and physical rehabilitation following stroke. Coping with posttraumatic stress disorder in returning troops: Wounds of war II. 2010:169-84 Online First. *Ineligible study design*
- 281. Wright C, Babber A, Price S. USING VIRTUAL REALITY IN PATIENTS WITH PALLIATIVE CARE NEEDS. BMJ Supportive and Palliative Care 2019;9(Supplement 4):A71 Online First. *Ineligible study design*
- 282. Xie J, Zeng Q. Application of virtual reality technology combined with moderate perineal protection in natural childbirth. Ginekologia polska 2022 Online First. *Ineligible setting or follow-up*
- 283. Yanagisawa T, Fukuma R, Seymour B, et al. BCI training to move a virtual hand reduces phantom limb pain: A randomized crossover trial. Neurology 2020;**95**(4):E417-E26 Online First. *Ineligible study design*
- 284. Yilmaz DS, Baki AE. Effect of game based exercise programs on pain, functional mobility and balance in patients with knee osteoarthritis: Randomized controlled study. Annals of the Rheumatic Diseases 2019;78(Supplement 2):498-99 Online First. *Ineligible study design*
- 285. Yohannan SK, Tufaro PA, Hunter H, et al. The efficacy of Nintendo WiiTM during post-burn rehabilitation. Journal of Burn Care and Research 2011;**32**(SUPPL. 2):S66 Online First. *Ineligible study design*
- 286. Yohannan SK, Tufaro PA, Hunter H, et al. The utilization of Nintendo R Wii TM during burn rehabilitation: a pilot study. Journal of burn care & research : official publication of the American Burn Association 2012;**33**(1):36-45 Online First. *Ineligible study design*
- 287. Zavala J, Martínez D, Gutiérrez H. Effects of virtual reality added to physiotherapy training in patients with total knee arthroplasty. Fisioterapia 2019;**41**(6):322-28 Online First. *Ineligible study design*



- 288. Zeher MJ, Armiger RS, Burck JM, et al. Using a virtual integration environment in treating phantom limb pain. Studies in Health Technology & Informatics 2011;**164**:730-36 Online First. *Ineligible study design*
- 289. Zhang C. Application effect of virtual reality technology in postoperative pain of patients with vocal cord disease. Chinese Evidence-based Nursing 2021;7(13):1794-97 Online First. *Not published in English*

## **APPENDIX C. ONGOING STUDIES**

Trial #	Study Title	Status	Total N*	Location
KQ1 Studies				
NCT04468074	Virtual Reality Treatment for Adults With Chronic Back Pain	Completed (no publication)	72	Boulder, Colorado, USA
NCT05634291	Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain	Completed (no publication)	36	San Diego, California, USA
NCT05285462	Feasibility of Virtual Reality Delivery of Pain Neuroscience Education	Completed (no publication)	52	Nashville, Tennessee, USA
NCT04849897	Virtual Reality Guided Imagery for Chronic Pain	Completed (no publication)	36	Los Angeles, California, USA
NCT05398549	Effects of Virtual Reality in Adhesive Capsulitis on Pain, Range of Motion and Function	Completed (no publication)	36	Lahore, Punjab, Pakistan
NCT04572074	Virtual Reality for Cancer Pain Management	Completed (only protocol paper)	128	Washington, D.C., USA
NCT05701891	Virtual Reality Integrated Within Physiotherapy for Patients With Complex Chronic Low Back Pain	Recruiting (only protocol paper)	120	Nijmegen, Netherlands
NCT05483816	Multisensory Stimulation to Target Sensory Loss and Chronic Pain in Neuropathic Patients	Recruiting (no publication)	80	Zurich, Switzerland
NCT05172492	Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home	Recruiting (no publication)	120	Bordeaux, Gironde, France
NCT05085821	Cardio-visual Stimulation in Augmented Reality for Pain Reduction	Recruiting (no publication)	50	Nancy, France
NCT02995434	Immersive Multimedia as an Adjunctive Measure for Pain Control in Cancer Patients	Recruiting (no publication)	100	Surrey and Vancouver, British Columbia, Canada
NCT05859321	Virtual Reality Based Physical Therapy for Patients With Lower Back Pain	Recruiting (no publication)	84	Lahore, Punjab, Pakistan
NCT05838924	Changing Lower Back Pain Through Virtual Reality	Recruiting (no publication)	60	Valencia, Spain
NCT05776992	Effect of Various Virtual Reality Exercise Individuals With Low Back Pain	Recruiting (no publication)	52	Istanbul, Turkey

Trial #	Study Title	Status	Total N*	Location
NCT05546749	Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot	Recruiting (no publication)	40	Bronx, New York, USA
NCT05726123	Therapeutic Intervention With Neuromodulation and Inverse Virtual Reality in Patients With Fibromyalgia	Recruiting (no publication)	60	Madrid, Spain
NCT05595317	The Effects of Non-Immersive Virtual Reality Exercises on Muscle Excitability in Knee Osteoarthritis	Recruiting (no publication)	44	Erzurum, Turkey
NCT04867187	rTMS Efficacy Coupled With Mirror Therapy	Recruiting (no publication)	64	Bron and Saint- Étienne, France
NCT05296265	Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain	Recruiting (no publication)	40	Elkins Park and Philadelphia, Pennsylvania, and Seattle, Washington, USA
NCT05254509	Virtual Reality, Debriefing and Chronic Pain	Recruiting (no publication)	50	Pittsburgh, Pennsylvania, USA
NCT04933474	Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain	Recruiting (no publication)	300	Los Angeles, California, USA
NCT05005026	Virtual Walking Intervention for Neuropathic Pain in Spinal Cord Injury	Recruiting (no publication)	250	Birmingham, Alabama & Richmond, Virginia, USA; Sydney, New South Wales, Australia
NCT04906707	Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease (RelieVRx)	Recruiting (no publication)	50	Atlanta, Georgia, USA
NCT05160038	Embodied Virtual Reality for Chronic Pain	Recruiting (no publication)	80	Zurich, Zurich, Switzerland
NCT04907643	Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting (no publication)	360	Los Angeles, California, USA
NCT04253691	Sleep and Pain Intervention for Chronic Insomnia Using Virtual Reality Pilot Study	Recruiting (no publication)	60	Columbia, Missouri, USA
NCT05348174	Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.	Not yet recruiting (only protocol paper)	80	Clemson, Columbia, and Greenville, South Carolina, USA

Trial #	Study Title	Status	Total N*	Location
NCT05971966	Effects of Virtual Reality Rehabilitation and Muscle Energy Technique in Patients With Patellofemoral Pain Syndrome.	Not yet recruiting (no publication)	32	Islamabad, Punjab, Pakistan
NCT05933941	Virtual Reality as a Treatment Tool for Chronic Neck Pain in Patients With Fibromyalgia	Not yet recruiting (no publication)	50	Madrid, Spain
NCT05880511	Augmented Reality Sensorimotor Training to Treat Chronic Neck	Not yet recruiting (no publication)	40	Hamilton, Ontario, Canada
NCT05810428	Artificial Intelligence to Predict Surgical Outcomes and Assess Pain Neuromodulation in Trigeminal Neuralgia Subjects	Not yet recruiting (no publication)	50	Milan, Italy
NCT05639764	Immersive Virtual Reality for Pain-related Movement Dysfunctions in Patients With Chronic Shoulder Pain	Not yet recruiting (no publication)	66	Málaga, Spain
NCT05263037	EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain	Active not recruiting (no publication) <sup>‡</sup>	1093	Van Nuys, California, USA
NCT04241172	TKR Rehabilitation Through the Immersive Virtual Reality in Aquatic Scenarios	Active not recruiting (no publication)	96	Rome, Italy
NCT03592394	Virtual Reality for Chronic Neuropathic Pain	Unknown (no publication)	40	White Plains, New York, USA
NCT04651478	Mental Representation Techniques for the Treatment of Parkinson´s Disease-related Pain	Unknown (only protocol paper)	32	Madrid, Spain
NCT04955613	6Degrees VR System for Treatment of Phantom Limb Pain	Unknown (no publication)	122	Ramat Gan, Israel
NCT04411264	Evaluation of the Effect of Virtual Reality on Pain in the Management of Chronic Wounds.	Unknown (no publication)	124	Limoges and Saint- Pierre, France
NCT04237766	Movement Visualization in Patients With Hemophilic Arthropathy	Unknown (no publication)	140	NR
NCT04966468	Look of Life 2.0. Virtual Reality for Cancer Patients in Home Palliative Care	Unknown (no publication)	60	Bologna, Italy
NCT05088668	Augmented Reality for Shoulder Pain and Scapular Dyskinesis	Suspended	52	Alcala de Henares, Spain
ACTRN12623000745640	Supercharging Chronic Pain Education: Efficacy of Experiential Immersive Education (iED) using Virtual Reality for Pain Beliefs in Adults with Chronic Non-Cancer Pain.	Not yet recruiting	90	Southport, Queensland, Australia
ISRCTN59420095	Trunk Flexion Improvement in People with Low Back Pain Through Visual-Haptic Illusion: A Randomised Controlled Trial	Completed (publication intended 3/31/23)	60	Savona, Italy

Trial #	Study Title	Status	Total N*	Location
ISRCTN12473220	At-Home Virtual Reality as a Therapeutic Approach for Individuals with Chronic Temporomandibular Joint Disorders	Completed (publication intended 12/30/24)	54	Baltimore, Maryland, USA
KQ2 Studies				
NCT04010266	RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use	Active not recruiting (no publication)	113	Danville and Wilkes- Barre, Pennsylvania, USA
NCT03987334	Virtual Reality Rehabilitation in Neck Pain Subjects	Unknown (no publication)	72	Milan, Italy
NCT03476148	Home Rehabilitation Using Interactive Device Versus Inpatient Rehabilitation in Total Knee Arthroplasty	Unknown (no publication)	60	NR

*Notes.* \*Total participants are actual enrolled for completed studies; all others are estimated totals.

<sup>‡</sup> After the database searches were completed, including of registries for clinical trials, a report of this trial was published in December 2023 (Maddox et al 2023, doi: 10.1016/j.mcpdig.2023.09.003).

Abbreviations. NR=not reported; USA=United States of America.

#### APPENDIX D. RISK OF BIAS ASSESSMENTS

#### RANDOMIZED CONTROLLED TRIALS (ROB-2)

Trial Name or Author Year	Bias from randomization process	Bias from deviation from intended interventions (Assignment)	Bias from deviation from intended interventions (Adherence)	Bias from missing outcome data	Bias in measurement of outcome	Bias in selection of reported result	Overall risk of bias (Low, Some concerns, High)
Afzal, 2022 <sup>38</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Low	Some concerns
Ambrosino, 2020 <sup>75</sup>	Some concerns	Low	Low	Low	Some concerns	Some concerns	Some concerns
Bahat, 2020 <sup>90</sup>	Low	Low	Some concerns	Low	Some concerns	Low	Some concerns
Carvalho, 202058	Some concerns	Low	High	High	Some concerns	Some concerns	High
Cetin, 2022 <sup>51</sup>	Low	High	High	High	Some concerns	Low	High
Chuan, 2023 <sup>71</sup>	Some concerns	Low	Some concerns	Low	Low	Low	Some concerns
Collado-Mateo, 2017 <sup>60</sup>	Low	Low	Some concerns	High	Some concerns	Low	High
Cuneo, 2023 <sup>70</sup>	Some concerns	High	High	High	Some concerns	Low	High
Darnall, 2020 <sup>72</sup>	Some concerns	Low	Some concerns	Some concerns	Some concerns	Some concerns	High
Ditchburn, 2020 <sup>76</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	High
Eccleston, 2022 <sup>27</sup>	Low	Low	Some concerns	Low	Low	Low	Some concerns
Eichler, 2019 <sup>84</sup>	Some concerns	Low	Low	High	Some concerns	Low	High
Elshazly, 201666	Some concerns	Low	Low	Low	Some concerns	Some concerns	Some concerns
Fatoye, 2022 <sup>36</sup>	Some concerns	High	High	High	Some concerns	Some concerns	High
Fuchs, 2022 <sup>82</sup>	Some concerns	Low	Some concerns	High	Some concerns	Some concerns	High
Garcia-Palacios, 2015 <sup>64</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	High
Gouveia, 2020 <sup>77</sup>	Low	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns
Groenveld, 2023 <sup>28</sup>	Some concerns	Low	Low	Low	Some concerns	Low	Some concerns
Harvie, 2022 <sup>24</sup>	Low	Low	Low	Low	Some concerns	Low	Some concerns in Domain 4 only
Janhunen, 2023 <sup>85</sup>	Low	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns
Jin, 2018 <sup>83</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	High

Trial Name or Author Year	Bias from randomization process	Bias from deviation from intended interventions (Assignment)	Bias from deviation from intended interventions (Adherence)	Bias from missing outcome data	Bias in measurement of outcome	Bias in selection of reported result	Overall risk of bias (Low, Some concerns, High)
Kammler- Sucker, 2023 <sup>26</sup>	Some concerns	Low	Low	Low	Some concerns	Low	Some concerns
Karahan, 2016 <sup>78</sup>	Low	Low	Low	Low	Some concerns	Some concerns	Some concerns
Kim, 2014 <sup>48</sup>	Some concerns	Low	Low	Low	Some concerns	Some concerns	High
Kim, 2020 <sup>43</sup>	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	High
Lewis, 2021 <sup>79</sup>	Low	Low	Some concerns	High	Some concerns	Low	High
Li, 2021 <sup>39</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	High
Lin, 202067	Some concerns	Low	Low	Low	Some concerns	Low	Some concerns
Maddox, 2022 <sup>32</sup>	Low	Low	Low	Low	Some concerns	Low	Some concerns in Domain 4 only
Mbada, 2019 <sup>50</sup>	High	Low	High	High	High	Some concerns	High
Mete, 2022 <sup>68</sup>	Some concerns	Some concerns	Some concerns	Low	Some concerns	Low	High
Monteiro-Junior, 2015 <sup>46</sup>	Some concerns	High	Low	High	Some concerns	Low	High
Nambi, 2020a <sup>37</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	Some concerns
Nambi, 2020c <sup>69</sup>	Low	Low	Low	Low	Some concerns	Some concerns	Some concerns
Nambi, 2021 <sup>41</sup>	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	High
Nambi, 2021 <sup>42</sup>	Some concerns	Some concerns	Some concerns	Low	Some concerns	Some concerns	High
Nambi, 2022 <sup>35</sup>	Low	Low	Low	Low	Some concerns	Low	Some concerns in Domain 4 only
Nusser, 2021 <sup>52</sup>	Some concerns	High	Low	High	Some concerns	Some concerns	High
Oh, 2014 <sup>49</sup>	Some concerns	Low	Low	High	High	Some concerns	High
Ozlu, 202365	Some concerns	High	High	High	Some concerns	Some concerns	High
Piqueras, 2013 <sup>86</sup>	Low	Low	High	High	Some concerns	Low	High
Polat, 2021 <sup>57</sup>	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns	High
Prvu Bettger, 2020 <sup>87</sup>	Low	Low	Low	Low	Some concerns	Low	Some concerns in Domain 4 only
Reynolds, 2022 <sup>73</sup>	Some concerns	High	High	High	Some concerns	Low	High
Rezaei, 2019 <sup>56</sup>	Some concerns	Low	Low	High	Some concerns	Low	High
Rodriguez- Hernandez, 2021 <sup>92</sup>	Some concerns	Low	Some concerns	High	Some concerns	Low	High

Trial Name or Author Year	Bias from randomization process	Bias from from inter interventi (Assignm	deviation nded ons ent)	Bias from deviation from intended interventions (Adherence)	Bias from missir outcome data	ig Bias in i of outco	measurement ome	Bias in selection of reported result	Overall risk of bias (Low, Some concerns, High)
Rothangel, 2018 <sup>80</sup>	Some concerns	Low		Some concerns	Low	Some co	oncerns	Low	Some concerns
Sarig Bahat, 2015 <sup>55</sup>	Low	Low		Low	Low	Some co	oncerns	Low	Some concerns in Domain 4 only
Sarig Bahat, 2018 <sup>54</sup>	Low	Low		Some concerns	Some concerns	Some co	oncerns	Low	Some concerns
Sato, 2021 <sup>40</sup>	Low	Some con	cerns	Some concerns	Low	Some co	oncerns	Some concerns	High
Shim, 2023 <sup>88</sup>	Low	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns		
Taveggia, 2016 <sup>94</sup>	Low	Some con	cerns	Some concerns	Low	Some co	oncerns	Low	Some concerns
Tejara, 2020 <sup>53</sup>	Low	Low Low		Low	Low	Some co	oncerns	Low	Some concerns in Domain 4 only
Thomas, 2016 <sup>45</sup>	Low	Low		Low	Low	Some co	oncerns	Low	Some concerns in Domain 4 only
Villafaina, 2019 <sup>59</sup>	Low	Low		Low	Some concerns	Some co	oncerns	Low	Some concerns
Wankhade, 2022 <sup>74</sup>	Some concerns	Some concerns		High	Low	Some co	oncerns	Some concerns	High
Yilmaz Yelvar, 2017 <sup>25</sup>	High	Low		High	Low	Some co	oncerns	Some concerns	High
Yoo, 2014 <sup>47</sup>	Some concerns	Low		Low	Low	Some co	oncerns	Some concerns	Some concerns
Zadro, 201944	Low	Low		Some concerns	Low	Some co	oncerns	Low	Some concerns

#### NONRANDOMIZED COMPARISON STUDIES (ROBINS-I)

Study Name or Author Year	Preliminary considerations	Bias due to confounding	Selection bias	Bias in classification of interventions	Bias due to departures from intended interventions	Bias due to measurement of outcomes	Bias due to missing data	Bias in the selection of reported results	Overall risk of bias (Low, Moderate, Serious, Critical, No Information)
Abd-Elsayed, 2021 <sup>91</sup>	Critical								Critical
# **APPENDIX E. CHRONIC BACK PAIN**

# Appendix Table E1. Detailed Characteristics for Included Trials on Chronic Low Back Pain

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
		Participants Randomized	Participants Randomized	-
Risk of Bias				Eligible Outcomes & Measures
		Demographics	Demographics	Reported (Time Points)
Follow-Up Duration				
0:4-(-)		Setting	Setting	Other Non-Eligible Outcomes
Site(s)		-	-	Reported
		Frequency; Duration	Frequency; Duration	
Funding source				
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	

VR Interventions				
Eccleston, 2022 <sup>27</sup>	Inclusion: Adults with LBP ≥3	N=14	N=17	Primary: NR
Some concerns	months, average pain intensity ≥ 4/10 over past week on NRS, ODI ≥26%, and medium (34-41) or high	Age, mean (SD): 55.1 (10.5)	Age, mean (SD): 52.8 (11.19)	Pain-related functioning (8 wk): • ODI
10 Months	(42-68) TSKscore; had clear, flat ground surface at home of at least 2 m <sup>2</sup> using the digital intervention for	Female: 86% Home	Female: 82% Home	PROMIS pain     interference
NR, Finland	pain; and could bend without severe pain.	15-60 minute sessions, 5 sessions per week, for 30 unique days designed to last	15-60 minute sessions, 5 sessions per week, for 30 unique days designed to	Pain intensity (8 wk): <ul> <li>NRS</li> <li>PROMIS pain intensity</li> </ul>
Business Finland	<b>Exclusion:</b> history of epilepsy, migraine, vertigo, or psychosis, a confirmed diagnosis of cancer, susceptibility to motion sickness requiring treatment, pregnancy, current physiotherapy that contraindicated intervention goals, severe or acute structural pathologies that the intervention could make worse, had psychotherapy in the previous 2	DTxP: Mentor guidance and instruction for tasks and building working alliance using an Oculus Quest headset. Participants entered the virtual world from inside cabin then engaged in gamified activities like fruit picking outside. 24 behavior change modules alternated new content and practice.	Relaxation instructions to enjoy virtual summer cabin and lakeshore environment with ambient wildlife sounds using an Oculus Quest headset. No DTxP content provided. N=11 Age, mean (SD): 57.1 (8.3) Female: 100%	Adverse events (8 wk): • Mild, moderate, severe • Treatment-related Pain catastrophizing (8 wk): • TSK Quality of life (8 wk): • European Quality of Life 5
	psychotherapy, reported any condition that affected posture or		Home	Opioid use (5 mo)
	balance, any prior participation in a digital therapeutics intervention for		NA	Pain global change (8 wk): • PGIC
	pain study		Usual care	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized		Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	Noperiou
-		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		N 00		D
Groenveld, 2023 <sup>28</sup>	Inclusion: 18 years and older with	N=20	N=21	Primary: SF-12
Some concerns	(lasting at least 3 months) reporting	Age, mean (SD): 51 (2.9)	Age, mean (SD): 52 (2.5)	Pain-related functioning (4 wk, 4
	higher on an 11-point Likert scale in	Female: 85%	Female: 80%	BPI
4 Months	the week preceding enrollment. Additionally, the person has an	Home	NA	• 001
Rijnstate Hospital, Netherlands	estimated waiting period of at least 6 weeks on the day of recruitment on	Four weeks of thrice daily sessions lasting	NA	<ul> <li>Pain intensity (30 days):</li> <li>VAS</li> </ul>
Nethenands	the waiting list, is not yet receiving treatment, apart from analgesics or	between 10 and 30 minutes.	Usual care	Adverse events (4 mo)
This work was supported by the European Regional Development Fund (ERDF) [PROJ-00840, 2018]	<ul> <li>Exclusion: People with radicular pain that is worse than the CLBP, participating in another trial to evaluate new ways of treating pain, severe anxiety or depression, unable to handle VR due to delirium, dementia, epilepsy, severe hearing/visual impairment, skin of the head or face not intact, and high risk of Meticillin-resistant Staphylococcus aureus</li> </ul>	Pain education and psychological therapy VR treatment using the Oculus Gof. Patients embark on a 'journey' through the nervous system and can play five games, each rooted in different psychological treatment principles.	N=10	Pain Catastrophizing (4 wk, 4 mo):         • PCS         Non-eligible outcomes:         • Pain Coping and Cognition List (PCCL)         • Nottingham Extended Activities of Daily Living (NEADL)         • Positive Health Questionnaire         • Hospital Anxiety and Depression Scale (HADS)
Harvie, 2022 <sup>24</sup>	Inclusion: Adults referred to the Metro South Health Persistent Pain	11-20	IN- IU	Fillidiy. NRO
Some concerns	Management Service for the management of CLBP (duration at	Age, mean (SD): 51.9 (14.5)	Age, mean (SD): 56.9 (14.3)	Pain global change (1 wk): • PGIC
1 Week	least six months), scored at least	Female: 45%	Female: 50%	Pain catastrophizing (1 wk):
I WEEK	moderate on Question 7 (How much bodily pain have you had during the past 4 weeks?') and	Clinic	Clinic	Photograph Series of     Daily Activities
Metro South Health Persistent Pain	Question 8 ('During the past 4 weeks, how much did pain interfere with your normal work [including	1 session, three 6 minute long experiences with 5 minute intervals between each.	1 session, three 6 minute blocks with 5 minute intervals	Physical performance (1 wk):     Maximum grip strength



Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
Management Service, Australia Seeding grant from The Hopkins Centre; Early Career Research Fellowship from the National Health and Medical Research Council of Australia (GNT1142929)	both work outside the home and housework]?') of the SF-36 <b>Exclusion:</b> Diagnosis of, or the presence of red flags, indicating serious spinal pathology (i.e., infection, tumour, recent fracture, significant structural deformity, such as unstable/unstabilized spondylolisthesis or progressive scoliosis, inflammatory disorder, and neuropathic radicular syndrome or cauda equina syndrome). They were also excluded if they had an inability to tolerate visual stimulation (e.g., susceptibility to migraines aggravated by light) or inability to tolerate the head mounted display (e.g., sensitivity to touch around the face and head).	Embodiment experiences and movement (e.g., boxing, creating earthquakes) using the Oculus Rift S head mounted display with touch controllers with three avatar characters: a boxer, superhero, and rock climber using the Oculus Rift S.	VR control condition. Embodiment of cartoon-like virtual hands. Explored 3 scenarios in Vacation Simulator app: built sandcastle, stood in sea at beach, cooked barbecue at beach using the Oculus Rift S.	Non-eligible: • Body image • Embodiment

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Kammler-Sücker, 2023 <sup>26</sup>	Inclusion: Chronic back pain lasting	N=17	N=16	Primary: NR
Some concerns	for more than 6 months and an age of 18–75 years.	Age, mean (SD): 46.1 (17.6)	Age, mean (SD): 51.9 (17.4)	Pain-related functioning (sessions 1-3):
117 Davs	Exclusion: Any acute primary	Female: 71%	Female: 56%	NRS
Th Days	causes for back pain (e.g., injuries or inflammation), acute neurological	Clinic	Clinic	Pain intensity (sessions 1-3):
VR Core Facility at the Center for Innovative Psychiatric and Psychotherapeutic Research (CIPP) at Central Institute for Mental Health (Mannheim, Germany), Gernaby Reinhart Koselleck award of the Deutsche Forschungsgemeinschaft to HF (FL 156/41-1)	inflammation), acute neurological complications, inability or medical prohibition to lift weights of up to 15 kg, and a history of epileptic seizures triggered by flickering lights.	Three sessions at least 4 and a maximum of 117 days apart. Due to the pandemic situation they had to reschedule the participants when there was a ban on laboratory activity. The mean duration between sessions was 13.65 ± 16.08 days. 3D photos taken for avatar creation in AVA. The avatars were animated with prerecorded movements of a healthy model (motion capture with an infrared 12-camera system, OptiTrack, Corvallis, OR). Participants copied movements from virtual models based on previous kinematic studies.	The subsequent three experimental sessions (sessions 1–3) were at least 4 and a maximum of 117 days apart. Due to the pandemic situation they had to reschedule the participants when there was a ban on laboratory activity. The mean duration between sessions was 13.65 ± 16.08 days. Control group watched a virtual 2D screen inside the virtual environment showing a videotaped movement model (VID).	• NRS
Maddox, 2022 <sup>29-33</sup>	<b>Inclusion</b> : People aged 18-85, with self-reported diagnosis of chronic	N=94	N=94	Primary: DVPRS
Some concerns in domain	low back pain without radicular	Age, mean (SD): 51.5 (13.5)	Age, mean (SD): 51.4 (12.9)	<ul> <li>Non-eligible outcomes (8 wk):</li> <li>PROMIS physical</li> </ul>
4 only	an average pain intensity of 4 or	Female: 75.3%	Female: 78.7%	function
18 Months	more out of 10 for the past month.	Home	Home	disturbance
United States	<b>Exclusion:</b> People with gross cognitive impairment, current or prior diagnosis of epilepsy, seizure	56 sessions 2-16 minutes in length for 8 weeks	Each VR experience is 2-16 minutes in length (average of 6 minutes).	
AppliedVR	disorder, dementia, migraines, or other neurological diseases that may prevent the use of virtual reality or	EaseVRx (AppliedVR) incorporates evidence-based principles of CBT, mindfulness, and pain neuroscience	Nonimmersive, 2D content within a VR headset as the most rigorous VR placebo. The Sham VR headset	

Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
	adverse effects medical condition predisposing to nausea or dizziness, hypersensitivity to flashing light or motion, no stereoscopic vision or severe hearing impairment, injury to eyes, face, or neck that impedes comfortable use of virtual reality, cancer-related pain, moderate depressive symptoms as indicated by the Patient Health Questionnaire- 2 (PHQ-2 [44,45]) depression screen score of 2 or more, previous use of EaseVRx for pain, current or recent completion of participation (past 2 months) in any interventional research study, currently pregnant or planning to become pregnant during the study period.	education. Participants complete modules that include pain education, relexation/interoception, mindful escapes, pain distraction games, and dynamic breathing.	displayed 2D nature footage (eg, wildlife in the savannah) with neutral music that was selected to be neither overly relaxing, aversive, nor distracting. The experience of Sham VR is similar to viewing nature scenes on a large-screen television and is not interactive. Twenty videos were rotated over the 56 sessions, with average duration of sessions closely matching those of EaseVRx.	
Yelvar, 2016 <sup>25</sup>	Inclusion: Diagnosis of subacute	N=23	N=23	Primary: NR
High	for disc herniation, spina bifida, or spinal stenosis, no visual problems,	Age, mean (SD): 46.3 (3.4) Female: 45.5%	Age, mean (SD): 52.8 (11.5) Female: 81.8%	Pain-related functioning (2 wk): • ODI
2 Weeks	no nerve root compression, no neurological problems, and patients	Clinic	Clinic	• VAS
Turgut Ozal University Hospital Department of Physical Therapy and Rehabilitation, Turkey NR	who have fear of avoidance.	Five times a week for 2 weeks Embodiment using iPod with video glasses where participants passively viewed a virtual walking video clip and were asked to imagine they were walking. They also underwent physical therapy (15 minutes of hotpack therapy, 15 minutes of TENS, and 5 minutes of deep heat with ultrasound, and therapeutic exercises, including extension exercise, posterior pelvic tilt, cat-camel exercise, and stretching of the lumbar extensor muscle).	Five times a week for 2 weeks Participants underwent physical therapy (15 minutes of hot pack therapy, 15 minutes of TENS, and 5 minutes of deep heat with ultrasound, and therapeutic exercises, including extension exercise, posterior pelvic tilt, cat–camel exercise, and stretching of the lumbar extensor muscle).	<ul> <li>Pain catastrophizing (2 wk): <ul> <li>TSK</li> </ul> </li> <li>Physical performance (2 wk): <ul> <li>Timed-up and go test (TUG)</li> <li>6-minute walk test</li> </ul> </li> <li>Quality of life (2 wk): <ul> <li>Nottingham Health Profile</li> </ul> </li> </ul>

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		Demographics		Eligible Outcomes & Measures Reported (Time Points)
Follow-Up Duration		Soffing	Sotting	Other Non Eligible Outcomes
Site(s)		Setting	Setting	Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	

AR Intervention				
Afzal, 2022 <sup>38</sup>	Inclusion: Adults aged 25-50 with a history of CI BP	N=45	N=45	Primary: VAS
Some concerns		Age, mean (SD): 38.2 (11.8)	Age, mean (SD): 37.5 (12.5)	Pain-related functioning (4 wk)
	<b>Exclusion:</b> "Patients with congenital deformity history of trauma fracture	Female: 69.0 %	Female: 64.3%	
4 Weeks	of the spine, or the lower extremity, any systematic disease, or	Clinic	NR	
Government Services Hospital, Lahore, Pakistan, Pakistan	neurological diseases, those on corticosteroid and pregnant females were excluded."	3 sessions per week for a total of 12 sessions	3 sessions per week for a total of 12 sessions	
None		"kinetic exergames, like the body ball game and reflex ridge, with on-screen display for 5 minutes each, along with RPT patients were subjected to trunk slide flexion, sitting to avoid obstacles, jumping and combined movement of arms for 5 minutes After 30 seconds of rest, the body ball game, including moving arm, head pushing and kicking of ball, for 5 minutes was introduced."	"RPT with 10 minutes of heat therapy by a moist hot pack, and hamstring stretching. Back strengthening exercises included 10 repetition of bridging, prone leg raises, trunk extension in prone with arms behind the back, trunk rotation exercises, knee to chest, and prone position with a diagonal elevation of the arm and the leg."	
Fatoye, 2022 <sup>36</sup>	Inclusion: Patients with LBP of not	N=29	N=28	Primary NR
High	less than 3 months, as determined by the standard McKenzie Institute Lumbar Spine Assessment	Age, mean (SD): 47.6 (11.5)	Age, mean (SD): 48.8 (10.2)	Pain-related functioning (8 wk) <ul> <li>ODI</li> </ul>
8 Weeks	Algorithm. Patients who demonstrated Directional Preference	NR	NR	Non-eligible: Resource use, cost,
	(DP) for extension.	NR	NR	cost-effectiveness
Obafemi Awolowo University; Ladoke	Exclusion: Patients with DP for	Three times a week for 8 weeks	Three times a week for 8 weeks	
Akintola University of	tlexion, positive history of red flags indicative of serious spinal	Microsoft Kinect interactive video game to achieve therapeutic activities comparable	Participants did the McKenzie extension protocol, where they stand	

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s):	Primary Outcome
Risk of Bias				Eligible Outcomes & Measures Reported (Time Points)
Follow-Up Duration				Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Technology Teaching Hospital, Nigeria This research was partially funded by an African Doctoral Dissertation Research Fellowship (ADDRF) re- entry grant awarded by the African Population and Health Research Centre (APHRC) in partnership with the International Development Research	pathology; any obvious spinal deformity or neurological disease; pregnancy; previous spinal surgery; and previous experience of MDT extension protocol, as well as, those with underlying systemic or visceral disease and specific condition such as dementia, cognitive dysfunction, visual impairment and previous history of epilepsy were excluded.	to the McKenzie "extension in standing" protocol. Participants were asked to head virtual balls on the screen as though they were coming towards them, moving only their trunk and head.	upright with feet slightly apart, place their hands on the small of their back, then stretch their trunk backwards as far as they can 10 times.	
Centre (IDRC). Kim, 2014 <sup>48</sup>	Inclusion: Suffer from chronic lower	N=15	N=15	Primary: RMDQ, VAS, ODI
	back pain	Age, mean (SD): 44.3 (NR)	Age, mean (SD): 50.5 (NR)	Pain Catastrophizing (4 wk):
High	Exclusion: None listed	Female: 100%	Female: 100%	• FABQ
4 Weeks		Clinic	Clinic	
A K hospital, Korea		12 sessions over the course of four	Each movement was comprised of two	
NR		weeks, with each session lasting 30 minutes.	sets lasting 30 minutes. One set included 10 repetitions.	
		"A 30-minute virtual reality-based yoga program using Wii Fit activities such as deep breathing, the half-moon pose, warrior pose, tree pose, chest to knee pose, chair pose, and palm tree pose There were seven exercise programs. Three minutes of exercise were performed followed by one minute of rest."	"Trunk stabilizing exercise was performed with contraction exercise for the transverse abdominis and multifidus followed by curl ups in order to contract the rectus abdominis. The dead bug exercise, quadruped opposite arm and leg reach exercises, bridge, side bridge on knees, middle anterior plank position, and balancing on unstable surfaces were performed."	

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias			Domographics	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Kim, 2019 <sup>43</sup>	Inclusion: People aged 20–64 years	N=24	N=24	Primary: NRS
High	with nonspecific LBP lasting at least 3 months, with an average numeric rating scale (NPS) in the provides 7	Age, mean (SD): 26 (3.8)	Age, mean (SD): 28.8 (9.1)	Pain-related functioning (8 wk, 6 mo):
C Martha	days of $\geq 4$ (scale 0–11)	Female: 31.8%	Female: 57.7%	ODI     DNDO
6 Months	<b>Exclusion:</b> Presented with specific	Clinic	Clinic	• KMDQ
Korea University, Republic of Korea	causes of LBP, had other sensory or motor dysfunctions resulting from	16 46-minute sessions over 8 weeks	16 46-minute sessions over 8 weeks	Pain Catastrophizing (8 wk, 6 mo):
NR	neurological disorders, had any cardiovascular or psychological disease, had any other mental or physical limitation, had surgery or trauma within the past 6 months, or were pregnant or planning to become pregnant	Equine therapy using the SHR system, that simulates a horse gait. The workout consists of walking, slow trotting, and fast trotting at a real horse gait.	"The STB exercise with suspension (Redcord AS, Arendal, Norway) consisted of a supine pelvic lift, supine and prone bridging exercise, and side- lying hip abduction Time required to perform each movement was about 10 seconds."	<ul> <li>FABQ work</li> </ul>
		N 44	N 40	Differentin
Li 2021 <sup>39</sup>	<b>Inclusion</b> : People aged between 18 and 40 years with persistent or	N=11	N=12	Primary NR
High	periodic LBP for longer than 3 months, and no referred symptoms	Age, mean (SD): 21.91 (2.4)	Age, mean (SD): 23.75 (4.1)	<ul> <li>Pain-related functioning (2 wk):</li> <li>ODI</li> </ul>
2 Weeks	of radiating pain below the knee or paresthesia during the straight-leg	Female: 72.7%	Female: 83.3%	Pain intensity (2 wk):
	raise test.	Home; Clinic	Home; Clinic	• VAS
Sun Yat-sen University, China	<b>Exclusion:</b> People with a history of pelvic or spinal column surgery in	6 3-minute sessions per day, with a 2 minute break between sessions, 5 days a week for 2 weeks	Approximately 1 30-minute session, 5 days a week for 2 weeks	Non-eligible: Muscle activation times, electromyography
"This research project was supported by the National Natural Science Foundation of China (grant numbers	specific lumbar pathological condition and/or severe or progressive scoliosis, body mass index (BMI) ≥30kg/m2, history of a treatment program within the past	Participants played Fruit Ninja on the Microsoft Kinect, wherein participants waved their hands to crush fruit in the game. Participants were asked to limit	Participants did Motor Control Exercise (MCE) with ultrasound-guided abdominal drawing-in maneuver (ADIM). 3 sets of 10 repetitions holding for 10 sec, with 2 min breaks between sets. Four-point kneeling lifting each	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
82002375, 81772434, and 32071316); the Guangdong Province Medical Science Technology Research Grant (grant number A2019452) and the Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515011356); the Guang zhou Science and Technology Program key projects (grant numbers 201704020122 and 201907010034); and the Non Profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2020-JKCS-005)."	three months, pregnant, history of severe dysfunction of vital organs (heart, lungs, and kidneys) and/or cognitive deficits, and history of visual or hearing problems.	bending their trunk or turning. They also received 20 minutes of magnetic therapy.	arm/leg for 5 sec, 3 reps each with 15 sec breaks. Raised contralateral arm and leg in bird dog position, held 5 sec, 3 reps with 15 sec breaks. They also received 20 minutes of magnetic therapy. N=11 Age, mean (SD): 25.4(3.7) Female: 63.6% Home; Clinic 20 minute sessions, 5 days a week, two weeks Participants received 20 minutes, medium heat level conventional magnetic therapy	
Mbada, 2019 <sup>50</sup>	Inclusion: Adults with long-term	N=28	N=29	Primary: ODI, RMDQ, VAS, TSK, FABO work, FABO physical
High	directional preference for extension.	Age, mean (SD): 32.6 (11.5)	Age, mean (SD): 48.8 (10.2)	Modified Biering-Sørensen test of Static Muscular Endurance
8 Weeks	Exclusion: Patients who	Female: 45.5%	Female: 79.2%	(bSME)
Obafemi Awolowo University (OAU)	for flexion, lateral, or no directional preference.	NR Thrice weekly for 8-week[s]	NR Thrice weekly for 8-week[s]	QoL (8 wk): • SF-12 mental • SF-12 physical
Teaching Hospital, Ile Ife, Nigeria (OAUTHC); Department of Medical Rehabilitation, OAU; and Ladoke Akintola University of Technology Teaching Hospital,		Microsoft Kinect interactive video game to achieve therapeutic activities comparable to the McKenzie "extension in standing" protocol. Participants were asked to head virtual balls on the screen as though they were coming towards them, moving only their trunk and head.	Participants did the McKenzie extension protocol, where they stand upright with feet slightly apart, place their hands on the small of their back, then stretch their trunk backwards as far as they can up to 10 times. Participants also received a 9-item	

Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
Osogbo, Nigeria (LAUTECH), Nigeria This research was partially funded by an African Doctoral Dissertation Research Fellowship re-entry grant awarded by the African Population and Health Research Centre in partnership with the International Development Research Centre (IDRC).			back care education guide on activities of daily living.	
Monteiro-Junior, 2015 <sup>46</sup>	Inclusion: People with chronic lower	N=17	N=17	Primary: NRS, Sit-to-stand test
High	back pain, not participating in systematic exercise program	Age, mean (SD): NR (NR)	Age, mean (SD): NR (NR)	Non-eligible: Balance, Total Mood
8 Weeks	Exclusion: People without medical	Women: 100%	Women: 100%	
	recommendation (Physical Activity Readiness Questionnaire (PAR-	Clinic	Clinic	
⊢ısıoprime Clinical of Physiotherapy, Brazil	Q),who underwent spine surgery, with cancer, with acute	Eight weeks with three sessions a week	Eight weeks with three sessions a week	
NR	musculoskeletal injuries in lower limbs, with neurological illnesses; and with vestibular noncontrolled disorders.	The intervention lasted eight weeks and sessions were performed three times a week. In core exercises the postures adopted by subjects lasted 15-30 seconds or in accordance with the capacity of each person. Each exercise (squat, lunge, chair abductor, chair adductor, leg curl, knee extension, unilateral plantar flexion) was performed three times (i.e., sequential method) with 10 repetitions. Participants also did 30 minutes of virtual physical training (eight exercises) using Nintendo Wii-motion and Wii Balance Board.	Control group performed strength training and core exercises. Weight load was moderate and was increased gradually based on pain reduction. Each exercise was performed in 3 sets of 10 repetitions.	

#### Evidence Synthesis Program

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		Demographice	Demographics	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	•
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Nambi 2020a <sup>37</sup>	Inclusion: University male football	N=15	N=15	Primary: NR
Some concerns	chronic (≥3 months) LBP, and 4 to 8	Age, mean (SD): 21.25 (1.2)	Age, mean (SD): 20.23 (1.6)	Pain intensity (4 wk, 8 wk, 6 mo): • VAS
		Male: 100%	Male: 100%	
6 Months	Exclusion: People with severe	Home; Clinic	Home; Clinic	Physical performance (4 wk, 8 wk, 6 mo):
Prince Sattam bin Abdul Aziz University; University Hospital and King Khalid Hospital, Saudi Arabia Deanship of Scientific Research at Princess Nourah Bint Abdulrahman University through the Fast-track Research Funding Program	musculoskeletal, neural, somatic, and psychiatric conditions, waiting for spine surgery, having alcohol or drug abuse, and involving in other weight and balance training programs were excluded from the study. Participants with other soft tissue injuries, fracture at the lower limbs and pelvic bone, and deformities were also excluded from the study.	30 minute sessions, 5 days a week for 4 weeks Participants used the ProKin system to play a shooting game. The game was controlled by participants moving their trunk back and forth and left and right. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and five minutes ultrasound therapy.	5 days a week for 4 weeks Participants used the Isokinetic Dynamometer to perform extension and flexion exercises consisting of 3 sets of 15 repetitions. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and five minutes ultrasound therapy.	<ul> <li>40 m sprint performance</li> <li>4x5 sprint</li> <li>Submaximal shuttle running</li> <li>Countermovement jump</li> <li>Squat jump</li> </ul> Non-eligible: Self-reported player wellness (Likert scale)
			N=15	-

Age, mean (SD): 20.8 (1.6)

Male: 100%

Home; clinic

5 days per week for 4 weeks

Participants did conventional balance training for core muscles, including active isotonic and isometric exercises for abdominal muscles (ie, internal oblique, external oblique, transverse abdominis, and rectus abdominis) and deep abdominal muscles. They also underwent 20 minutes of hot pack

### Evidence Synthesis Program

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	

therapy and 5 minutes ultrasound therapy.

Nambi, 2020b <sup>42</sup>	Inclusion: University male students	N=20	N=20	Primary: VAS, TSK
High	in the age group of 18–25 years with cLBP (3 months) and 4 to 8 pain intensity on the VAS	Age, mean (SD): 23.2 (1.5) Male: 100%	Age, mean (SD): 22.8 (1.6) Male: 100%	Non-eligible: Stress hormone levels
6 Months	Exclusion: Participants with severe	NR	NR	
Prince Sattam Bin Abdulaziz University Hospital, Al-Kharj; King Khalid Hospital, Saudi Arabia self-funded	musculoskeletal-, neural-, somatic- and psychiatric conditions, who were waiting for spine surgery, with alcohol or drug abuse symptoms, are involved in other weight and balance training programs, have other soft tissue injuries, fracture at the lower limbs and pelvic bone, or deformities.	30 minute sessions 5 days a week for 4 weeks Participants used the ProKin system to play a shooting game. The game was controlled by participants moving their trunk back and forth and left and right. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and five minutes ultrasound therapy. Exercises other than the ones in the protocol were at the decision of the supervising	5 days a week for 4 weeks Participants used the Isokinetic Dynamometer to perform extension and flexion exercises consisting of 3 sets of 15 repetitions. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and five minutes ultrasound therapy. Exercises other than the ones in the protocol were at the decision of the supervising therapist and were documented in the	
		therapist and were documented in the log book.	log book.	

#### Evidence Synthesis Program

Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
			N=20 Age, mean (SD): 23.3 (1.5) Male: 100% NR	

5 days a week for 4 weeks

Participants did conventional balance training for core muscles, including active isotonic and isometric exercises for abdominal muscles (i.e., internal oblique, external oblique, transverse abdominis, and rectus abdominis) and deep abdominal muscles. They also underwent 20 minutes of hot pack therapy and 5 minutes ultrasound

			therapy.	
Nambi, 2021 <sup>41</sup>	Inclusion: Male American university	N=18	N=18	Primary: VAS, TSK
High	with chronic (≥3 mo) LBP, and 4 to 8 pain intensity on a VAS	Age, mean (SD): 22.3(1.6)	Age, mean (SD): 21.9 (1.8)	Non-eligible: Stress hormone levels
	. ,	Male: 100%	Male: 100%	
6 Months	<b>Exclusion:</b> Participants with severe musculoskeletal, neural, somatic,	Home	Home	
King Khalid University Hospital and Department	and psychiatric conditions, as well as those waiting for spine surgery,	30 minutes in each session for 5 days a week for 4 weeks.	5 days a week for 4 weeks	
of Physical Therapy	having alcohol or drug abuse issues,		Participants used the Isokinetic	
Prince Sattam Bin	or involved in other weight and	Participants used the ProKin system to	Dynamometer to perform extension	
Abdulaziz University	other soft tissue injuries, freeture et	play a shooting game. The game was	and flexion exercises consisting of 3	
Saudi Arabia	the lower limbs and pelvic hone, and	controlled by participants moving their	sets of 15 repetitions. They also	
	deformities	trunk back and forth and left and right.	performed a home-based exercise	
ND		I hey also performed a home-based	protocol and underwent 20 minutes of	
NK		exercise protocol and underwent 20	not pack therapy and live minutes	
		minutes of not pack inerapy and live	than the ones in the protocol were at	
		minutes unasound inerapy. Exercises	than the ones in the protocol were at	

#### Evidence Synthesis Program

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized		Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		other than the ones in the protocol were at the decision of the supervising therapist and were documented in the log	the decision of the supervising therapist and were documented in the log book.	

book.

#### N=18

Age, mean (SD): 21.4 (1.8)

Male: 100%

Home

15 times per set for 3 sets, 5 times per week for 4 weeks.

Participants did conventional balance training for core muscles, including active isotonic and isometric exercises for abdominal muscles (i.e., internal oblique, external oblique, transverse abdominis, and rectus abdominis) and deep abdominal muscles. They also underwent 20 minutes of hot pack therapy and 5 minutes ultrasound therapy.

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Nambi, 2023 <sup>35</sup>	Inclusion: Male soccer players aged 18–25 years, chronic non-specific	N=20	N=20	Primary: VAS
Some concerns in domain	LBP for three or more months, and	Age, mean (SD): 23.2 (1.6)	Age, mean (SD): 22.9 (1.7)	Non-eligible: Radiological measures. inflammatory
4 only	10-centimetre VAS	Male: 100%	Male: 100%	biomarkers
4 Weeks	Exclusion: People with lumbar	Clinic	Clinic	
Department of Physiotherapy, Prince	Department of Physiotherapy, Prince Sattam bin Abdulaziz University, Saudi Arabia, Sing Khalid Hospital, Riyadh, Saudi Arabia, Saudi Arabia Department of Physiotherapy, Prince Sattam bin Abdulaziz University Hospital and King Khalid Hospital, Riyadh, Saudi Arabia, Saudi Arabia	Thirty minutes per session, five days a week, for 4 weeks	Thirty minutes per session, five days a week, for 4 weeks	
Sattam bin Abdulaziz University, Saudi Arabia,; University Hospital and King Khalid Hospital, Riyadh, Saudi Arabia, Saudi Arabia Prince Sattam bin		Participants used the ProKin system to play a shooting game. The game was controlled by participants moving their trunk back and forth and left and right. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and five minutes ultrasound therapy	Participants used the Isokinetic Dynamometer to perform extension and flexion exercises consisting of 3 sets of 15 repetitions. They also performed a home-based exercise protocol and underwent 20 minutes of hot pack therapy and 5 minutes ultrasound therapy.	
Abdulaziz University project number	physical training programs		N=20	-
(PSAU/2023/R/1444)			Age, mean (SD): 22.8 (1.8)	
			Male: 100%	
			Clinic	
			Thirty minute per session, five days a week, for 4 weeks	
			Participants did conventional balance training for core muscles, including active isotonic and isometric exercises for abdominal muscles (i.e., internal oblique, external oblique, transverse abdominis, and rectus abdominis) and deep abdominal muscles. They also underwent 20 minutes of hot pack	

# Evidence Synthesis Program

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias				Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	

therapy and 5 minutes ultrasound therapy.

Oh, 2014 <sup>49</sup>	Inclusion: Complaining of back pain	N=10	N=9	Primary: VAS
Hiah	in everyday life for over 3 months	Age, mean (SD): 20.6 (0.7)	Age, mean (SD): 20.3(0.5)	
. iigii	Exclusion: Past or present	Male: 100%	Male: 100%	
8 Weeks	neurological, hypertension, cardiopulmonary diseases, and operation for lower back pain	Clinic	Clinic	
Hanseo University, Korea		10 min (short period) a day for 5 days a week for 8 weeks	20 min (middle period) a day for 5 days a week for 8 weeks	
NR		Equine therapy using a horse simulator machine to perform a 5 minute warm-up, walking for 5 minutes, then 4 maximal warm-up and 4 maximal test repetitions.	Equine therapy using a horse simulator machine to perform a 5 minute warm- up, walking for 5 minutes, then 4 maximal warm-up and 4 maximal test repetitions.	
			N=10	-
			Age, mean (SD): 20.4 (0.3)	
			Male: 100%	
			Clinic	
			8 weeks	
			Equine therapy using a horse simulator machine to perform a 5 minute warm- up, walking for 5 minutes, then 4 maximal warm-up and 4 maximal test repetitions.	

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Follow-Up Duration		Setting	Setting	Other Non-Fligible Outcomes
Site(s)				Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
			N=9	
			Age, mean (SD) 20.7 (0.4)	
			Male: 100%	
			NA	
			8 weeks	
			Usual care	
Sato, 2021 <sup>40</sup>	Inclusion: People with low back	N=20	N=20	Primary: VAS
High	months and were referred to the	Age, mean (SD): 49.3 (12.59)	Age, mean (SD): 55.6 (11.0)	Pain catastrophizing (8 wk)
	improvement after receiving	Female: 55%	Female: 40%	• TSK
8 Weeks	conservative treatment at another orthopedic clinic	NR	Clinic	Non-eligible: pain self-efficacy
Chiba University Hospital, Japan	<b>Exclusion:</b> People with nerve stenosis whose symptoms could be explained on magnetic resonance	One 40 minute session a week for 8 weeks	Patients came in every 2 weeks to be interviewed for pain. Medication doses, frequency and duration were not	questionnaire (PSEQ)
	imaging (MRI), severe intermittent claudication (100 meters or less), cases where lower limb manual muscle tests were graded 4/5 or less, or patients who were unable to ambulate independently, a history of spinal surgery within 1 year, restricted movement due to heart disease or other diseases, receiving exercise therapy at a health care facility during the study period, and significant cognitive impairment	Adventure game. In Adventure Mode, the player controls the character by jogging or squatting. In a battle scene, in addition to an aerobics menu, intensive resistance training and yoga exercises that exert stress on the muscles of the whole body are aimed at defeating the enemy and clearing the stage. They continued taking already prescribed medication.	New oral treatments were given to each patient in the following order: (1) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), (2) tramadol, and (3) duloxetine. Each drug was started at the standard dose; if pain relief was not adequate, then the dose was gradually increased to its highest recommended level. If pain relief was still inadequate, the next drug was added.	

Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
Thomas, 2016 <sup>45</sup>	Inclusion: LBP category 1-3	N=27	N=26	Primary: VAS
Some concerns in domain 4 only	(Classification System of the Quebec Task Force on Spinal Disorders)	Age, mean (SD): 23.9 (6.8) Female: 46.2%	Age, mean (SD): 26.7 (8.5) Female: 50.0%	Pain-related functioning (4 days): • RMDQ
12 Days Ohio University, US NR	Exclusion: Age <18 or >50; LBP duration < 3 months and has not sought treatment; Tampa Scale for Kinesiophobia score < 35; health conditions that preclude safe participation; personal history of spine surgery or hip arthroplasty; currently taking narcotic pain medication; currently receiving treatments for back pain; personal history of exclusionary neurological, cardiorespiratory, or musculoskeletal disorders; active cancer or reports recent, unexplained weight loss; is blind; reports being pregnant; current or pending litigation related to back pain; clinically significant range for substance abuse (DAST>6), alcohol abuse (AUTID- C>7 for males and > 6 for females)	Clinic 3 sessions, separated by no more than 48 hours The virtual dodgeball intervention was displayed on a 60 inch high definition 3D- TV. The participant played dodgeball against four virtual opponents in a basketball arena. The participant had to attempt to block or duck balls launched by the opponents. The intervention consisted of 3 sessions, separated by no more than 48 hours.	NA NA Usual care	<ul> <li>RMDQ</li> <li>Adverse events (4 days)</li> <li>Pain catastrophizing (4 days):         <ul> <li>TSK</li> </ul> </li> <li>Non-eligible: Lumbar spine flexion, Game experience survey, Center for Epidemiological Studies - Depression</li> </ul>

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias	S Duration	Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Yoo, 2014 <sup>47</sup>	Inclusion: Complaining of back pain	N=24	N=23	Primary: VAS
Some concerns	months	Age, mean (SD): 20.4 (1.3)	Age, mean (SD): 20.7 (1.45)	Non-eligible: Night pain, exercise, drug relief, stiffness,
8 Weeks	Exclusion: Past or present	Male: 100%	Male: 100%	walking freedom, walking discomfort_standing still
0 Weeks	neurological, hypertension or cardiopulmonary diseases, chronic	Clinic	NA	twisting, hard chair, soft chair,
Hanseo University Hospital, Korea	disease and spine surgery.	3 days a week for 8 weeks	None	interference, work modification,
			Usual care	PT, Extensor PTBW, PT ratio,
NR		using a horse simulator machine. They		extensor TWBW, TW ratio
		first completed a 10-minute warm-up, then did the completed the work out		
		phase (including walking, sitting trotting,		
		minute cool-down.		
Zadro, 2019 <sup>44</sup>	Inclusion: Older than 55,	N=30	N=30	Primary: PSEQ, FEQ-I
	nonspecific mechanical LBP for at	Age. mean (SD): 68.8 (5.5)	Age, mean (SD): 67.8 (6)	Pain-related functioning (8 wk):
Some concerns	of $\geq$ 3 out of 10 on the numeric rating			PSFS
8 Weeks	scale, sufficient English language ability to understand exercise	Women: 30%	Women: 21.7%	RMDQ
	instructions, ability to mobilize	Home	Home	Pain intensity (8 wk):
The University of Sydney (participants from the	independently without the use of walking aids, access to a high-	Three 60 minute sessions a week for 8	NA	NRS
community)Outpatient	definition multimedia-interface-	weeks	Usual care	Pain catastrophizing (8 wk):
Physiotherapy Department of Westmead	compatible television at nome.	Wii U console with Wii Fit U software. PT		
Hospital (participants on	Exclusion: Diagnosis of serious	visited home, set up equipment, guided first 1-2 hour session. Preselected		
the waiting list), Australia	pathology in the spine (such as fracture, metastatic disease, spinal	flexibility, bodyweight, aerobic exercises		
NR	stenosis, or caudaequina	to encourage progression, monitor		
	syndrome), evidence of nerve root	adverse events. Used symptoms in 24 hrs		

#### Evidence Synthesis Program

Author, Year Risk of Bias Follow-Up Duration Site(s) Funding source	Inclusion/Exclusion Criteria	Intervention: Participants Randomized Demographics Setting Frequency; Duration Detailed Intervention Characteristics	Comparator(s): Participants Randomized Demographics Setting Frequency; Duration Detailed Comparator Characteristics	Primary Outcome Eligible Outcomes & Measures Reported (Time Points) Other Non-Eligible Outcomes Reported
	compromise, any medical condition or disability that will prevent participation in the exercise program, including:, cardiovascular risk factors assessed with the PAR- Q, a screening tool recommended for all adults willing to initiate an exercise program, cognitive limitations, as indicated by a score of < 25/30 on the Mini-Mental State Examination, a reliable and valid test of cognitive function, high risk of falls, as indicated by a score of > 15 on the Falls Risk Assessment Tool, a reliable measure of the risk of falls in older adults, physical therapist treatment for LBP in the preceding 6 months.	after to guide increasing/decreasing duration and intensity.		

Abbreviations: BPI=Brief Pain Inventory; DVPRS-II=Defense and Veterans Pain Rating Scale; FABQ=Fear Avoidance Beliefs Questionnaire; MODI=Modified Oswestry Disability Index; NR=not reported; ODI=Oswestry Disability Index; PCS=Pain Catastrophizing Scale; PGIC=Patient Global Impression of Change; PSFS=Patient Specific Functional Scale; QoL=quality of life; RMDQ=Roland-Morris Disability Questionnaire; SF-12=Short Form Health Survey; VAS=Visual Analog Scale.

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Pain-Related Fu	unctioning or Interfe	rence		
Afzal, 2022 <sup>38</sup> AR Some concerns	MODI	69.2 (9.1) 4 wk: 16.0 (6.8), -53.1*	65.1 (8.9) 4 wk: 40.6 (8.6), -24.5*	Diff ∆*: 4 wk: -28.6
Eccleston, 2022 <sup>27</sup> VR	ODI	36.0 (7.6) 8 wk: 28.8 (15.6), -7.2*	VR control 37.2 (9.4) 8 wk: 38.5 (16.2), 1.3*	Diff ∆*: 8 wk: -8.5
Some concerns			Usual care 36.2 (7.6) 8 wk: 32.8 (8.6), -3.4*	Diff ∆*: 8 wk: -3.8
	PROMIS pain interference	64.5 (3.7) 8 wk: 59.0 (6.6), -5.5*	VR control 63.1 (3.4) 8 wk: 62.6 (5.3), -0.5*	Diff ∆*: 8 wk: -5.0
			Usual care 63.1 (2.5) 8 wk: 60.9 (3.8), -2.2*	Diff ∆*: 8 wk: -3.3
Fatoye, 2022 <sup>36</sup> AR High	ODI	14.2 (9.4) 8 wk: 3.5 (3.5), -10.7*	21.1 (10.7) 8 wk: 6.8 (5.1), -14.4*	Diff ∆*: 8 wk: 3.7
Groenveld, 2023 <sup>28</sup> VR	ODI	40.1 (19.1) 4 wk: 32.4 (15.1), -7.7* 4 mo: 37.3 (14.5), -2.8*	42.8 (18.8) 4 wk: 38.8 (17.7), -4.0* 4 mo: 40.9 (17.6), -1.9*	Diff ∆*: 4 wk: -3.7 4 mo: -0.9
Some concerns	BPI-Interference	5.9 (1.7) 4 wk: 4.1 (2.4), -1.8* 4 mo: 4.6 (2.1), -1.3*	6.3 (2.0) 4 wk: 4.8 (2.5), -1.5* 4 mo: 5.2 (2.0), -1.1*	Diff ∆*: 4 wk: -0.3 4 mo: -0.2
Kammler-Sück er, 2023 <sup>26</sup> VR	NRS	2.7 (2.0) Session 2 (~14 days): 2.5 (2.2), -0.2*	1.7 (1.8) Session 2 (~14 days): 2.3 (2.4), 0.5*	Diff ∆*: Session 2 (~14 days): -0.7
Some concerns		Session 3 (~27 days): 2.2 (2.2), -0.4*	Session 3 (~27 days): 1.7 (2.1), 0.0*	Session 3 (~27 days): -0.4
Kim, 2014 <sup>48</sup> AR	ODI	34.9 (6.2) 4 wk: 13.8 (7.7), -21.1*	36.2 (5.0) 4 wk: 24.6 (10.9), -11.6*	Diff ∆*: 4 wk: -9.5
High	RMDQ	18.6 (2.8) 4 wk: 7.5 (4.8), -11.2*	19.1 (2.9) 4 wk: 12.6 (6.5), -6.5*	Diff ∆*: 4 wk: -4.7
Kim, 2019 <sup>43</sup> AR High	ODI	20.2 (7.7) 4 wk: 14.7 (8.1), -5.52* 8 wk: 11.6 (9.0), -8.7* 6 mo: 8.3 (6.3), -12.0*	21.8 (7.1) 4 wk: 19.5 (9.3), -2.3* 8 wk: 14.8 (9.4), -7.0* 6 mo: 9.2 (3.3), -12.5*	Diff ∆*: 4 wk: -3.21 8 wk: -1.7 6 mo: 0.6
	RMDQ	7.0 (4.4) 4 wk: 3.3 (3.8), -5.2* 8 wk: 2.9 (4.5), -4.1* 6 mo: 1.9 (1.2), -5.2*	5.1 (2.7) 4 wk: 4.8 (2.5), -3.3* 8 wk: 2.5 (2.3), -2.7* 6 mo: 1.8 (1.1), -3.3*	Diff ∆*: 4 wk: -3.4 8 wk: -1.4 6 mo: -1.8

# Appendix Table E2. Detailed Results for Chronic Low Back Pain Studies



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Li 2021 <sup>39</sup>	ODI	15.7 (6.4)	MCE	Diff $\Delta$ *:
AR		2 wk: 12.8 (6.3), -2.9*	18.4 (9.4)	2 wk: 1.3
High			2 wk: 14.3 (21.3), -4.1*	
			CG	Diff $\Delta$ *:
			12.7 (4.8)	2 wk: 0.2
			2 wk: 9.6 (7.2), -3.1*	
Maddox,	DVPRS-II overall	4.8 (NR)	5.1 (NR)	Diff ∆*:
2022 <sup>32,33</sup>	interference	8 wk: 2.3 (NR), -2.5*	8 wk: 3.3 (NR), -1.8*	8 wk: -0.7
VR		3 mo: 2.7 (NR), -2.1*	3 mo: 3.8 (NR), -1.3*	3 mo: -0.8
Some		4 mo: 2.9 (NR), -1.9*	4 mo: 4.1 (NR), -1.0*	4 mo: -0.9
concerns in		5 mo: 3.1 (NR), -1.7*	5 mo: 4.1 (NR), -1.0*	5 mo: -0.7
Domain 4 Only		8 mo: 3.0 (2.6), -1.8*	8 mo: 4.2 (2.2), -0.9*	8 mo: -0.9
		20 mo: 3.3 (2.7), -1.5*	20 mo: 4.3 (2.5), -0.8*	20 mo: -0.7
		26 mo: 2.8 (2.1), -2.0*	26 mo: 3.8 (2.3), -1.3*	26 mo: -0.7
Mbada, 2019 <sup>50</sup>	ODI	18.7 (NR)	27.8 (NR)	Diff $\Delta$ *:
AR		8 wk: 21.1 (NR), 2.4*	8 wk: 25.7 (NR), -2.1*	8 wk: 4.5
High	RMDQ	6.8 (NR)	11.3 (NR)	Diff ∆*:
		8 wk: 5.7 (4.7), -1.1*	8 wk: 8.9 (4.1), -2.4*	8 wk: 1.3
Yilmaz Yelvar.	ODI	20.7 (7.2)	26.1 (11.0)	Diff ∆*.
2016 <sup>25</sup>	•=-	2 wk: 16.9 (5.5)3.8*	2 wk: 21.1 (9.9)5.1*	2 wk <sup>.</sup> 1 2
VR		(),	(,,	2
High				
Zadro, 2019 <sup>44</sup>	RMDQ	6.3 (4.8)	7.4 (5.2)	Diff $\Delta$ *:
AR		8 wk: 4.9 (4.5), -1.4*	8 wk: 6.4 (4.4), -1.0*	8 wk: -0.4
Some	PSFS	5.3 (1.4)	4.3 (2.1)	Diff ∧*:
concerns		8 wk: 6.5 (2.1), 1.2*	8 wk: 4.8 (2.5), 0.5*	8 wk: 0.7
Pain Intensity or	r Severity			
Afzal 2022 <sup>38</sup>	VAS	65(12)	66(10)	Diff A*:
AR	1110	4 wk: 1 0 (0 6) -5 5*	$4 \text{ wk} 33(08) -33^*$	4 wk <sup>-</sup> -2 2
Some concerns		(0.0), 0.0		
Eccleston.	NRS	6.0 (1.4)	VR control	Diff ∧*:
2022 <sup>27</sup>		8 wk: 4.1 (1.7)1.9*	6.1 (1.4)	8 wk: -0.6
VR			8 wk: 4.8 (2.3), -1.3*	
Some			Usual care	Diff A*:
concerns			57(16)	8 wk: -0.6
			8 wk: 4.4 (2.4)1.3*	6 WK. 0.0
	PROMIS pain	66.5 (4.1)	VR control	Diff A*
	intensity	8 wk: 60.0 (7.5) -6.5*	65 1 (5 4)	8 wk: -3 3
	-		8 wk: 61.9 (8.3), -3.2*	0 0.0
			Usual care	Diff ∆∗:
			63.0 (5.5)	8 wk: -4.5
			8 wk: 61.0 (5.9), -2.0*	0 ma 1.0
Groenveld	VAS – Daily	6.1 (NR)	7.0 (NR)	Diff ∆∗:
2023 <sup>28</sup>	Worst	30 days: 5.3 (NR), -0.8*	30 days: 6.8 (NR), -0.2*	30 davs: -0.6
VR	VAS – Dailv Least	3.7 (NR)	4.1 (NR)	Diff ∧*:



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Some concerns		30 days: 4.1 (NR), 0.4*	30 days: 4.9 (NR), 0.8*	30 days: -0.4
Harvie, 2022 <sup>24</sup> VR Some concerns in Domain 4 only	NRS, average pain over past week	6.4 (1.4) <sup>†</sup> 1 wk: 6.1 (1.3) <sup>†</sup> , -0.3*	6.6 (2.7) <sup>†</sup> 1 wk: 5.8 (1.9) <sup>†</sup> , -0.8*	Diff ∆*: 1 wk: 0.5
Kammler-Sück er, 2023 <sup>26</sup> VR Some concerns	NRS	2.6 (1.1) 14 days: 2.4 (1.8), -0.2* 27 days: 2.5 (2.1), -0.1*	1.9 (1.6) 14 days: 2.1 (2.3), 0.2* 27 days: 1.8 (1.7), -0.1*	Diff ∆*: 14 days: -0.4 27 days: 0.02
Kim, 2014 <sup>48</sup> AR High	VAS	7.0 (0.9) 4 wk: 2.3 (1.1), -4.7*	7.0 (0.8) 4 wk: 4.6 (1.9), -2.3*	Diff ∆*: 4 wk: -2.4
Kim, 2019 <sup>43</sup> AR High	NRS	4.7 (1.0) 4 wk: 2.25 (1.06),-2.45* 8 wk: 1.3 (0.9), -3.4* 6 mo: 1.4 (1.3), -3.3*	4.7 (0.8) 4 wk: 2.09 (1.46), =2.64* 8 wk: 1.6 (1.6), -3.1* 6 mo: 1.2 (1.0), -3.5*	Diff ∆*: 4 wk: 0.19 8 wk: -0.3 6 mo: 0.2
Li 2021 <sup>39</sup> AR High	VAS	4.4 (1.4) 2 wk: 3.2 (1.1), -1.2*	MCE 4.6 (1.8) 2 wk: 2.2 (1.9), -2.4*	Diff ∆*: 2 wk: 1.2
			CG 3.6 (1.4) 2 wk: 2.2 (1.2), -1.5*	Diff ∆*: 2 wk: 0.3
Maddox, 2022 <sup>32,33</sup> VR Some concerns in Domain 4 only	DVPRS-pain intensity	5.1 (1.2) 8 wk: 3.0 (0.8), -2.2* 3 mo: 3.6 (NR), -1.5* 4 mo: 3.8 (NR), -1.3* 5 mo: 3.7 (NR), -1.4* 8 mo: 3.6 (2.2), -1.5* 20 mo: 4.2 (2.2), -0.9* 26 mo: 3.9 (2.1), -1.2*	5.2 (1.1) 8 wk: 4.0 (0.8), -1.2* 3 mo: 4.4 (NR), -0.8* 4 mo: 4.5 (NR), -0.7* 5 mo: 4.5 (NR), -0.7* 8 mo: 4.6 (1.8), -0.6* 20 mo: 5.3 (1.9), 0.1* 26 mo: 4.5 (2.0), -0.7*	Diff ∆*: 8 wk: -1.0 3 mo: -0.7 4 mo: -0.6 5 mo: -0.7 8 mo: -0.9 20 mo: -1.0 26 mo: -0.5
Mbada, 2019 <sup>50</sup> AR High	VAS	4.1 (1.8) 8 wk: 3.5 (1.7), -0.6*	5.0 (1.9) 8 wk: 3.5 (2.3), -1.5*	Diff ∆*: 8 wk: 0.9
Monteiro- Junior, 2015 <sup>46</sup> AR High	NRS	6.5 (1.1) 8 wk: 1.7 (1.9), -4.8*	6.6 (1.2) 8 wk: 1.4 (2.9), -5.2*	Diff ∆*: 8 wk: 0.4
Nambi 2020 <sup>37</sup> AR Some concerns	VAS	7.1 (0.6) 4 wk: 3.9 (0.5), -3.2* 8 wk: 1.2 (0.4), -5.9* 6 mo: 0.8 (0.4), -6.3*	IKT-G 7.3 (0.5) 4 wk: 4.8 (0.4), -2.5* 8 wk: 2.7 (0.3), -4.6* 6 mo: 1.9 (0.3), -5.4*	Diff ∆*: 4 wk: -0.7 8 wk: -1.3 6 mo: -0.9
			Control-G 7.3 (0.6) 4 wk: 6.2 (0.4), -1.1*	Diff ∆*: 4 wk: -2.1 8 wk: -4.0



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
		¥	8 wk: 5.4 (0.4), -1.9* 6 mo: 4.2 (0.5), -3.1*	6 mo: -3.2
Nambi, 2020b <sup>42</sup> AR High	VAS	7.5 (0.4) 4 wk: 2.4 (0.2), -5.1* 6 mo: 0.6 (0.1), -6.9*	7.3 (0.3) 4 wk: 2.7 (0.3), -4.6* 6 mo: 0.9 (0.2), -6.4* 7.4 (0.4) 4 wk: 4.5 (0.4), -2.9* 6 mo: 3.5 (0.3), -3.9*	Diff ∆*: 4 wk: -0.5 6 mo: -0.5 Diff ∆*: 4 wk: -2.2 6 mo: -3.0
Nambi, 2021 <sup>41</sup> AR High	VAS	7.8 (0.6) 4 wk: 1.8 (0.3), -6.0* 6 mo: 0.5 (0.2), -7.3*	CPR 7.5 (0.5) 4 wk: 3.6 (0.4), -3.9* 6 mo: 2.8 (0.3), -4.7* Control 7.6 (0.4) 4 wk: 3.8 (0.5), -3.8*	Diff Δ*: 4 wk: -2.1 6 mo: -2.6 Diff Δ*: 4 wk: -2.2 6 mo: -2.9
Nambi, 2023 <sup>35</sup> AR Some concerns in Domain 4 only	VAS	7.2 (0.4) 4 wk: 1.8 (0.3), -5.4*	6 mo: 3.2 (0.2), -4.4*\ Isokinetic 7.3 (0.3) 4 wk: 2.5 (0.5), -4.8* Conventional exercise 7.2 (0.3) 4 wk: 4.8 (0.4) - 2.4*	Diff Δ*: 4 wk: -0.6 Diff Δ*: 4 wk: -3.0
Oh, 2014 <sup>49</sup> AR High	VAS	Horse simulator 30 minutes 5.6 (0.7) 8 wk: 3.4 (1.0), -2.1 Horse simulator 20 minutes 4.9 (0.5)	Control 3.1 (0.6) 8 wk: 3.8 (0.9), 0.7*	Diff ∆*: 8 wk: -2.8 Diff ∆*: 8 wk: -4.5
		8 wk: 1.1 (0.1), -3.8" Horse simulator 10 minutes 3.8 (0.5) 8 wk: 1.4 (0.4), -2.3*	-	Diff ∆*: 8 wk: -3.0
Sato, 2021 <sup>40</sup> AR High	VAS	7.4 (2.0) 8 wk: 4.8 (3.0), -2.6*	7.0 (0.9) 8 wk: 6.6 (1.1), -0.4*	Diff ∆*: 8 wk: -2.2
Yilmaz Yelvar, 2016 <sup>25</sup> VR High	VAS	6.0 (1.1) 2 wk: 2.5 (1.8), -3.5*	5.6 (2.4) 2 wk: 4.9 (3.4), -0.7*	Diff ∆*: 2 wk: -2.8
Yoo, 2014 <sup>47</sup> AR Some concerns	VAS	4.4 (2.1) 8 wk: 2.2 (2.2), -2.1*	1.5 (0.1) 8 wk: 1.0 (0.0), -0.5*	Diff ∆*: 8 wk: -1.6
Zadro, 2019 <sup>44</sup> AR Some concerns	NRS	5.2 (1.6) 8 wk: 3.8 (2.4), -1.4*	4.8 (1.7) 8 wk: 4.4 (2.3), -0.4*	Diff ∆*: 8 wk: -1.0

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Adverse Events	;			
Eccleston, 2022 <sup>27</sup> VR Some concerns	NR	DTxP (n=12) All: 12 (100%) Mild: 4 (33%) Moderate: 10 (83%) Severe: 6 (50%) Treatment-related: 3 (25%) Serious: 0	VR control (n=17) All: 14 (83%) Mild: 6 (35%) Moderate: 11 (65%) Severe: 5 (29%) Treatment-related: 6 (35%) Serious: 0	Diff ∆*: All: 18% Severe: 21%
			Usual care (n=11) All: 7 (64%) Mild: 2 (18%) Moderate: 6 (55%) Severe: 4 (36%) Treatment-related: 2 (18%) Serious: 0	Diff ∆*: All: 36% Severe: 14%
Groenveld, 2023 <sup>28</sup> VR Some concerns	NR	3 (20%) reported mild and temporary symptoms of dizziness	No AEs assessed	Diff ∆: NC
Thomas, 2016 <sup>45</sup> AR Some concerns in Domain 4 only	NR	No AEs reported	No AEs reported	Diff ∆*: 4 days: 0
Pain Catastroph	nizing & Kinesiophob	ia		
Eccleston, 2022 <sup>27</sup> VR Some concerns	TSK	41.9 (4.4) 8 wk: 33.7 (7.4), -8.2*	VR control 43.2 (6.0) 8 wk: 43.1 (8.5), -0.1*	Diff ∆*: 8 wk: -8.1
			Usual care 42.5 (5.4) 8 wk: 39.8 (7.1), -2.7*	Diff ∆*: 8 wk: -5.5
Groenveld, 2023 <sup>28</sup> VR Some concerns	PCS	21.7 (12.2) 4 wk: 23.4 (13.8), 1.7* 4 mo: 23.9 (12.5), 2.2*	24.7 (7.8) 4 wk: 25.7 (9.5), 1.0* 4 mo: 27.1 (9.7), 2.4*	Diff ∆*: 4 wk: 0.7 4 mo: -0.2
Kim, 2014 <sup>48</sup> AR High	FABQ	65.5 (9.6) 4 wk: 17.6 (10.7), -47.9*	70.8 (4.6) 4 wk: 41.6 (18.0), -29.2*	Diff ∆*: 4 wk: -18.7
Kim, 2019 <sup>43</sup> AR High	FABQ-physical	15.4 (4.1) 4 wk: 9.0 (3.64), -6.4* 8 wk: 8.8 (5.9), -6.6* 6 mo: 4.1 (4.1), -11.2*	11.9 (5.6) 4 wk: 16.3 (9.55), 4.4* 8 wk: 11.1 (9.1), -0.8* 6 mo: 9.7 (7.1), -2.3*	Diff ∆*: 4 wk: -10.8 8 wk: -5.7 6 mo: -8.9



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
	FABQ-work	17.1 (5.3)	20.5 (7.9)	Diff ∆*:
		4 wk: 15.2 (7.1), -1.9*	4 wk: 22.4 (5.62), 1.9*	4 wk: -3.78
		8 wk: 11.4 (7.5), -5.7*	8 wk: 14.7 (6.5), -5.8*	8 wk: 0.1
		6 mo: 13.9 (7.1), -3.3*	6 mo: 16.5 (9.0), -4.0*	6 mo: 0.7
Mbada, 2019 <sup>50</sup>	FABQ-work	21.2 (NR)	25.7 (NR)	Diff ∆*:
AR		8 wk: 24.5 (NR), 3.3*	8 wk: 22.6 (NR), -3.1*	8 wk: 6.4
High	TSK	16.5 (NR)	29.9 (NR)	Diff ∆∗·
		8 wk: 28.8 (NR), 12.3*	8 wk: 18.7 (NR), -11.2*	8 wk: 23.5
Nambi	TSK	57 5 (4 8)	ІКТ	Diff A*
2020b <sup>42</sup>		4 wk: 26.4 (3.5)31.1*	58.1 (4.5)	4 wk <sup>·</sup> -0 5
AR		6 mo: 20.1 (2.5), -37.4*	4 wk: 27.5 (3.8), -30.6*	6 mo: -0.5
High			6 mo: 21.2 (2.4), -36.9*	
			Control	Diff ∆*:
			57.9 (4.3)	4 wk: -19.4
			4 wk: 46.2 (4.1), -11.7*	6 mo: -18.1
			6 mo: 38.6 (3.9), -19.3*	
Nambi, 2021 <sup>41</sup>	TSK	56.5 (3.2)	CPR	Diff ∆*:
AR		4 wk: 28.3 (3.3), -28.1*	58.0 (3.8)	4 wk: -8.7
High		6 mo: 20.1 (2.8), -36.4*	4 wk: 38.5 (3.5), -19.5*	6 mo: -8.0
			6 mo: 29.7 (2.2), -28.4*	
			Control	Diff ∆*:
			57.7 (4.1)	4 wk: -15.9
			4 wk: 45.4 (3.3), -12.3*	6 mo: -17.8
			6 mo: 39.1 (2.9), -18.6*	
Sato, 2021 <sup>40</sup>	PCS	43.5 (8.0)	40.8 (0.0)	Diff ∆*:
AR		8 wk: 39.9 (7.8), -3.6*	8 wk: 42.1 (6.9), 1.4*	8 wk: -4.9
High	TSK	42.5 (5.9)	38.9 (5.4)	Diff ∆*:
		8 wk: 39.7 (4.6), -2.8*	8 wk: 36.2 (3.2), -2.7*	8 wk: -0.1
Yilmaz Yelvar,	Tampa Scale of	43.7 (4.3)	40.4 (5.6)	Diff ∆: NC
2016 <sup>25</sup>	Kinesiophobia	2 wk: 29.6 (4.0), -14.2*	2 wk: NR (5.4), NC	
VR	(TSK)			
High				
Zadro, 2019 <sup>44</sup>	TSK	33.6 (6.1)	34.7 (5.8)	Diff ∆*:
AR		8 wk: 32.3 (7.1), -1.3*	8 wk: 35.9 (5.8), 1.2*	8 wk: -2.5
Some				
Pain Global Cha	ange			
Eccleston,	PGIC (assessed	8 wk: 2.7 (1.4)	VR control	Diff ∆:
2022 <sup></sup>	only at lollow-up)	5 mo: 3.0 (1.5)	8 WK: 3.8 (1.5)	8 wk: -1.1
v r. Some			5 mo: 3.0 (1.5)	5 mo: 0.0
concerns				
				D:// .
		A	o wk. 3.9 (U.7)	o wk: -1.2
Harvie, 2022 <sup>24</sup>	PGIC (assessed	At least minimally	At least minimally improved:	
VIT	enily at lonow-up)	No change: 55%	No change: 89%	improved): 26%



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline mean (SD) Follow-Up Mean (SD), M ean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Some concerns in Domain 4 only		Minimally worse: 5%	Minimally worse: 0%	1 wk minimally worse: 5%
Quality of Life				
Eccleston, 2022 <sup>27</sup> VR	European Quality of Life 5 (EuroQoL-5D-5L) Health State (	47.7 (16.8) 8 wk: 66.1 (22.2), 18.4*	VR control 63.8 (15.1) 8 wk: 58.1 (26.8), -5.7*	Diff ∆*: 8 wk: 24.1
concerns			Usual care 55.7 (19.6) 8 wk: 62.0 (23.9), 6.3*	Diff ∆*: 8 wk: 12.1
Groenveld, 2023 <sup>28</sup> VR	SF-12-physical	34.9 (7.5) 4 wk: 39.1 (6.3), 4.2* 4 mo: 38.5 (8.7), 3.6*	32.9 (7.7) 4 wk: 34.8 (7.1), 1.9* 4 mo: 36.8 (7.5), 3.9*	Diff ∆*: 4 wk: 2.3 4 mo: -0.3
Some concerns	SF-12-mental	45.6 (7.2) 4 wk: 48.9 (7.5), 3.3* 4 mo: 46.4 (10.1), 0.8*	43.0 (8.9) 4 wk: 46.0 (10.9), 3.0* 4 mo: 46.2 (11.8), 3.2*	Diff ∆*: 4 wk: 0.3 4 mo: -2.4
Mbada, 2019 <sup>50</sup> AR High	SF-12-mental	71.8 (6.0) 8 wk: 19.4 (11.6), -52.4*	70.0 (9.1) 8 wk: 26.6 (13.3), -43.4*	Diff ∆*: 8 wk: -9.0
	SF-12-physical	68.8 (6.1) 8 wk: 11.6 (8.7), -57.2*	64.3 (10.8) 8 wk: 16.3 (13.0), -48.0*	Diff ∆*: 8 wk: -9.2
Yilmaz Yelvar, 2016 <sup>25</sup> VR High	Nottingham Health Profile	226.1 (75.9) 2 wk: 196.1 (109.2), -30.0*	158.4 (125.8) 2 wk: 140.9 (117.9), -17.5*	Diff ∆*: 2 wk: -12.5
Physical Perform	mance			
Mbada, 2019 <sup>50</sup> AR High	Biering-Sorensen test of Statis Muscular Endurance (BSME)	35.3 (22.5) 8 wk: -21.9 (14.6), -57.2*	20.6 (13.3) 8 wk: -15.1 (7.9), -35.7*	Diff ∆*: 8 wk: -21.5
Monteiro- Junior, 2015 <sup>46</sup> AR	Floor to Sit to Stand-Sit (max 5 pts)	2.3 (1.5) 8 wk: 3.3 (0.9), 1.0*	2.8 (1.0) 8 wk: 3.2 (0.9), 0.4*	Diff ∆*: 8 wk: 0.6
High	Floor to Sit to Stand-Stand Up (max 5 pts)	1.7 (1.6) 8 wk: 2.5 (1.0), 0.8*	2.5 (1.2) 8 wk: 2.8 (1.3), 0.3*	Diff ∆*: 8 wk: 0.5
Yilmaz Yelvar, 2016 <sup>25</sup>	Timed-up and go test (TUG)	7.7 (1.0) 2 wk: 5.3 (0.9), -2.5*	8.0 (1.7) 2 wk: 7.6 (1.3), -0.4*	Diff ∆*: 2 wk: -3.9
VR High	6-minute walk test	414.3 (120.7) 2 wk: 504.9 (130.8), 90.6*	401.1 (64.0) 2 wk: 400.7 (59.9), -0.4*	Diff ∆*: 2 wk: 91.0
Opioid Use				
Groenveld, 2023 <sup>28</sup> VR Some concerns	Used opioids at least once weekly	N (%): 1 wk: 9 (47) 4 wk: 5 (28), -19*	N (%): 1 wk: 7 (37) 4 wk: 7 (37), 0*	Diff ∆*: 4 wk: -19%



Notes. \* Calculated by study team.

<sup>†</sup> Values derived from figures using plotdigitizer.com, SD calculated from 95% CI whenever possible.

Abbreviations. AE=Adverse events; BPI=Brief Pain Inventory; CI=confidence intervals; DVPRS-II= Defense and Veterans Pain Rating Scale; MODI=Modified Oswestry Disability Index; NC=not calculable; NR=not reported; NRS=numeric rating system; ODI=Oswestry Disability Index; PCS=Pain Catrastrophizing Scale; PGIC=Patient Global Impression of Change scale; PSFW=Patient Specific Functional Scale; RMDQ=Roland-Morris Disability Questionnaire; SD=standard deviation; SF-12=Short Form Health Survey; TSK=Tampa Scale of Kinesiophobia; VAS=Visual Analog Scale.

# **APPENDIX F. CHRONIC NECK PAIN**

# Appendix Table F1. Detailed Characteristics for Included Trials on Chronic Neck Pain

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
r unung source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
VR Intervention				
Cetin, 2022 <sup>51</sup>	<b>Inclusion:</b> "aged between 18 and 65 years with a minimum of 6 months of neck	N=21	N=20	Primary: ROM, Joint Position Sense Error (JPSE)
High	pain, a baseline NDI score of at least 20% (10 points), and the neck region as the primary pain area."	Age, mean (SD): 40.0 (11.88)	Age, mean (SD): 41.94 (10.76)	Pain-related functioning (6 wk)
6 weeks	primary pain area.	Female: 70.5%	Female: 64.7%	<ul> <li>ProFitMap-Neck</li> </ul>
Hacettepe University Hospital's Neurosurgery	<b>Exclusion:</b> "having undergone cervical spine surgery; having rheumatologic, vestibular, neurological, or	Clinic	Clinic	Pain intensity (6 wk) <ul> <li>VAS</li> </ul>
	cardiopulmonary diseases; having receiving interventions including exercise or physical therapy in the previous 6	3 x 40 min (20 min control exercises + 20 min VR) per week; 6 weeks	3 x 40 min per week; 6 weeks	Adverse events (6 wk)
	months; and being pregnant."	"Two VR applications were installed: "Ocean Rift" and "Gala 360". "Ocean Rift" provides a VR experience that allows watching sea animals that can be selected with the remote control. "Gala 360" provides views from countries and cities all over the world The patients were seated in a chair that allowed 360° movement and were asked to look in all directions during the VR applicationThey were encouraged to move their necks by expressions such as "follow that dolphin, the sea turtles you chose will come soon, there may be a starfish below. Now you are in front of the Eiffel Tower, you can look around"."	"The MC exercises included strengthening of the deep cervical flexors (DCFs), deep cervical extensors (DCEs), and axioscapular muscles; stretching exercises; and postural correction exercises. The 3- level treatment protocol developed by Jull was used in the training of the cervical muscles in our study (Jull et al., 2004). In the first level, craniocervical flexion (CCF) exercises were used for low-load endurance training of the DCFs and cervical extension exercises were used for endurance training of the DCEs. The exercises were performed slowly to provide MC and increase kinesthetic awareness. The ability to do the CCF exercises for 10 s was used as a	<ul> <li>Quality of life (6 wk)</li> <li>SF-36 (domain scores only)</li> <li>Physical performance (6 wk)</li> <li>ROM &amp; JPSE (flexion, extension, right/left lateral flexion, right/left rotation)</li> <li>Non-eligible: Pain pressure thresholds, HADS</li> </ul>

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s) Europing source		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
			reference to indicate progress in the exercises. In the second level, elastic bands were used to increase the strength and endurance of the DCFs and DCEs. In the third level, the aim was to gain dynamic balance, and this was achieved by the patient holding an exercise ball against a wall with the front/back of the head. All patients were informed about neutral spinal posture from the first session. They were trained to actively correct postures and maintain them for 10 s (in sitting and standing positions)."	
Nusser, 2021 <sup>52</sup>	<b>Inclusion:</b> "Diagnoses [of non-traumatic chronic neck pain (more than 3 months)]	N=17	N=20	Primary outcome NR
High	were primarily made by patients' general practitioners and confirmed by the physician in charge at the rehabilitation	Mean (SD) age: 51.2 (8.8)	Mean (SD) age: 49.8 (8.1)	<ul><li>Pain-related functioning (3 wk)</li><li>NDI</li></ul>
3 weeks	hospital. Further inclusion criteria were such that the patients must be adults aged	6 20-minute sessions over 3 weeks	3 weeks	Pain intensity/severity (3 wk)
Federseeklinik Bad Buchau, Germany	18 years or more and have taken no pain medication or muscle relaxants for 24	Clinic	Clinic	• NRS
NR	<b>Exclusion:</b> " traumatic neck pain, neck pain originating from whiplash, cervical fracture/dislocation, operations in the cervical spine area, damage to the inner ear, vertebrobasilar insufficiency, basic neurological diseases, range of motion of the cervical spine < 10° in flexion, extension, and/or rotation."	"In addition to the "standard rehabilitation programme," patients in the VRG completed a total of 120 min of "neck-specific sensorimotor training" (NSST) using a VR device in individual therapy. Due to the required concentration, the training was divided into 6 20min sessions A globe was shown, moving in a virtual space on predetermined trajectories, on the monitor The patient was asked to follow by moving the head the orbital pathways of the globe A 3Space Fastrak System (Polhemus Inc	"The CG underwent a "standard rehabilitation programme", including a combination of individual and group therapies instructed by physiotherapists and certified sports scientists the programme comprised different forms of general and neck- specific exercise therapy, such as strengthening, mobilization, relaxation, medical training therapy, functional gymnastics, aqua therapy, physical therapy, and traditional "back school" Patients also received special lectures from orthopaedists	Adverse events (3 wk) Physical performance (3 wk) • ACROM

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding Source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		Colchester, VT, USA) was used for head movement tracking Before each training session, the current maximum active cervical range of motion (ACROM) of the patient was determined in a total of 8 directions: flexion, extension, right, and left rotation, and the diagonals in between In every NSST session, the VRG patients underwent each of the following tasks twice: the Head Repositioning Test (HRT), the Head to Target Test (HTT), and a dynamic exercise including 5 different trajectories Rest breaks of approximately 3 min were given between tasks, and extended if any side effect ( <i>eg</i> , motion sickness, nausea, or headaches) was reported." N=18 Mean (SD) age: 53.1 (5.7) 4 x 30-minute sessions over 3 weeks Clinic "The SMG received the "standard rehabilitation programme" plus a total of 120 min of "general sensorimotor training". This training was instructed by a physiotherapist or a certified sports scientist. The objective was training and improvement in patients' coordination through skill exercises (eg, passing an obstacle course,	and psychologists, who provided information about chronic pain, along with therapeutic goals, and an emphasis on the importance of being proactive."	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding Source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		dribbling, rope skipping, tossing balls through rings), balance exercises ( <i>eg</i> , standing with eyes closed, single leg stance, slacklining), small game forms ( <i>eg</i> , juggling, curling, throwing and catching), and partner games, such as badminton or table tennis."		
Tejara, 2020 <sup>53</sup>	<b>Inclusion:</b> "(a) non-specific chronic neck pain; (b) age 18 to 65 years"	N=22	N=22	Primary: Pain intensity, pain modulation (CPM), temporal
Some concerns	Exclusion: "(a) pregnancy; (b) specific	Age, mean (SD): 32.72 (11.63)	Age, mean (SD): 26.68 (9.21)	summation (TS)
4 months	neck pain caused by metastasis, neoplasia, infectious or inflammatory disorders, here fractures or traumatio	Female: 50%	Female: 54.5%	Pain-related functioning (4 wk, 4 mo)
Rey Juan Carlos University; CEU San	precedents with neck injuries; (c) positive neurological signs or evidence of spinal	Clinic	Clinic	• NDI
Pablo University; Community of Madrid,	compression (abnormal diuse sensitivity, hyperreflexia, or diuse weakness); (d)	2 sessions/week for 4 weeks	2 sessions/week for 4 weeks	Pain intensity/severity (4 wk, 4 mo)
Spain	cervical osteoarthritis; (e) spondyloarthritis; (f) neck pain associated with vertigo	"Two VR mobile applications were	"This group performed three series of	• VAS
NR	(vestibular involvement); (g) neck pain associated with whiplash injuries; (h)	the free mobile application "Fulldive VR" The nation was immersed in	30 s rest between exercises. The	Pain catastrophizing (4 wk, 4 mo)
	previous cervical surgeries; (i) headacnes prior to the onset of neck pain and without cervical origin; and (e) inability to provide	an environment that simulated the living room of a house and at the	verbal corrections for the proper execution of the exercises, using the	<ul> <li>Pain Catastrophizing Scale (PCS)</li> </ul>
	informed consent."	same time they could visualize a gallery of previously selected photos.	same verbal commands for all participants. Flexion exercise: in a	<ul> <li>Pain Anxiety Symptom Scale (PASS-20)</li> </ul>
		Then, they had to change the images in the viewfinder by tilting their neck bilaterally, as well as naming the	sitting position, a ball was placed between the wall and the neck of the patient that performed a controlled	Fear Avoidance Beliefs     Questionnaire (FABQ)
		photos that were displayed Once the patient felt comfortable with the	neck flexion with a previously maintained cranio-cervical flexion.	• TSK
		system and adapted to the headset, then after one minute rest, the	Extension exercise: in a sitting position, the participant was asked to	Physical performance (4 mo)
		difficulty of the exercise program was	perform a controlled neck extension	
		application "VR Ocean Aquarium 3D" where flexion, extension and rotation	returning to the initial position. Rotation and tilt exercises: in a sitting	Non-eligible: CPM; TS; fear- avoidance beliefs; pain

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		movements were added. The patient was immersed in a virtual environment that simulated an ocean, moving forward and observing different marine animals by making the neck movements. The patient named the animals they were visualizingIn the first sessions, the patients were instructed to perform a previous cranio-cervical flexion before starting any movement. Then, the therapist controlled the contraction of the superficial musculature with their hands. Gradually, the aid of the physiotherapist was removed so that the participants could integrate deep muscle contraction and the correct cranio-cervical posture innately For these patients to carry out the same work as the control group, the physiotherapist counted and controlled in each exercise the number of movements the patient performed, in order to not exceed the dose proposed: 3 series of 10 repetitions of each exercise with 30 s rest between exercises."	position, the subject who had previously done a cranio-cervical flexion to activate the deep flexor musculature was asked to perform the movement."	pressure thresholds; pain- related anxiety
Bahat, 2017 <sup>54,120</sup>	Inclusion: "Adults aged 18 years or more with neck pain for more than 3 months	N=30 (+18 added in phase 2)	N=30 (+14 added phase 2)	Primary: NDI, global perceived effect (GPE), cervical motion
Some concerns	NDI score greater than 12%, and VAS during the recent week greater than 20	Age, median (IQR): 48 (38.5, 57.5)	Age, median (IQR): 48 (35.5, 59)	velocity (mean & peak)
4 months <sup>54</sup> , 5 months <sup>120</sup>	mm. Lastly, VR assessment indicated a reduction of mean velocity of at least one SD from control values."	Female: 63%	Female: 70%	Pain-related functioning (4 wks)
University of Queensland, Australia		Home	Home	

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Physiotherapy Research Fellowships (HMR); Queensland Government (2013003214)	<b>Exclusion:</b> "Existing vestibular pathology; cervical fracture/dislocation; systemic diseases, epilepsy or other neurological condition; cardiovascular, or respiratory disorders affecting physical performance; history of traumatic head injury; inability to provide informed consent; inability to complete the assessment, or pregnancy."	5-minute sessions, 4 times a day (20 mins/day total), 4 days a week, for 4 weeks	5-minute sessions, 4 times a day (20 mins/day total), 4 days a week, for 4 weeks	<ul><li>Pain intensity/severity (4 wks)</li><li>VAS</li></ul>
		"Three modules were developed, including range of motion (ROM), velocity and accuracy modules. These modules enable elicitation of cervical	"Kinematic training with a head- mounted laser beam aimed at a 70 by 70 cm poster. Tasks in the laser group were similar to the VR exercises, such	<ul> <li>Adverse events (4 wks)</li> <li>Side effects post-intervention for VR group only, includes both phases 1+2</li> </ul>
		motion by the patient's response to the provided visual stimuli. A full kinematic report for each patient was generated after completion of the modules. During the VR session, the virtual pilot	as following the line with the laser, moving quickly from one circle to another, etc. The laser beam provided visual feedback relating to head motion, but unlike the VR, laser	Pain catastrophizing (4 wks) TSK
		flying the red airplane was controlled by the patient's head motion and	training velocity was not controlled."	• Velocity
		interacted with targets appearing from four directions (to elicit flexion,	N-30	<ul> <li># of velocity peaks</li> <li>Time to peak velocity</li> </ul>
		extension, right rotation, left rotation). The VR software did not elicit side	Age, median (IQR): 48 (35, 59)	<ul> <li>Inne to peak velocity percentage</li> </ul>
		flexion movement"	Female: 77%	<ul><li>Accuracy error</li><li>Cervical ROM</li></ul>
			Home	
			NA (waitlist control)	
Sarig Bahat, 2015 <sup>55</sup>	Inclusion: "age 18 years or more; prolonged neck pain for more than three	N=16	N=16	Primary: NDI, cervical ROM, head movement velocity &
Some concerns	months; and the NDI score greater than 10%"	Age, mean (SD): 40.63 (14.18)	Age, mean (SD): 41.13 (12.59)	accuracy
4 months	Exclusion: "existing vestibular pathology;	Female: 68.8%	Female: 68.8%	Pain-related functioning (4 wk, 4 mo)
Neck Pain and Whiplash	cervical fracture/dislocation; systemic diseases; neurological, cardiovascular, or	Clinic	Clinic & Home	NDI
Research Unit, University of Queensland, Brisbane, Australia	respiratory disorders affecting physical performance; history of traumatic head injury; inability to provide informed			Pain intensity/severity (5 wk, 4 mo)
	consent; or pregnancy."			• VAS

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Tunung source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
University of Haifa		4-6 supervised sessions (30 minutes each) over 5 weeks, 30-minutes at least 3 x per week over 3 months	4-6 supervised sessions (30 minutes each) over 5 weeks, KT home sessions x 3 months	Adverse events (4 mo) <ul> <li>Motion sickness</li> </ul>
		"Three modules were developed, including range of motion (ROM), velocity and accuracy modules. These modules enable elicitation of cervical motion by the patient's response to the provided visual stimuli During the VR session, the virtual pilot flying the red aeroplane (in the web version) is controlled by the patient's head motion and interacts with targets appearing from four directions (flexion, extension, right rotation, left rotation)The VR training program was tailored to each participant and progressed according to the patients' performance In the VR training system, range of motion was individually challenged by positioning targets further away, velocity by reducing targets lifetime (the shorter time a target appeared it required faster response), and accuracy by increasing velocity of the moving target to pursuit in the accuracy module."	"The KT group undertook a 30-minute training session using a laser pointer that was mounted on the participant's head and projected onto a poster for feedback. Kinematic training involved active neck movements to increase ROM, quick head movement in between targets to facilitate quick cervical motion control, static head positioning while moving the body was used to advance head stability, and smooth head movement following a target was used to train accurate head neck movement. These exercises were supervised by the physiotherapist and performed in the clinic by the KT group, and then encouraged to be performed at home. The kinematic home exercises were tailored to each individual and their performance re-evaluated and progressed during each supervised session."	Pain catastrophizing (5 wk, 4 mo) • TSK
				<ul> <li>Pain global change (4 mo)</li> <li>Global Perceived Effect (GPE) on pain</li> </ul>
				<ul> <li>Physical performance (4 mo)</li> <li>ROM (flexion, extension, right rotation, left rotation)</li> <li>Peak Velocity (flexion, extension, right rotation, left rotation),</li> <li>Mean Velocity (flexion, extension, right rotation, left rotation),</li> <li>TTP% (flexion, extension, right rotation), left rotation),</li> <li>Sway SD (pitch, yaw),</li> <li>Accuracy (pitch, yaw)</li> <li>Sensorimotor (eyes closed balance, single leg stance, and step test)</li> </ul>
				Non-eligible: cervical ROM, head movement velocity and accuracy

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s) Funding source		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
AR Interventions				
Rezaei, 2019 <sup>56</sup>	Inclusion: " history of nontraumatic NP for more than 3 months and age between	N=22	N=22	Primary: Patient-reported neck pain & disability
High	20 and 55 years."	Age, mean (SD): 36.19 (9.8)	Age, mean (SD): 31.23 (9.49)	Pain-related functioning (4 wk,
9 weeks	<b>Exclusion:</b> "a score ≥15 and ≤9 (out of possible 50) on NDI, history of cervical	Female: 42.9%	Female: 52.4%	9 wk) • NDI
Community health system in Iran	before examination, neurological signs and symptoms in the upper extremities, nerve	Clinic	Clinic	Pain intensity (4 wk, 9 wk)
Vice Chancellor for	injury, spinal cord compression, cervical spine pathology or surgery and cancer."	21 min sessions, 2 sessions per week for 4 weeks (8 total)	21 min sessions, 2 sessions per week for 4 weeks (8 total)	• VAS
Research of Shiraz				Physical performance (4 wk, 9
Research of Shiraz University of Medical Sciences (grant no. 92- 6895)		"A new video game (Cervigame® version 1.01) was designed for training The main visual component of the game is a rabbit attempting to reach carrots. The virtual carrots appear continuously along the line of the movement pattern being trained. This avatar is controlled by the patient's head movements Stages increase in difficulty as obstaclesappear in predefined positionsThe best score in each stage was obtained by capturing all carrots without colliding with any obstacles Based on the patient's head movement (along a line or in a plane) the stages are divided into two main categories: unidirectional and two-directionalThe order of 50 stages progresses from easy to hard, based on the stage category, number and acuity of the angles, shape and variation in the range of trajectories and the arrangement of obstacles. In	" Exercises consisted of eye-follow, gaze stability, eye-head coordination and position sense and movement sense practice. In the eye-follow exercise, patients moved their eyes to follow the target while seated with their head stationary. The target was a pen held by a physical therapist, who initially moved it slowly in one plane and then increased the speed and changed the direction of movement. For the gaze stability exercise, patients actively moved their head in all directions while visually fixing on the target. The exercise for eye-head coordination began by moving the head and eyes to the same side. Then participants moved their eyes first to keep focused on the target, and then moved their head. Finally, they moved their eyes in one direction while simultaneously rotating their head in the opposite direction. These exercises were initially done slowly in	<ul> <li>Physical performance (4 wk, 9 wk)</li> <li>Dynamic balance: Y-balance test</li> </ul>
#### Evidence Synthesis Program

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	
Follow-Up Duration Site(s) Funding source		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
r unung source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		the first 3 treatment sessions, the patients play only unidirectional stages. Combinations of unidirectional and two-directional stages are played alternately in the fourth and fifth sessions. In the last 3 sessions, only two-directional stages are played."	a restricted range of movements, then the speed and range of movements gradually increased. Exercises were done in both vertical and horizontal directions. For joint position sense and movement sense exercises, participants wore a laser pointer attached to a headband. The patients sat 1 meter from a point marked on the wall, and were instructed to move their head until the laser beam was aimed on the point, and then to close their eyes and memorize their head- neck position for 5 s. Maximal movement of the head was performed in one direction (flexion, extension, rotation or lateral flexion), after which the patients tried to recover their initial head position as closely as possible, and opened their eyes. The relocation error indicated by the distance of the laser beam from the point marked on the wall was used as feedback. Movement sense was practiced by using the head-mounted laser pointer to trace a moving object held by the physical therapist. The task was progressed by increasing the speed and changing the pattern of movement."	

Abbreviations: ACROM=acute cervical range of motion; AR=augmented reality; CG=control group; CPM=conditioned pain modulation; HADS=Hospital Anxiety-Depression Scale; IQR=interquartile range; JPSE=Joint Position Sense Error; MC=motor control exercises; mo=month; NDI=Neck Disability Index; NR=not reported; NRS=Numeric Rating Scale; ROM=range of motion; SD=standard deviation; SF-36=Short Form-36; SMG=sensorimotor group; TS=temporal summation; TSK=Tampa Scale of Kinesiophobia; TTP=time-to-peak; VAS=Visual Analog Scale; VR=virtual reality.

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Pain-Related Fund	tioning or Interference	9		
Cetin, 2022⁵¹ VR High	ProFitMap – Neck	69.3 (11.3) 6 wk: Follow-up NR, 12.97	65.22 (13.49) 6 wk: Follow-up NR, 10.59	Diff ∆: 6 wk: 2.37
Nusser, 2021 <sup>52</sup> VR High	NDI	18.7 (5.2) 3 wk: 11.4 (7.5), -7.3*	SMG 21.5 (6.4) 3 wk: 13.7 (7.9), -7.8* Control 18.2 (6.7) 3 wk: 13.7 (7.0), -4.5	Diff Δ*: 3 wk: 0.5 Diff Δ*: 3 wk: -2.8
Rezaei, 2019 <sup>56</sup> AR High	NDI	13.0 (1.3) 4 wk: 4.57 (2.39), -8.43 9 wk: 4.38 (3.3), -8.62	12.28 (1.38) 4 wk: 8.14 (3.13), -4.14 9 wk: 9.22 (3.66), -3.06	Diff ∆: 4 wk: -4.29 9 wk: -5.56*
Sarig Bahat, 2017 <sup>54</sup> VR Some concerns	NDI	32.88 (12.5) 4 wk: 23.75 (15.7), -9.13*	Laser 32.19 (13.3) 4 wk: 26.88 (14.0), -5.31* Control 4.48 (10.7) 4 wk: 23.60 (11.8), -1.12*	Diff Δ*: 4 wk: -3.82 Diff Δ*: 4 wk: -8.01
Sarig Bahat, 2015 <sup>55</sup> VR Some concerns	NDI	20.38 (7.6) 4 wk: 12.85 (7.5), -7.76 (6.2) 4 mo: 13.57 (7.9), -6.92 (6.0)	20.19 (6.5) 4 wk: 14.0 (15.1), -5.64 (7.0) 4 mo: 14.0 (8.5), -3.42 (14.9)	Diff ∆*: 4 wk: -2.12 4 mo: -3.5
Tejara, 2020 <sup>53</sup> VR Some concerns	NDI	13.72 (6.68) 4 wk: 6.9 (6.28), -6.82* 4 mo: 4.95 (6.60), -8.77*	14.09 (9.32) 4 wk: 7.45 (5.36), -6.64* 4 mo: 5.77 (4.67), -8.32*	Diff ∆*: 4 wk: -0.18 4 mo: -0.45
Pain Intensity				
Nusser, 2021 <sup>52</sup> VR High	NRS	4.9 (2.1) 3 wk: 2.2 (1.2), -2.7*	SMG: 4.4 (3.1) 3 wk: 2.9 (2.2), -1.5* CG: 4.2 (2.6) 3 wk: 3.2 (3.0), -1.0*	Diff ∆*: 3 wk: -1.2 Diff ∆*: 3 wk: -1.7
Rezaei, 2019 <sup>56</sup> AR High	VAS	47.11 (10.24) 4 wk: 10.75 (8.43), -36.36 9 wk: 9.75 (11.03), -37.54	38.95 (10.07) 4 wk: 19.63 (9.15), -19.32 9 wk: 20.17 (11.97), -18.78	Diff ∆*: 4 wk: -17.04 9 wk: 18.76
Sarig Bahat, 2015 <sup>55</sup> VR Some concerns	VAS	35.72 (17.7) 5 wk: 22.1 (24.1), -13.62* 4 mo: 26.95 (16.5), -8.77	35.17 (16.7) 5 wk: 27.72 (21.9), -7.45* 4 mo: 30.33 (18.5), -4.84	Diff ∆*: 5 wk: -21.07 4 mo: -3.93
Sarig Bahat, 2017 <sup>54</sup> VR Some concerns	VAS	47.49 (20.9) 4 wk: 31.1 (23.6), -16.39*	52.47 (19.5) 4 wk.: 35.97 (22.9), -16.5* 45.78 (21.5) 4 wk: 39.45 (22.0), -6.33*	Diff ∆*: 4 wk: 0.11 Diff ∆*: 4 wk: -10.06
Tejara, 2020 <sup>53</sup> VR Some concerns	VAS	4.97 (1.88) 4 wk: 2.67 (1.91), -2.3* 4 mo: 2.17 (1.99), -2.8*	4.27 (1.35) 4 wk: 3.11 (1.47), -1.16* 4 mo: 1.72 (2.09), -2.55*	Diff ∆*: 4 wk: -1.14 4 mo: -0.25

# Appendix Table F2. Detailed Results for Chronic Neck Pain Studies



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Adverse Events				
Cetin, 2022⁵¹ VR High	Count of adverse events	No AE observed	No AE observed	Diff ∆*: 0
Nusser, 2021 <sup>52</sup> VR High	Count of adverse events	"Besides the weight of the helmet, no other negative side effects were general. Therefore, all patients (no participation) could complete the m as planned."	Diff ∆: NC	
Sarig Bahat, 2017 <sup>54</sup> VR Some concerns	Side effects post- intervention, includes phases 1+2	"There were a few cases of side effects from the VR use. Out of 14 dropouts at post-intervention assessment, 5 were due to VR- associated sickness and headache."	AE not assessed	Diff ∆: NC
Sarig Bahat, 2015 <sup>55</sup> VR Some concerns	Count of participants who experienced motion sickness	"Four participants experienced mo device during assessment. Two pa to randomization, and therefore we experienced delayed motion sickne and after being randomized to the further participation. There were no	Diff ∆: NC	
Pain Catastrophizir	ng & Kinesiophobia			
Sarig Bahat, 2017 <sup>54</sup> VR	TSK	35.22 (7.4) 4 wk: 33.26 (7.8), -1.96*	Laser 34.79 (5.9) 4 wk: 34.58 (8.2), -0.21*	Diff ∆*: 4 wk: -1.75
Some concerns			Control 32.64 (7.2) 4 wk: 33.96 (6.2), 1.32*	Diff ∆*: 4 wk: -3.28
Sarig Bahat, 2015 <sup>55</sup> VR Some concerns	TSK	32.75 (6.8) 5 wk: 30.13 (5.7), -2.13 (4.2) 4 mo: 31.23 (6.5), -1.23 (6.8)	30.38 (5.8) 5 wk: 28.64 (9.9), -1.5 (8.3) 4 mo: 30.0 (5.9), -0.92 (4.5)	Diff ∆*: 5 wk: -0.63 4 mo: -0.31
Tejara, 2020 <sup>53</sup> VR Some concerns	TSK	22.9 (7.11) 4 wk: 18.9 (10.73), -4.0* 4 mo: 12.09 (7.77), -10.81*	21.4 (6.63) 4 wk: 18.36 (7.48), -3.04 4 mo: 17.5 (6.89), -3.9	Diff ∆*: 4 wk: -0.96 4 mo: -6.91
	PCS	17.36 (11.49) 4 mo: 4.95 (8.08), -12.41*	11.95 (9.39) 4 mo: 4.86 (8.4), -7.09*	Diff ∆*: 4 mo: -5.32
	PASS-20	27.52 (20.52) 4 mo: 12.33 (16.09), -15.19*	26.59 (16.5) 4 mo: 15.9 (11.3), -10.69*	Diff ∆*: 4 mo: -4.5
	FABQ	28.25 (16.43) 4 mo: 12.3 (13.48), -15.95*	25.68 (13.02) 4 mo: 16.59 (14.32), -9.09*	Diff ∆*: 4 mo: -6.86
Quality of Life				
Cetin, 2022⁵¹ VR High	SF-36 – Physical functioning	Median (IQR): 75.0 (60.0-85.0) 6 wk median (IQR): NR, 15.0 (5.0-17.5)	Median (IQR) 75.0 (60.0-90.0) 6 wk median (IQR): NR, 5.0 (0.0-17.5)	Median (95% CI) diff at 6 weeks: 2.94 (-5.17, 11.05)
	SF-36 – Role limitations due to physical health	Median (IQR): 66.7 (33.3-83.3) 6 wk median (IQR): NR, 25.0 (0.0-46.0)	Median (IQR): 33.3 (33.3-66.7) 6 wk median (IQR): NR, 25.0 (10.0- 50.0)	Median (95% CI) diff at 6 weeks: - 3.62 (27.62, 20.36)

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
	SF-36 – Role limitations due to emotional health	Median (IQR): 55.0 (55.0-60.0) 6 wk median (IQR): NR, 33.3 (0.0-33.5)	Median (IQR): 45.0 (32.6-55.0) 6 wk median (IQR): NR, 33.4 (0.0- 66.7)	Median (95% CI) diff at 6 weeks: - 5.86 (-18.76, 7.03)
Physical Performa	ance			
Cetin, 2022 <sup>51</sup> VR High	Flexion	49.05 (7.89) 6 wk: NR, 10.64 (7.44)	44.64 (9.92) 6 wk: NR, 8.47 (7.21)	Diff ∆: 6 wk: -2.17
	Extension	62.47 (11.88) 6 wk: NR, 10.05 (9.25)	61.23 (9.44) 6 wk: 7.70 (7.05)	Diff ∆: 6 wk: -2.35
	Right lateral flexion	40.23 (8.35) 6 wk: 7.63 (8.84)	39.42 (7.83) 6 wk: 7.30 (5.81)	Diff ∆: 6 wk: -0.33
	Left lateral flexion	42.56 (8.25) 6 wk: 4.96 (7.41)	43.66 (7.23) 6 wk: 4.92 (5.78)	Diff ∆: 6 wk: -0.04
	Right rotation	56.76 (9.83) 6 wk: 6.05 (13.6)	51.47 (8.43) 6 wk: 8.52 (6.06)	Diff ∆: 6 wk: 2.47
	Left rotation	55.0 (9.18) 6 wk: 7.35 (9.0)	49.11 (8.33) 6 wk: 9.41 (9.98)	Diff ∆: 6 wk: 2.05
Nusser, 2021 <sup>52</sup> VR High	Flexion	40.9 (14.6) 3 wk: 48.5 (13.3), 7.6*	SMG 38.9 (12.2) 3 wk: 37.9 (14.8), -1.0*	Diff ∆*: 3 wk: 8.6
			CG 45.8 (12.9) 3 wk: 42.9 (12.6), -2.9	Diff ∆*: 3 wk: 10.5
	Extension	35.4 (12.8) 3 wk: 37.7 (15.1), 1.9*	SMG 39.1 (12.7) 3 wk: 44.6 (12.9), 5.5*	Diff ∆*: 3 wk: -3.6
			CG 43.1 (13.3) 3 wk: 39.8 (14.7), -3.3*	Diff D*: 3 wk: 5.2
	Left rotation	57.4 (12.7) 3 wk: 65.2 (16.9), 7.8*	SMG 51.7 (17.9) _3 wk: 55.8 (15.5), 4.1*	Diff ∆*: 3 wk: 3.7
			CG 59.3 (10.1) 3 wk: 59.9 (9.3), 0.6	Diff ∆*: 3 wk: 7.2
	Right rotation	55.6 (10.4) 3 wk: 59.5 (14.0), 3.9*	SMG 54.6 (13.7) 3 wk: 58.6 (13.4), 4.0*	Diff ∆*: 3 wk: -0.1
			CG 61.8 (15.3) 3 wk: 64.0 (0.2), 2.2*	Diff ∆*: 3 wk: 1.7
Rezaei, 2019 <sup>56</sup> AR High	Dynamic balance: Y-balance test	78.65 (5.37) 4 wk: 84.67 (7.01), 6.02* 9 wk: 86.24 (8.15), 7.59*	81.55 (8.76) 4 wk: 88.69 (8.92), 7.14* 9 wk: 88.98 (10.7), 7.43*	Diff ∆*: 4 wk: -1.12 9 wk: 0.16
Sarig Bahat, 2015 <sup>55</sup> VR Some concerns	Flexion	38.69 (14.6) 5 wk: 57.31 (11.3), 18.62* 4 mo: 55.38 (11.2), 16.69*	43.94 (14.3) 5 wk: 49.87 (17.2), 5.93* 4 mo: 58.4 (11.4), 14.46*	Diff ∆*: 5 wk: 12.69 4 mo: 2.23



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
	Extension	48.72 (15.1)	51.09 (13.2)	Diff $\Delta^*$ :
		5 wk: 57.45 (14.1), 8.73*	5 wk: 54.19 (12.8), 3.1*	5 wk: 5.63
		4 mo: 57.64 (8.8), 8.92*	4 mo: 54.5 (11.0), 3.41*	4 mo: 5.51
	Right rotation	62.32 (13.1)	57.06 (16.6)	Diff ∆*:
		5 wk: 71.84 (14.0), 9.52*	5 wk: 77.21 (10.6), 20.15*	5 wk:
		4 mo: 72.04 (16.2), 9.72*	4 mo: 88.89 (21.4), 31.83	4 mo:
	Left rotation	58.58 (15.3)	57.94 (15.3)	Diff ∆*:
		5 wk: 77.74 (16.0)	5 wk: 72.58 (13.6)	5 wk: 5.16
		4 mo: 70.38 (20.6)	4 mo: 84.26 (23.3)	4 mo: -13.88
	Eyes closed	28.05 (15.3)	4.48 (20.1)	Diff ∆*:
	balance	5 wk: 26.67 (11.6)	5 wk: 25.08 (17.3)	5 wk: 1.59
		4 mo: 31.73 (19.2)	4 mo: 27.87 (32.1)	4 mo: 3.86
Sarig Bahat,	Flexion	60.54 (10.1)	Laser	Diff ∆*:
201754		4 wk: 61.38 (7.1), 0.84*	64.7 (7.2)	4 wk: 0.1
VR Some concerns			4 wk: 65.44 (9.0), 0.74*	
			Control	Diff ∆*:
			62.98 (7.3)	4 wk: -0.7
			4 wk: 64.52 (6.0), 1.54*	
	Extension	63.17 (11.9)	Laser	Diff $\Delta^*$ :
		4 wk: 64.67 (11.0), 1.5*	62.91 (14.6)	4 wk: -0.87*.
			4 wk: 65.28 (12.8), 2.37*	
			Control	Diff $\Delta^*$ :
			65.42 (11.2)	4 wk: -0.19
			4 wk: 67.11 (7.9), 1.69*	
	Right rotation	73.77 (16.2)	Laser	Diff $\Delta^*$ :
		4 wk: 75.28 (13.3), 1.51*	78.14 (14.7)	4 wk: -1.0
			4 wk: 80.65 (14.2), 2.51*	
			Control	Diff $\Delta^*$ :
			78.87 (12.2)	4 wk: 1.3
			4 wk: 79.08 (11.5), 0.21	
	Left rotation	76.86 (14.5)	Laser	Diff D*:
		4 wk: 77.43 (11.9), 0.57*	77.18 (15.9)	4 wk: 0.3
			4 wk: 77.45 (15.0), 0.27*	
			Control	Diff D*:
			78.93 (16.0)	4 wk: -1.67
			4 wk: 81.17 (12.3), 2.24*	

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Tejara, 2020 <sup>53</sup>	Flexion/	110.22 (19.19)	116.13 (22.34)	Diff $\Delta^*$ :
VR	extension	4 mo: 112.03 (23.99), 1.81*	4 mo: 117.60 (24.27), 1.47*	4 mo: 0.34
Some concerns				
	Lateroflexion	79.54 (20.61)	87.21 (17.96)	Diff $\Delta^*$ :
		4 mo: 84.93 (21.47), 5.39*	4 mo: 86.42 (16.79), -0.79*	4 mo: 6.18
	Rotation	114.1 (18.97)	118.48 (15.19)	Diff ∆*:
		4 mo: 121.9 (18.49), 7.8*	4 mo: 124.3 (15.55), 5.82*	4 mo: 1.98

#### Notes. \* Calculated by review team.

Abbreviations. AR=augmented reality; CG=control group; Diff ∆= difference in change scores; FABQ=Fear Avoidance Beliefs Questionnaire; JPSE=Joint Position Sense Error; KT=kinematic therapy; mo=month; NDI=Neck Disability Index; NC=not calculable; NR=not reported; NRS=Numeric Rating Scale; PASS-20=Pain Anxiety Symptom Scale; PCS=Pain Catastrophizing Scale; QoL=quality of life; ROM=range of motion; SD=standard deviation; SF-36=Short Form-36; SMG=sensorimotor group; TSK=Tampa Scale of Kinesiophobia; TTP=time-to-peak; VAS=Visual Analog Scale; VR=virtual reality; wk=week.

# **APPENDIX G. FIBROMYALGIA**

# Appendix Table G1. Detailed Characteristics for Included Trials on Fibromyalgia

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias				Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding Source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Carvalho, 2019 <sup>58</sup>	Inclusion:	N=16	N=19	Primary: FIQ, Exercise capacity
High	≥18 years of age	Age, mean (SD): 55.64 (9.16)	Age, mean (SD): 47.70 (15.46)	<ul><li>Pain-related functioning (4, 7 wk)</li><li>FIQ (domain scores for physical</li></ul>
7 Weeks	Female gender	Women: 100%	Women: 100%	function and total)
Federal University of Alfenas, Alfenas, Mina Gerais	American College of Rheumatology concordant fibromyalgia diagnosis	Clinic	Clinic	<ul> <li>Physical performance (4, 7 wk)</li> <li>Number of steps up/down (25 cm height)</li> </ul>
Research Support Foundation of Minas Gerais (APQ 02794-11):	Exclusion:	1-hour sessions three times weekly; 7 weeks	1-hour three times weekly; 7 weeks	Other non-eligible outcomes
Tutorial Education Program (PET- MEC-SESU); Coordination for the Improvement of Higher Education Personnel (CAPES)—Finance Code 001.	Male gender Cardiovascular, pulmonary, orthopedic, neurological, or dermatological conditions, affecting muscle strength and physical capabilities Pregnancy	<ul> <li>Wie exergames: Participants completed 6 Wii Fit Plus subgames:</li> <li>Jogging Plus which involves stationary running. Activity requires active and constant movement of the lower limb muscles for 15 minutes.</li> <li>'Bird's-eye Bull's-eye game which requires active movement of the upper limbs in isolation from weight and balance training for 9 minutes.</li> <li>Yoga game which involves control of expiratory and inspiratory movements and active control of the body's center of gravity for 3 minutes.</li> </ul>	Chain muscle stretching: Positions were held during four deep and prolonged expirations. Stretches were chosen from an existing isometric stretching program to include multiple positions and globally engage muscle groups. Position 1: orthostatic position, feet parallel, semiflexion of the knees, pelvic retroversion, arms outstretched and slightly backward, wrists and fingers flexed in extension, gluteal muscles contracted, scapular adduction, and erect spine. Variation 2 of this position, which is performed with the hands in contact, was also used. Position 15: standing position,	<ul> <li>reported</li> <li>Pain threshold (algometry)</li> <li>Vitals during exercise (HR, BP, etc.)</li> </ul>

		Super Hula Hoop game which	flexed, and arms flexed with the bands supported on the back of the	
		movements as well as balance	head.	
		control for 9 minutes.		
		Stop game which consists of active	Position 16: dorsal decubitus	
		and alternating movements of the	floor and arms crossed	
		lower limb muscles, which requires		
		control of balance and unipodal	Position 19: dorsal decubitus	
		discharge for 9 minutes.	position, lower limbs in hip flexion at	
		Rhythm Parade which consists of	shoulders and elbows in 90 flexion.	
		stationary walking with active and	foot dorsiflexion, and scapular	
		rhythmic movements of the lower	adduction.	
		limp muscles for 9 minutes.	Position 21: dorsal decubitus	
			position, knees and hips semiflexed	
			vertically and in external rotation,	
			the soles of the feet in contact, and	
			of the body.	
			Position 35: dorsal decubitus	
			slight abduction, and leas extended	
			at 90.	
			Position 36: seated position, erect	
			spine, lower limbs semiflexed, feet	
			supported on the floor, horizontal	
			arms, and wrist extension at 90.	
			Position 38: seated position, erect	
			supported on the floor, upper limbs	
			in extension behind the body, and	
			hands in contact with one another.	
			Position 40: seated position	
			shoulder abduction, and hands	
			positioned behind the head."	
Collado-Mateo, 2017aºº; Collado- Mateo, 2017b <sup>61</sup>	Inclusion:	N=42	N=41	Primary: EuroQoL-5D
Matoo, 20115	Female gender	Age, mean (SD):	Age, mean (SD):	Pain-related functioning (8 wk)
Some concerns	-	52.52 (9.73)	52.47 (8.75)	• FIQ
8 Weeks	Age 30 to 75 years	Women: 100%	Women: 100%	• FIQ-80 (without work)
0 110000	American College of Rheumatology			<ul> <li>FIQ-100 (physical impairment)</li> </ul>
Recruitment via 2 local FM	concordant fibromyalgia diagnosis	Clinic	Clinic	Physical performance (8 wk)
associations (per #2284)	by a rheumatologist			• TUG
			NK; NK	

Spanish National R+D+i plan (no. DEP2012-39828); Government of Extremadura; EU Development Funds (no GR10127); Spanish Ministry of Education, Culture and Sport (no. FPU14/01283)	Exclusion: Pregnancy Any change to usual care therapies during 8 weeks of treatment Contraindications for physical exercise.	<ul> <li>2 1-hour sessions per week; 8 weeks</li> <li>VirtualEx-FM: Exergame program focused on postural control, coordination of upper and lower limbs, aerobic conditioning, strength and mobility in 3 virtual environments.</li> <li>First, participants complete a warm- up by imitating an expert on video displaying upper and lower limb joint movements.</li> <li>Second, participants complete an aerobic dance routine by following dance steps marked by a kinesiologist and dance teacher.</li> <li>Third, participants train postural control and coordination by following on-screen prompts to reaching for a virtual apple using a specified limb. All activity is completed in groups of three. Training is designed to improve physical conditioning.</li> <li>Fourth, walk training is developed using a circuit comprising a trail of footprints on a virtual floor.</li> <li>Participants must step on the virtual footprints and walk on the circuit.</li> <li>Participants are guided regarding mplitude, cadence, and different types of step.</li> </ul>	Comparator group continued usual care without intervention.	Functional reach
Polat, 2021 <sup>57</sup>	Inclusion:	N=20	N=20	Primary: FIQ
High	2010 American College of Rheumatology concordant	Age, mean (SD): 47.0 (7.1)	Age, mean (SD): 42.6 (8.7)	Pain intensity (4, 8 wk) <ul> <li>VAS</li> </ul>
8 Weeks	diagnosis of fibromyalgia	Women: 100%	Women: 100%	Physical performance (4, 8 wk)
Gazi University Department of	Age 18 to 65 years	Home Clinic	Home Clinic	6-minute walk
Rehabilitation	≥8 years of formal education	4 weeks of cycling program for 20-	4 weeks of cycling program for 20-	Quality of life (4, 8 wk) • European Quality of Life 5
NK	Unchanged fibromyalgia medication regimen for $\geq$ 3 months.	minute sessions, 3 days per week and augmented reality exercise for 15-minute sessions, 3 days per	minute sessions, 3 days per week and additional non-aerobic exercise program for 15-minute sessions 3	(EuroQoL-ວມ-ວL) Other non-eligible outcomes
	Exclusion:	week.	days per week	reported (4, 8 wk)

Diagnosis of secondary fibromyalgia	Home exercises for additional 4 weeks	Home exercises for additional 4 weeks	<ul><li>Symptom Severity Scale</li><li>Fatigue Severity Scale</li><li>HADS</li></ul>
Presence of intellectual deficits, visual deficits, inflammatory rheumatic disease or orthopedic surgery in preceding 6 months	Cycling program: cycling to 60-70% age adjusted maximum heart rate with 5 minutes of stretching prior to and after exercise.	Cycling program: cycling to 60-70% age adjusted maximum heart rate with 5 minutes of stretching prior to and after exercise.	
	Beach Volleyball: Kinect Sports' videogame that involved participant replicating several movements in volleyball including serves, bumps, sets, and spikes. system. Home exercise program: moderate- intensity aerobic physical activity for 30 minutes on 5 days each week, muscle strengthening and balance exercises 2 days a week, and flexibility exercises with stationary stretches every day for 4 weeks.	Non-aerobic exercises were performed in a single series containing 10 repetitions at an intensity of 40% of the estimated 1 repetitive maximum, including upper and lower extremity large muscle groups in standing and sitting positions, as a standard exercise protocol with moderate intensity. Additional training in balance and flexibility exercises were completed alongside muscle strengthening. Home exercise program: moderate- intensity aerobic physical activity for 30 minutes on 5 days each week, muscle strengthening and balance exercises 2 days a week, and flexibility exercises with stationary stretches every day for 4 weeks.	

Garcia-Palacios, 2015 <sup>64</sup>	Inclusion:	N=61	N=30	Primary: FIQ
High	Age 18 to 70 years old	Age, mean (SD): NR	Age, mean (SD): NR	<ul> <li>Pain-related functioning (6 wk)</li> <li>BPI- interference</li> </ul>
6 Weeks	American College of Rheumatology concordant diagnosis of	Women: 100%	Women: 100%	Pain intensity (6 wk)
Universitat Jaume I and Rheumatology Service of Hospital	fibromyalgia by a rheumatologist			• BPI- intensity
General de Castellon	Exclusion:		1 accession in the 4 weeks often the	Quality of life (6 wk)
NR	Severe mental disorders such as	week	pretreatment assessment	Quality of Life Index (QLI-Sp)
	schizophrenia, bipolar disorder, mental retardation, substance abuse or dependence, nor a mental disorder in need of immediate treatment	EMMA: Augmented reality display of 5 predefined scenarios aimed at promoting emotions and motivation. Scenarios include projected images, sounds and narratives.	Partiipcants continued "usual care in a rheumatology unit in a public setting in Spain that consists of follow-up sessions by a rheumatologist to review the	Other non-eligible outcomes reported • Chronic Pain Coping Inventory, • Beck Depression Inventory II (BDI-II) • Accentability and Satisfaction
	Requesting or suing for disability."	Scenarios chosen were beach and the meadow settings. Program structure involved a session with rationale of activity management for fibromyalgia and instructions to	medication treatment."	

	enhance motivation to start to perform meaningful activities (VR1). Another session explores overcoming barriers that prevent performance of activities (VR2). Lastly, a third session type provides instructions to acknowledge personal strengths that could motivate participants to get involved in meaningful activities (VR3). VR1 was used in session 2 of the program, VR2 was used in sessions 3 and 5, and VR3 was used in sessions 4 and 6."		
Inclusion:	N=28	N=27	Primary: EuroQoL-5D, VAS
Female gender Age 30 to 75 years 2010 American College of Rheumatology concordant fibromyalgia diagnosis by rheumatologist <b>Exclusion:</b> Any change to usual care therapies during the 24 weeks of the treatment Contraindications for physical exercise programs Pregnancy	Age, mean (SD): 54.04 (9.56)Female: 100%Clinic1 hour sessions twice per week; 24 weeks.VirtualEx-FM: Exergame program focused on postural control, coordination of upper and lower limbs, aerobic conditioning, strength and mobility in 3 virtual environments. Activity completed in groups of two participants.First, participants complete a warm- up by imitating an expert on video displaying upper and lower limb joint movements.Second, participants complete an aerobic dance routine by following dance steps marked by a kinesiologist and dance teacher.Third, participants train postural control and coordination by following on-screen prompts to reaching for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constrained by a screen for a virtual apple using a constra	Age, mean (SD): 53.41 (9.92) Female: 100% Clinic NR; NR Participants continued care as usual, including previous medication use.	<ul> <li>Pain-related functioning (24, 48 wk)</li> <li>FIQ</li> <li>Physical performance (24, 48 wk)</li> <li>6-minute walk test</li> <li>Sit-to-stand test</li> <li>10 step stair test (seconds)</li> <li>TUG</li> <li>Arm curl</li> <li>back scratch test</li> <li>sit and reach test (single and dual-task conditions)</li> </ul>
	Inclusion:         Female gender         Age 30 to 75 years         2010 American College of         Rheumatology concordant         fibromyalgia diagnosis by         rheumatologist         Exclusion:         Any change to usual care therapies         during the 24 weeks of the         treatment         Contraindications for physical         exercise programs         Pregnancy	enhance motivation to start to perform meaningful activities (VR1). Another session explores overcoming barriers that prevent performance of activities (VR2). Lastly, a third session type provides instructions to acknowledge personal strengths that could motivate participants to get involved in meaningful activities (VR3). VR1 was used in sessions 2 of the program, VR2 was used in sessions 3 and 5, and VR3 was used in sessions 3 and 5, and VR3 was used in sessions 3 and 5, and VR3 was used in sessions 4 and 6."Inclusion:N=28Female gender Age 30 to 75 yearsAge, mean (SD): 54.04 (9.56)2010 American College of Rheumatology concordant fibromyalgia diagnosis by rheumatologistVirtualEx-FM: Exergame program focused on postural control, 	enhance motivation to start to perform meaningful activities (VR1). Another session explores overcoming barriers that prevent performance of activities (VR2). Lastly, a third session type provides instructions to acknowledge personal strengths that could motivate participants to get involved in meaningful activities (VR3). VR1 was used in session 2 of the program, VR2 was used in sessions 3 and 5, and VR3 was used in sessions 4 and 6.*Inclusion:N=28N=27Female genderAge, mean (SD): 54.04 (9.56)Age, mean (SD): 53.41 (9.92)Age 30 to 75 yearsFemale: 100%Female: 100%Z010 American College of RheumatologistFemale: 100%Female: 100%Exclusion:VirtualEx-FM: Exergame program focused on postural control, cordination of upper and lower limbs, aerobic conditioning, strength and mobility in 3 virtual environments. Activity completed in groups of two participants.Participants continued care as usual, including previous medication use.PregnancyFirst, participants complete a varie aerobic condination of upper and lower limb joint movements.First, participants complete a varie arising a virtual apple using a specified limb. All activity is completed in groups of three.First, participants complete a second, participants complete a second, participants complete a second, articipants complete a virtual apple using a specified limb. All activity is completed in groups of three.First, participants complete a second, participants dance teacher.

Training is designed to improve physical conditioning.

Fourth, walk training is developed using a circuit comprising a trail of footprints on a virtual floor. Participants must step on the virtual footprints and walk on the circuit. Participants are guided regarding mplitude, cadence, and different types of step.

Abbreviations. 3D=3 dimensional; ACR=American College of Rheumatology; BP=blood pressure; BPI=Beck pain inventory; CG=control group; cm=centimeters; EuroQoL-5D=European Quality of Life 5 dimensions; FIQ=Fibromyalgia Impact Questionnaire; FM=fibromyalgia; FMS=fibromyalgia syndrome; HADS=Hospital Anxiety and Depression Scale; HR=heart rate; NR=not reported; QLI-Sp=Quality of Life Index (Spanish version) SD=standard deviation; TAU=treatment as usual; TUG=timed up and go test; VAS=Visual Analog Scale; VR=virtual reality; wk=weeks.

#### Author, Year Effect Measure Intervention Comparator Comparison VR or AR **Baseline Mean (SD) Baseline Mean (SD) Risk of Bias** Follow-Up Mean (SD), Mean Follow-UpMean (SD), Mean Change Change Pain-Related Functioning or Interference Carvalho, 201958 FIQR Diff $\Delta^*$ : 64.6 (16.1) 72.0 (9.1) AR 4 wk: 41.4 (13.6), -23.2\* 4 wk: 63.1 (13.6), -8.9\* 4 wk: -14.3 High 7 wk: 33.4 (6.3), -31.2\* 7 wk: 46.4 (13.0), -25.6\* 7 wk: -5.6 FIQR-physical function 7.2 (3.4) 7.5 (5.2) Diff $\Delta^*$ : subscale 4 wk: 5.1 (3.4), -2.1\* 4 wk: 6.0 (5.3), -1.5\* 4 wk: -0.6 7 wk: 4.6 (1.9), -2.6\* 7 wk: 3.5 (2.6), -4.0\* 7 wk: 1.4 Collado-Mateo, FIQ-100 (8 wk) 50.6 (12.9) 49.2 (15.3) Diff ∆\*: -8.3 201760 44.9 (13.8), -5.7\* 51.8 (16.4), 2.5\* AR FIQ-80 (without work) (8 42.6 (10.2) 42.4 (12.5) Diff $\Delta^*$ : -6.1 Some concerns wk) 43.3 (12.9), 0.9\* 37.3 (10.4), -5.3\* FIQ 100-physical 2.85 (1.73) 2.6 (2.1) Diff ∆\*: -0.3 impairment (8 wk) 2.53 (1.87), -0.32\* 2.5 (2.0), -3.0\* Garcia-Palacios, FIQ (6 wk) 60.6 (21.4) Diff ∆\*: -15.7 61.6 (19.9) 2015<sup>64</sup> 42.4 (15.7), -19.2\* 57.0 (17.5), -3.6\* AR Diff ∆\*: -5.7 **BPI-Interference** 32.2 (14.8) 32.3 (16.7) High (6 wk) 31.2 (17.7), -1.0\* 37.1 (12.9), 4.7\* Polat. 202157 FIQ-80 Diff $\Delta^*$ : 54.7 (13.3) 58.5 (9.2) AR 4 wk: 42.7 (11.8), -12\* 4 wk: 51.7 (9.1), -6.8\* 4 wk: -5.2 High 8 wk: 40.1 (12.8), -14.6\* 8 wk: 50.7 (12.1), -7.8\* 8 wk: -6.8 Villafaina, 201959 Diff $\Lambda^*$ : FIQR 53.2 (16.9) 54.2 (20.0) AR 24 wk: 51.6 (18.3), -1.6\* 24 wk: 55.4 (20.1), 1.2\* 24 wk: -2.8 Some concerns 48 wk: 51.1 (19.0), -2.1\* 48 wk: 52.1 (18.4), -2.1\* 48 wk: 0.01 Pain Intensity Garcia-Palacios, **BPI-Intensity** 23.6 (5.1) 22.4 (7.9) Diff ∆\*: 0.7 2015<sup>64</sup> (6 wk) 22.6 (6.3), -0.9 20.7 (8.3), -1.7 AR High Polat, 202157 VAS 6.40 (1.4) 6.45 (1.3) Diff $\Delta^*$ : AR 4 wk: 4.3 (1.3), -2.2\* 4 wk: 4.9 (1.4), -1.6\* 4 wk: -0.6 High 8 wk: 3.9 (2.1), -2.6\* 8 wk: 4.8 (1.6), -1.7\* 8 wk: -0.9 Villafaina, 201959 VAS (24 wk) 62.1 (19.3) 60.4 (19.3) Diff ∆\*: -11.1 AR 58.9 (16.3), -3.26 68.2 (17.3), 7.8 Some concerns Quality of Life Collado-Mateo, EuroQoL-5D 0.6(0.2)0.6 (0.2) Diff ∆\*: 0.1 201760 0.7 (0.2), 0.1\* 0.6 (0.2), 0.0\* (8 wk) AR Some concerns Garcia-Palacios, Quality of Life Index 4.5 (1.2) 5.0 (1.2) Diff ∆\*: 1.4 2015<sup>64</sup> (6 wk) 6.1 (1.4), 1.6\* 5.3 (1.3), 0.2\* AR High Polat, 202157 EuroQoL-5D 0.5 (0.2) 0.5 (0.1) Diff $\Delta^*$ : AR 4 wk: 0.7 (0.2), 0.2\* 4 wk: 0.6 (0.2), 0.1\* 4 wk: 0.1 (4 wk) High 8 wk: 0.8 (0.2), 0.3\* 8 wk: 0.6 (0.2), 0.1\* 8 wk: 0.2 Villafaina, 201959 EuroQoL-5D 0.5 (0.3) 0.57 (0.3) Diff ∆\*: 0.1 AR

### Appendix Table G2. Detailed Results for Fibromyalgia Studies



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-UpMean (SD), Mean Change	Comparison
Some concerns	(24 wk)	0.6 (0.2), 0.1*	0.52 (0.2), 0.0*	
Physical Performan	се			
Carvalho, 2019 <sup>58</sup> AR High	Number of Steps up/down (25 cm height)	97.6 (16.4) 4 wk: 112.1 (15.0), 14.5* 7 wk: 112.6 (12.1), 15.0*	93.0 (36.1) 4 wk: 95.7 (35.9), 2.7* 7 wk: 103.4 (30.9), 10.4*	Diff ∆*: 4 wk: 11.8 7 wk: 4.6
Collado-Mateo, 2017b <sup>61</sup> AR	TUG (8 wk)	6.7 (0.9) 6.2 (0.6), -0.5*	6.7 (0.8) 6.9 (1.1), 0.2*	Diff ∆*: -0.7
Some concerns	Functional reach (cm) (8 wk)	19.7 (7.5) 23.0 (5.2), 3.3*	19.5 (5.7) 18.4 (6.6), -1.1*	Diff ∆*: 4.4
Polat, 2021 <sup>57</sup> AR	6-minute walk test (m)	467.0) 6.7 (1.3), -0.8*	443.2.8), 1.0*	Diff ∆*: -1.8
Villafaina, 2019 <sup>59</sup> ; Martin-Martinez, 2019 <sup>62</sup>	TUG (24 wk)	7.5 (2.0) 6.7 (1.3), -0.8*	7.7 (1.6) 8.8 (2.8), 1.0*	Diff ∆*: -1.8
AR Some concerns	6-minute walk test (m)	491.2 (80.2) 24 wk: 506.5 (70.2), 15.3* 48 wk: 499.7 (80.1), 8.6*	517.5 (58.4) 24 wk: 498.2 (68.5), -19.2* 48 wk: 481.7 (92.3), -35.8*	Diff ∆*: 24 wk: 34.6 48 wk: 44.3
	Sit-to-stand test	10.9 (2.9) 24 wk: 11.8 (2.5), 0.8* 48 wk: 11.1 (2.7), 0.2*	11.67 (2.5) 24 wk: 11.00 (2.4), -0.7* 48 wk: 11.00 (2.9), -0.7*	Diff ∆*: 24 wk: 1.5 48 wk: 0.8
	10 step stair test (s)	5.4 (2.8) 24 wk: 5.2 (2.1), -0.2* 48 wk: 5.3 (1.8), -0.2*	5.5 (1.9) 24 wk: 5.6 (2.3), 0.1* 48 wk: 5.9 (2.3), 0.4*	Diff ∆*: 24 wk: -0.4 48 wk: -0.6

Notes. \*Calculated by review team.

Abbreviations. 5D=5 dimension; 5L=5 level; BPI=Beck Pain Inventory; cm=centimeters; Diff  $\Delta$ = difference in change scores; EuroQoL-5D=European Quality of Life 5 Dimensions; FIQ=Fibromyalgia Impact Questionnaire; FIQR= 2009 Revised Fibromyalgia Impact Questionnaire; SD=standard deviation; TUG=timed up and go test; VAS=Visual Analogue Scale; wk=weeks.

# **APPENDIX H. CHRONIC KNEE PAIN**

# Appendix Table H1. Detailed Characteristics for Included Trials on Chronic Knee Pain

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Follow-Up Duration		Setting	Setting	Other Non-Eligible Outcomes
Funding source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
VR Intervention				
Ozlu, 2023 <sup>65</sup>	Inclusion: Age between 40 and 64 years	N=41	N=41	Primary outcome NR
High		Age, mean (SD): 53.3(10.4)	Age, mean (SD): 53.7(9.7)	Pain-related functioning (3, 7
7 weeks	American College of Rheumatology concordant diagnosis of stage 2 or 3 knee OA	Female: 48.6%	Female: 68.4%	• WOMAC
Kutahya Health Sciences University, Turkey	Minimental status test score of ≥22	Clinic	Clinic	<ul><li>Pain intensity (3, 7 wk)</li><li>VAS</li></ul>
No funding	Exclusion:	15 mins VR (in addition to time for ultrasound and TENS) per day, 5 days a week (total 15 sessions) 3 weeks	27 mins per day, 5 days/week (total 15 sessions) 3 weeks	Physical performance (3, 7 wk)
	Recent or previous operation on the affected lower extremity	Fish Game: Participants wear Oculus VR glasses and intercept incoming	Therapeutic ultrasound to affected knee for 7 minutes	Berg Balance Scale
	History of lower extremity injury including fracture, meniscus and/or ligament tear	virtual fish using lateral flexion movement of the trunk. Training focused on weight transfer, balance	Transcutaneous electrical nerve stimulation on both knees for 20 minutes	
	History of intra-articular injection to the affected knee in preceding 6 months, knee	and proprioception of the patients.		
	physical therapy in preceding 6 months	Monkey Game: Participants wear Oculus VR glasses and intercept		
	History of rheumatological disease, septic arthritis, cardiovascular disease or other impairment affecting ability to exercise, balance, hearing or vision	incoming virtual bananas using lateral stepping movements. Training focused on patient depth sense.		

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	•
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
AR Interventions				
Elshazly, 2016 <sup>66</sup>	Inclusion:	AR Physical Activity: N=20	Sensorimotor Training (SMT): N=20	Primary outcome NR
Some concerns	Male and Female	Age, mean (SD): 58(6)	Age, mean (SD):	Pain-related functioning (4, 8 wk)
8 weeks	Age between 35 and 65 years	NR	60(8)	WOMAC Pain intensity
Prince Sattam Bin Abdul Aziz University, Saudi	$\ge$ 3 months of symptomatic osteoarthrits	NR	NR	(4, 8 wk) • VAS
Arabia	Ambulate at least 30 feet with or without assistance	15-30 minute sessions. 3 times weekly	NR	<ul><li>Physical performance (4, 8 wk)</li><li>Position sense</li></ul>
Grant from deanship of scientific research, Prince Sattam Bin Abdul	Not in any sports or physical therapy	8 weeks	3 times weekly; 8 weeks	<ul><li>Quality of life (4, 8 wk)</li><li>CDC Health Related Quality</li></ul>
Aziz University, Saudi Arabia	Able to complete physical therapy three times weekly	Light Race: Participants use Xbox 360 Kinect to step on a virtual platform displayed on a monitor. On-screen	Participants were trained through three stages:	of Life
	Exclusion:	forward, backward, right and left in both sitting and standing positions for 10 repetitions with a two-minute rest between exercises Exercises focused	Static [ie, standing upright position (30 s), single leg stance with closed eyes, half-step position for 10 s, one-leg balance for 10 s]	
	6 months of enrollment	on lower limb strength, flexibility, coordination, and balance. Sessions	Dynamic [ie, forward stepping thrust,	
	History of metal implants, peripheral vascular disease, infection, fever, mental	were held in small groups of three or less subjects	T-band kicks exercise],	
	deficit, femur or tibial condyle fracture, joint effusion, laboratory abnormality, systemic or psychiatric illness, corticosteroid use in the preceding 30 days, malignancy, gout or any other disease preventing participation		Functional [ie, 1) walking exercise on a firm surface, then on a foam surface: (a) toe skipping, (b) heel skipping; 2) squatting exercise: (a) against a wall and away from the wall, (b) one leg squats on affected and non-affected limbs; 3) balance exercise on wobble board: (a) multidirectional rolling movement from sitting, (b) multidirectional rolling movement from standing on both legs between parallel bars with eyes open, then eyes	

#### Evidence Synthesis Program

Author Voar	Inclusion/Exclusion Critoria	Intervention:	Comparator(s):	Primary Outcome
Aution, redi	inclusion/Exclusion Criteria	Intervention. Porticipanto Pondomizod	Comparator(5). Porticipanto Pandomizod	Fillinary Outcoille
Pisk of Bias		Faricipants Randomized	Farucipants Randomized	Elizible Outcomes & Messures
NISK OF DIAS		Domographico	Domographico	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
1 ollow-op Buration		<b>0</b> ///	<b>0</b> ///	
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
0110(0)				Reported
Funding source		Frequency; Duration	Frequency; Duration	
-		Detailed Intervention	Detailed Comparator	
		Characteristics	Characteristics	
		onaracteristics		
			ciosed, (c) multidirectional rolling	
			movement from standing on one leg	

between parallel bars with eyes open, then eyes closed]."

Conventional Exercise Therapy (CET): N=20

Age, mean (SD): 59(7)

NR

NR

3 times weekly; 8 weeks

5 minutes warm up followed by 12 minutes of walking at comfortable pace and 5 minutes cool down.

Lin, 2020 <sup>67</sup>	Inclusion:	N=40	N=40	Primary: WOMAC (only separate domain scores for
Some concerns	Age 40 to 85 years	Age, mean (SD): 55.9(15.8)	Age, mean (SD): 58.1(16.9)	pain, stiffness, & function)
3 months	American College of Rheumatology concordant diagnosis of knee OA	Female: 60%	Female: 42.5%	<ul><li>Pain intensity (2, 4, 8, 16 wk)</li><li>Chronic Pain Grade</li></ul>
Shin Kong Wu Ho-Su Memorial Hospital,	Kellgren and Lawrence score ≥2	Clinic	Clinic	Questionnaire- overall grade; disability points; disability score; pain intensity
laiwan	Able to walk > 15 m	3 times per week; 4 weeks	3 times per week; 4 weeks	Adverse events (4 wk)

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Grants from Shin Kong Wu Ho-Su Memorial Hospital and Ministry of Science and Technology, Taiwan	Able to undergo 4 weeks of treatment and 3 months of follow-up	Hot packs applied to both knees for 20 min, transcutaneous electric nerve stimulation (TENS) for 20 min, 20 min of active video games or therapeutic exercise	Hot packs applied to both knees for 20 min, transcutaneous electric nerve stimulation (TENS) for 20 min, 20 min of active video games or therapeutic exercise	<ul> <li>Non-specific adverse events</li> <li>Physical performance (2, 4, 8, 16 wk)</li> <li>Biodex Stability System,</li> </ul>
	Not needing non-steroidal anti-inflammatory drugs during the research	Whack-a-mole: Participants use Hot	Therapeutic exercise includes	Postural Stability & Limits of Stability,
	Exclusion:	Plus gaming system and a step sensing pad. Participants step on step	stretching warm-up, stabilization exercises, weight-shift training for	Stair ascent, descent times
	Any infection, inflammation, autoimmune disease, or fracture	sensing pad to stamp on-screen moles into holes. Training focused on fast movement and improving lower limb range of motion, strength and coordination. Activity lasts 10 minutes. Archery: Participants use Hot Plus	knees and peivis, cycling for 10 min with approximately 40% to 60% heart rate reserve, and stretching cool- down. Sandbag and Thera-band were used in strength exercises with a maximum of 10 repetitions and 5 to 10 repetitions per session, for 3 to 5 sets. Activity lasts for a total of 20 min and supervised by physical therapists.	WHOQOL-BREF (domain scores for physical, psychological, social, &
	History or underlying disease affecting posture and balance, such as malignancy, dizziness, vertigo, or stroke History of any knee operation or internal fixation			environmental) Other non-eligible outcomes reported
		gaming system and a step sensing pad. Participant steps on sensing pad to shoot arrows at on-screen targets. Training focused on fast movement and improving lower limb range of		<ul> <li>HADS</li> <li>Multidimensional Fatigue Inventory</li> <li>Work Ability Index</li> </ul>
	Pregnancy or planning to become pregnant	motion, strength, and coordination. Activity last 10 minutes.		ý
	Undergoing any other treatment for knee OA."			
Mete, 2022 <sup>68</sup>	Inclusion:	N=32	N=32	Primary outcome NR
High	Aged 40 to 65 years	Age, mean (SD): NR Median age: 59.5 (55,64)	Age, mean (SD): NR Median age: 57 (51, 65)	Pain related functioning or interference (6 wk)
6 Weeks	Diagnosis of knee OA			WOMAC-stiffness
Physical therapy and rehabilitation clinic of	Kellgren Lawrence stage 2 or 3	Female: 80%	Female: 76.6%	WOMAC-runction Pain intensity (6 wk)     WOMAC-rain
medical center (name	Exclusion:	Ginito	Cinito	• VAS
ואר, in istandul, i urkey	History of surgery at knee, hip, ankle, or/and foot, systemic anti-inflammatory joint	20 games for 5 days per week; 6 weeks	5 days per week; 6 weeks	Pain Catastrophizing (6 wk) <ul> <li>TSK</li> </ul>

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes Reported
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Marmara University Scientific Research Projects Committee (Project Number: SAG- C-YLP-070617-0349)	disease, any condition with contraindication for electrical stimulation and/or exercise, previous knee physiotherapy in preceding 6 months and a history of corticosteroid injection in preceding 3 months	Crazy Wings: Participant controls an on-screen bird avatar through obstacles using knee movement. Sensors from the MarVAJED system were placed above and below knee, which evaluate the ROM of the joints, analyze the sensation of joint position, and allow control of on-screen avatars. Knee flexion and extension triggers bird avatar movement up and down, respectively. Training aimed to have participants complete squat exercises. Blasting Ball: Participant controls the size of a virtual ball size on a screen through knee flexion. Sensors from the MarVAJED system were placed above and below knee, which evaluate the ROM of the joints, analyze the sensation of joint position, and allow control of on-screen avatars. The ball would explode when the degree of knee flexion reached a peak value. Training aimed to have participants complete leg press exercises and increase degree of knee flexion.	Electrotherapy, exercise program, hot and cold pack therapy, therapeutic ultrasound, and conventional transcutaneus electrical nerve stimulation were completed. Participants with edema were treated with a cold pack, and participants without edema received hot pack. Exercise program consists of isometric strengthening of the quadriceps muscle, terminal knee extension, leg press exercise with elastic band, and hamstring stretching. Elastic band training involved 3 sets of 10 repetitions.	<ul> <li>Physical performance (6 wk)</li> <li>PEDALO Sensamove balance score</li> <li>Knee flexion/extension ROM</li> <li>Knee proprioception at 30, 60 degrees</li> <li>Peak torque of knee flexion/extension (absolute and normalized to body weight) at 120°, 240°</li> </ul>
Nambi, 2020c <sup>69</sup>	Inclusion:	N=20	SMT:	Primary outcome NR
Some concerns	Male gender	Age, mean (SD): 22.8(1.3)	N=20	Pain related functioning or interference (4, 8 wk, 3 mo)
3 months	Age 18 to 25 years	NR	Age, mean (SD): 22.6(1.4)	WOMAC-total
Prince Sattam Bin Abdulaziz University	≥3 months post-traumatic osteoarthritis following ACL injury as diagnosed by an ethere dia surger	Clinic	NR	Pain intensity (4, 8 wk, 3 mo) • VAS
Hospital and King Khalid	ortnopeaic surgeon	2 20-minute sessions per day, 5 days a week; 4 weeks	Clinic	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes & Measures
Follow-Up Duration		Demographics	Demographics	Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding source		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Hospital, Al-Kharj, Saudi Arabia	Pain rating 4 to 8 in visual analog scale (VAS)	Participants used the Pro-Kin system	5 days per week; 4 weeks	Other non-eligible outcomes reported
Research at Princess Nourah bint	Exclusion:	involved standing on the affected limb and following commands on a	Sensorimotor training exercises in three consecutive stages: Static phase where the participant stands straight	<ul> <li>Bone morphogenic protein levels (BMP 2,4,5 and 7)</li> <li>Inflammatory biomarkers</li> </ul>
Abdulrahman University through the Fast-track Research Funding Program	Other orthopedic, neural, systemic, psychological diagnosis	computer display screen to shoot virtual balls. Interaction with balls was controlled by having the participant follow specified knee movements	for 30 seconds on a hard plate and 30 seconds on a foam plate. Next, the participant was instructed to stand on	serum levels (CRP, TNF- alpha, IL2, IL4 and IL6)
Togram	Any pending surgical procedure	tonow specified thee movements.	eyes for 20 seconds on a hard plate and 20 seconds on a foam plate,	
	Participation in any other treatment and physical training		followed by a semi knee bending position for 10 seconds. Dynamic phase where the participant performs forward kicking for 30 seconds and T- band kicking for 30 seconds. Functional phase where the participant was informed to do toe jumping for 20 meters and heel jumping for 20 meters. Then the participant performs bilateral and unilateral squatting exercises for 10 repetitions with and without the support of a wall. All exercises were continued for 3 sets each with 5 repetitions and 3 minutes rest between the sets.	
			Control, Supervised Exercise:	
			Age, mean (SD): 21.9(1.3)	
			NR	
			Clinic or health care facility	
			5 days per week; 4 weeks	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
		Participants Randomized	Participants Randomized	•
Risk of Bias			· · · · · · · · · · · · · · · · · · ·	Eligible Outcomes & Measures
		Demographics	Demographics	Reported (Time Points)
Follow-Up Duration		Demographico	Bennographilos	
		Patting	Cotting	Other Nen Elizible Outeemee
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
0.10(0)				Reported
Fundina source		Frequency; Duration	Frequency; Duration	
· ······				
		Detailed Intervention	Detailed Comparator	
		Characteristics	Characteristics	
			Control group completed supervised	
			conventional exercise programs for	
			the knee muscles. Exercises laid	
			the knee muscles. Exercises late	
			special stress on the quadriceps,	
			hamstrings, gluter, and calf muscles.	
			The participants performed 10–15	
			repetitions in one set for 3 sets with 1	
			minute rest between the sets. Then	
			participants completed stretching	
			focused on each muscle group for 3	
			repetitions for 15 accords per muscle	
			repetitions for 15 seconds per muscle	
			group"	

Abbreviations. ACL=anterior cruciate ligament; AR=augmented reality; BMP=bone morphogenic protein; CET=conventional exercise therapy; CDC=Centers for Disease Control and Prevention; CRP=C reactive protein; HADS=Hospital Anxiety and Depression Scale; IL=interleukin; m=minutes; MarVAJED=Marmara visual auditory joint education device; Nm=Newton meter; NR=not reported; OA=osteoarthritis; PTOA=post-traumatic osteoarthritis; ROM=range of motion; s=seconds; SD=standard deviation; TENS= transcutaneous electric nerve stimulation; TNF=tumor necrosis factor; US=ultrasound; VAS=visual analogue scale; VRT=virtual reality training; WHO-BREF=World Health Organization Quality of Life-Brief Version; WOMAC=Western Ontario and McMaster Universities Arthritis Index.

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Pain-Related Fu	nctioning or Interfe	rence		
Elshazly, 2016 <sup>66</sup> AR Some concerns	WOMAC-total	71.6 (3.4) 4 wk: 39.8 (7.8), -31.9* 8 wk: 14.6 (3.1), -57.0*	Sensorimotor training (SMT) 71.7 (2.8) 4 wk: 53.3 (3.8), -18.4* 8 wk: 34.1 (3.9), -37.6*	Diff ∆*: 4 wk: -13.5 8 wk: -19.5
			Conventional exercise training (CET) 71.9 (3.05) 4 wk: 54.1 (6.1), -17.8* 8 wk: 44.8 (4.3), -27.2*	Diff ∆*: 4 wk: -14.05 8 wk: -29.9
Lin, 2020 <sup>67</sup> AR Some concerns	WOMAC- function	505.1 (328.4) 2 wk: 520.3 (296.7),15.2* 4 wk: 510.6 (303.5), 5.5* 8 wk: 472.5 (300.1), -32.6* 16 wk: 456.4 (298.2), -48.7*	581.0 (383.8) 2 wk: 557.1 (218.5), -23.9* 4 wk: 526.2 (314.6), -54.8* 8 wk: 458.4 (331.1), -122.6* 16 wk: 449.5 (220.2), -131.5*	Diff ∆*: 2 wk: 39.1 4 wk: 60.3 8 wk: 90.0 16 wk: 82.8
	Graded Chronic Pain Scale, Overall Pain Grade	1.5 (0.4) 2 wk: 1.3 (0.3), -0.2* 4 wk:1.2 (0.3), -0.3* 8 wk:1.2 (0.2), -0.3* 16 wk: 1.0 (0.2), -0.5*	1.4 (0.5) 2 wk: 1.4 (0.4), 0.0* 4 wk: 1.2 (0.1), -0.2* 8 wk: 1.3 (0.3), -0.1* 16 wk: 1.1 (0.2), -0.3*	Diff ∆*: 2 wk: -0.2 4 wk: -0.1 8 wk: -0.2 16 wk: -0.2
	Graded Chronic Pain Scale, disability score	38.6 (20.8) 2 wk: 35.7 (20.3), -2.9* 4 wk: 34.2 (21.2), -4.4* 8 wk: 33.2 (19.3), -5.4* 16 wk: 34.4 (19.2), -4.2*	39.3 (21.5) 2 wk: 38.3 (21.7), -1.0* 4 wk: 37.6 (20.4), -1.7* 8 wk: 36.7 (19.6), -2.6* 16 wk: 35.6 (20.3), -3.7*	Diff ∆*: 2 wk: -1.9 4 wk: -2.7 8 wk: -2.8 16 wk: -0.5
Mete, 2022 <sup>68</sup> AR High	WOMAC-total	Means NR Medians (IQR): 19.7 (18.2, 21) 6 wk: 7.59 (4.95, 9.4)	Means NR Medians (IQR): 15.1 (9.3, 18) 6 wk: 9.9 (6.4, 11.5)	Diff ∆: NC
	WOMAC- function	Means NR Medians (IQR): 6.74 (6.4, 7.2) 6 wk: 2.35 (2, 3.38)	Means NR Medians (IQR): 5.2 (5.7, 6.4) 6 wk: 3.23 (2.45, 3.18)	Diff ∆: NC
Nambi, 2020c <sup>69</sup> AR Some concerns	WOMAC-total	72.33 (4.2) 4 wk: 34.1 (3.4), -38.2* 8 wk: 22.4 (2.1), -49.9* 3 mo: 11.2 (2.1), -61.1*	SMT: 72.47 (4.5) 4 wk: 56.3 (3.8), -16.2* 8 wk: 32.4 (2.8), -40.1* 3 mo: 25.3 (2.1), -47.2*	Diff ∆*: 4 wk: -22.1 8 wk: -9.8 3 mo: -13.9
			CET: 71.2 (3.8) 4 wk: 62.3 (3.2), 8 wk: 52.3 (3.2), -18.9* 3 mo: 35.2 (2.8), -36.0*	Diff ∆*: 4 wk: -29.3 8 wk: -30.9 3 mo: -25.1

# Appendix Table H2. Detailed Results for Chronic Knee Pain Studies

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Ozlu, 2023 <sup>65</sup> VR High	WOMAC-total	31.66 (6.75) 3 wk: 23.1 (8.7), -8.6* 7 wk: 26.4 (9.4), -5.2*	33.0 (7.86) 3 wk: 33.1 (7.9), 0.1* 7 wk: 32.9 (7.9), -0.2*	Diff ∆*: 3 wk: -8.7 7 wk: -5.0
Pain Intensity or	Severity			
Elshazly, 2016 <sup>66</sup> VR Some concerns	VAS	6.81 (0.87) 4 wk: 3.7 (1.1), -3.1* 8 wk: 2.9 (0.97), -3.9*	SMT: 6.62 (1.17) 4 wk: 5.4 (0.96), -1.2* 8 wk: 4.5 (0.8), -2.1* CET: 6.68 (0.84) 4 wk: 5.37 (0.9) -1.3*	Diff ∆*: 4 wk: -1.9 8 wk: -1.8 Diff ∆*: 4 wk: -1.8 8 wk: -1.8
			8 wk: 4 74 (0 7) -1 9*	0 WK1.97
Lin, 2020 <sup>67</sup> AR Some concerns	WOMAC-pain	161.2 (114.7) 2 wk: 160.9(109.4), -0.3* 4 wk: 155.6 (103.1), -5.6* 8 wk: 119.8 (89.5), -41.4* 16 wk: 102.3 (88.9), -58.9*	170.2 (121.3) 2 wk: 169.2 (120.1), -1.0* 4 wk: 160.7 (118.2), -9.5* 8 wk: 148.7 (106.7), -21.5* 16 wk: 106.4 (97.3), -63.8*	Diff ∆*: 2 wk: 0.7 4 wk: 3.9 8 wk: -19.9 16 wk: 4.9
	WOMAC- stiffness	76.9 (60.4) 2 wk: 74.3 (59.1), -2.6* 4 wk: 72.8 (56.7), -4.1* 8 wk: 69.9 (52.2), -7.0* 16 wk: 64.4 (52.1), -12.5*	65.2 (53.7) 2 wk: 66.1 (52.4), 0.9* 4 wk: 67.2 (53.2), 2.0* 8 wk: 61.6 (51.6), -3.6* 16 wk: 63.4 (55.7), -1.8*	Diff ∆*: 2 wk: -3.5 4 wk: -6.1 8 wk: -3.4 16 wk: -10.7
	Graded Chronic Pain Scale, pain intensity	47.8 (20.3) 2 wk: 42.5(19.5), -5.3* 4 wk: 46.2 (19.3), -1.6* 8 wk: 44.6 (20.1), -3.2* 16 wk: 43.3 (19.4), -4.5*	48.4 (20.7) 2 wk: 49.7 (19.5), 1.3* 4 wk: 48.2 (21.2), -0.2* 8 wk: 47.3 (19.1), -1.1* 16 wk: 46.5 (18.2), -1.9*	Diff ∆*: 2 wk: -6.6 4 wk: -1.4 8 wk: -2.1 16 wk: -2.6
Mete, 2022 <sup>68</sup> AR High	VAS at rest	Means NR Medians (IQR): 32.2 (20.75, 40 6 wk: 10 (0, 12.5)	Means NR Medians (IQR): 36.6 (30, 40) 6 wk: 20 (10, 20)	Diff ∆: NC
	VAS with activity	Means NR Medians (IQR): 74.2 (60, 80) 6 wk: 30 (30, 40)	Means NR Medians (IQR): 65.2 (50, 70) 6 wk: 40 ( 30, 40)	Diff ∆: NC
	VAS at night	Means NR Medians (IQR): 43 (27.5, 40) 6 wk: 10 (0, 20)	Means NR Medians (IQR): 44 (20, 50) 6 wk: 20 (10, 30)	Diff ∆: NC
	WOMAC-pain	Means NR Medians (IQR): 6 (5.37, 7.12) 6 wk: 2.25 (1.5, 3)	Means NR Medians (IQR): 4.5 (4.3, 6) 6 wk: 3 (2.5, 4)	Diff ∆: NC
Nambi, 2020c <sup>69</sup> AR Some concerns	VAS	7.2 (0.5) 4 wk: 3.3 (0.4), -3.9* 8 wk: 2.5 (0.4), -4.7*	SMT: 7.4 (0.4) 4 wk: 5.8 (0.5), -1.6* 8 wk: 3.5 (0.5), -3.9*	Diff ∆*: 4 wk: -2.3 8 wk: -0.8

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
		3 mo: 0.5 (0.3), -6.7*	3 mo: 1.5 (0.4), -5.9*	3 mo: -0.8
			Control: 7.3 (0.4)	Diff $\Delta^*$ :
			4 wk: 6.5 (0.5), -0.8*	4 wk: -3.1
			8 wk: 4.2 (0.5), -3.1*	8 wk: -1.6
			3 mo: 3.8 (0.4), -3.5*	3 mo: -3.2
Ozlu, 2023 <sup>65</sup>	Visual analog	5.57 (0.88)	5.78 (0.74)	Diff $\Delta^*$ :
VR	scale (VAS)	3 wk: 4.11 (1.34), -1.46*	3 wk: 5.05 (1.43), -0.73*	3 wk: -0.73
High		7 wk: 4.05 (0.72), -1.52*	7 wk: 5.36 (0.99), -0.42*	7 wk: -1.1
Adverse Events				
Lin, 2020 <sup>67</sup> AR Some concerns	Adverse effects (during 4 wks of intervention)	"No adverse effects were repor group."	ted during or after treatment in either	NR
Pain Catastrophiz	zing & Kinesiophob	pia		
Mete, 2022 <sup>68</sup>	TSK	Means NR	Means NR	Diff $\Delta$ : NC
AR		Medians (IQR):	Medians (IQR):	
High		46.5 (42.7, 50)	48 (45, 49.25)	
		6 wk: 39 (36.7, 40)	6 wk: 45.5 (41, 48)	
Quality of Life				
Elshazly,	CDC Health	1.35 (0.48)	SMT:	Diff $\Delta^*$ :
201600	Related Quality	4 wk: 3.1 (0.5), 1.8*	1.60 (0.50)	4 wk: 0.9
AR	OI LIIE	8 wk: 4.5 (0.6), 3.2*	4 wk: 2.5 (0.5), 0.9*	8 wk: 1.4
Some concerns			8 wk: 3.3 (0.5), 1.7*	
			CET:	Diff $\Delta^*$ :
			1.6 (0.51)	4 wk: 1.1
			4 wk: 2.2 (0.4), 0.7*	8 wk: 2.2
			8 wk: 2.5 (0.5), 0.95*	
Lin, 2020 <sup>67</sup>	WHOQOL-	58.1 (10.2)	53.4 (12.1)	Diff $\Delta^*$ :
AR	BREF Physical	2 wk: 58.4 (9.1), 0.3*	2 wk: 53.1 (11.5), -0.3*	2 wk: 0.6
Some concerns		4 wk: 59.2 (7.4), 1.1*	4 wk: 53.2 (11.2), -0.2*	4 wk: 1.3
		8 wk: 59.3 (7.5), 1.2*	8 wk: 54.1 (10.3), 0.7*	8 wk: 0.5
		16 wk: 61.1 (6.6), 3.0*	16 wk: 54.5 (10.9), 1.1*	16 wk: 1.9
	WHOQOL-	57.2 (10.4)	58.7 (9.8)	Diff $\Delta^*$ :
	BREF	2 wk: 57.5 (10.1), 0.3*	2 wk: 58.9 (9.8), 0.2*	2 wk: 0.1
	Fsychological	4 wk: 58.1 (9.6), 0.9*	4 wk: 59.0 (9.4), 0.3*	4 wk: 0.6
		8 wk: 58.4 (9.7), 1.2*	8 wk: 59.4 (8.9), 0.7*	8 wk: 0.5
		16 wk: 60.0 (9.4), 2.8	16 wk: 60.2 (8.8), 1.5	16 wk: 1.3
	WHOQOLBREF	57.3 (12.60)	54.4 (12.60)	Diff $\Delta^*$ :
	, social	2 wk: 57.4 (11.2), 0.1*	2 wk: 55.9 (13.9), 1.5*	2 wk: -1.4
		4 wk: 58.2 (10.8), 0.9*	4 wk: 55.9 (14.4), 1.5*	4 wk: -0.6
		8 wk: 58.4 (10.1), 1.1*	8 wk: 57.3 (13.7), 2.9*	8 wk: -1.8
		16 wk: 60.3 (9.9), 3.0*	16 wk: 57.4 (13.2), 3.0*	16 wk: 0.0



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
	WHOQOL-	60.4 (9.8)	58.9 (10.6)	Diff ∆*:
	BREF,	2 wk: 60.8 (9.9), 0.4*	2 wk: 59.2 (10.2), 0.3*	2 wk: 0.1
	environmental	4 wk: 61.1 (10.1), 0.7*	4 wk: 59.3 (9.8), 0.4*	4 wk: 0.3
		8 wk: 61.3 (9.2), 0.9*	8 wk: 59.7 (10.1), 0.8*	8 wk: 0.1
		16 wk: 61.9 (9.3), 1.5*	16 wk: 60.2 (9.6), 1.3*	16 wk: 0.2
Physical Perform	ance			
Elshazly,	Position sense	118.9 (4.60)	SMT:	Diff ∆*:
201666		4 wk: 127.6 (2.06), 8.7*	120.5 (4.16)	4 wk: 5.7
VR		8 wk: 134.0 (1.16), 15.1*	4 wk: 123.5 (2.28), 3.0*	8 wk: 8.6
Some concerns			8 wk: 127.0 (1.93), 6.5*	
			CET:	Diff $\Delta^*$ :
			120.95 (3.79)	4 wk: 6.6
			4 wk: 123.1 (3.29), 2.15*	8 wk: 11.6
			8 wk: 124.45 (2.96), 3.5*	
Lin, 2020 <sup>67</sup>	Biodex Stability	0.7 (0.5)	0.8 (0.4)	Diff $\Delta^*$ :
AR	System,	2 wk: 0.6 (0.4), -0.1*	2 wk: 0.7 (0.5), -0.1*	2 wk: 0.0
Some concerns	Postural Stability	4 wk: 0.6 (0.5), -0.1*	4 wk: 0.6 (0.4), -0.2*	4 wk: 0.1
		8 wk: 0.5 (0.3), -0.2*	8 wk: 0.5 (0.3), -0.3*	8 wk: 0.1
		16 wk: 0.5 (0.2), -0.2*	16 wk: 0.5 (0.4), -0.3*	16 wk: 0.1
	Biodex Stability	40.2 (12.9)	41.5 (12.7)	Diff $\Delta^*$ :
	System, Limits	2 wk: 41.0 (12.6), 0.8*	2 wk: 42.1 (14.8), 0.6*	2 wk: 0.2
	of Stability	4 wk: 42.1 (12.1), 1.9*	4 wk: 41.9 (14.1), 0.4*	4 wk: 1.5
		8 wk: 43.4 (11.5), 3.2*	8 wk: 42.6 (13.2), 1.1*	8 wk: 2.1
		16 wk: 45.5 (10.7), 5.3*	16 wk: 44.3 (12.4), 2.8*	16 wk: 2.5
	10 meter	14.1 (7.6)	15.8 (7.3)	Diff $\Delta^*$ :
	walking time (s)	2 wk: 14.7 (6.7), 0.6*	2 wk: 15.3 (6.4), -0.5*	2 wk: 1.1
		4 wk: 12.6 (5.2), -1.5*	4 wk:14.4 (5.9), -1.4*	4 wk: -0.1
		8 wk: 12.1 (4.9), -2.0*	8 wk: 13.9 (5.6), -1.9*	8 wk: -0.1
		16 wk: 11.2 (4.1), -2.9*	16 wk: 13.8 (4.7), -2.0*	16 wk: -0.9
	Stair ascent time	18.8 (10.3)	17.5 (12.3)	Diff $\Delta^*$ :
	(s)	2 wk: 17.9 (10.2), -0.9*	2 wk: 16.8 (12.7), -0.7*	2 wk: -0.2
		4 wk: 17.3 (11.8), -1.5*	4 wk: 15.9 (12.4), -1.6*	4 wk: 0.1
		8 wk: 14.9 (12.7), -3.9*	8 wk:15.5 (13.2), -2.0*	8 wk: -1.9
		16 wk: 14.8 (11.9), -4.0*	16 wk: 14.9 (10.8), -2.6*	16 wk: -1.4
	Stair descent	17.9 (10.8)	15.5 (11.3)	Diff $\Delta^*$ :
	time (s)	2 wk: 17.8 (10.7), -0.1*	2 wk: 15.8 (11.2), 0.3*	2 wk: -0.4
		4 wk: 16.3 (10.5), -1.6*	4 wk: 14.5 (10.4), -1.0*	4 wk: -0.6
		8 wk: 15.9 (12.7), -2.0*	8 wk: 14.3 (10.2), -1.2*	8 wk: -0.8
		16 wk: 14.6 (11.9), -3.3*	16 wk: 14.1 (9.8), -1.4*	16 wk: -1.9
	Pedalo Balance	Means NR	Means NR	Diff ∆: NC
	Score	Medians (IQR):	Medians (IQR):	
	(percentage)	57 (50.2, 62.2)	70 (60, 78.5)	
		6 wk: 75 (65, 80)	6 wk: 72.5 (63.7, 80)	
Mete, 2022 <sup>68</sup>	Knee Flexion	Means NR	Means NR	Diff $\Delta$ : NC
AR	ROM (°) (6 wk)	Medians (IQR):	Medians (IQR):	
High		100 (95, 110.5)	110 (100, 120)	
		6 wk: 115.5 (110 and 120)	6 wk: 111.5 (104.7 and 120)	

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
	Knee proprioception at 30° (6 wk)	Means NR Medians (IQR) 6.25 (5.75, 8) 6 wk: 3.5 (3, 4)	Means NR Medians (IQR): 7 (6, 8) 6 wk: 6 (5, 7)	Diff ∆: NC
	Knee proprioception at 60° (6 wk)	Means NR Medians (IQR): 8 (6, 10) 6 wk: 4 (3, 5)	Means NR Medians (IQR): 9 (7.3, 10) 6 wk: 8 (6, 9)	Diff ∆: NC
	Peak Torque of knee flexion at 120° (normalized, Nm/kg) (6 wk)	Means NR Medians (IQR): 23.5 (14, 30) 6 wk: 36.9 (26.4, 47)	Means NR Medians (IQR): 20 (12, 26) 6 wk: 30.8 (24.3, 40.5)	Diff ∆: NC
	Peak Torque of knee extension at 120° (normalized, Nm/kg) (6 wk)	Means NR Medians (IQR): 27.9 (21.6, 39.2) 6 wk: 52.5 (43.7, 66.2)	Means NR Medians (IQR): 25.6 (17.7, 35.8) 6 wk: 40.2 (30.6, 60)	Diff ∆: NC
	Peak Torque of knee flexion at 240° (normalized, Nm/kg) (6 wk)	Means NR Medians (IQR): 16.4 (12.4, 23.5) 6 wk: 26 (21.3, 31.4)	Means NR Medians (IQR): 15.8 (10, 21.4) 6 wk: 22.12 (19, 28)	Diff ∆: NC
	Peak Torque of knee extension at 240° (normalized, Nm/kg) (6 wk)	Means NR Medians (IQR): 16.4 (13, 24.8) 6 wk: 36.8 (26.3, 44.2)	Means NR Medians (IQR): 20.3 (13.4, 26.4) 6 wk:31.7 (22.5, 39)	Diff ∆: NC
Ozlu, 2023 <sup>65</sup> VR High	6-minute walk test (m)	525.1 (70.5) 3 wk: 525.1 (70.5), 0.0* 7 wk: 526.3 (68.5), 1.1*	530.4 (54.6) 3 wk: 531.3 (54.6), 0.9* 7 wk: 532.5 (67.3), 2.1*	Diff ∆*: 3 wk: -0.9 7 wk: -0.9
	Berg Balance Scale	42.8 (4.8) 3 wk: 45.3 (4.2), 2.5* 7 wk: 46.0 (4.0), 3.6*	42.9 (5.9) 3 wk: 43.5 (6.07), 0.6* 7 wk: 43.2 (6.0), 0.3*	Diff ∆*: 3 wk: 1.9 7 wk: 2.9

Notes. \* Calculated by review team.

Abbreviations. AR=augmented reality; CET=conventional exercise training; Diff ∆= difference in change scores; IQR=interquartile range; NC=not calculable; Nm=Newton meter; NR=not reported; PT=physical therapy; ROM=range of motion; SD=standard deviation; SMT=sensorimotor training; VAS=visual analogue scale; VR=virtual reality; WHOQOL-BREF=World Health Organization Quality of Life-Brief Version; wk=weeks; WOMAC=Western Ontario and McMaster Universities Arthritis Index.



K

190

# **APPENDIX I. KQ1 OTHER CONDITIONS**

# Appendix Table I1. Detailed Characteristics for Included Trials on KQ1 Other Conditions

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time
Follow-Up Duration		Setting	Setting	Points)
Site(s)				Other Non-Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
VR Intervention				
Cuneo, 2023 <sup>70</sup>	Inclusion: "All participants met the International Classification of Headache	N=25	N=25	Primary: mean monthly headache days
High	Disorders (ICHD-3 beta) criteria for chronic migraine, as diagnosed by UW	Age, mean (SD): 42.71 (16.07)	Age, mean (SD): 42.05 (14.65)	Pain-related functioning (12
12 weeks	disorders. All subjects had experienced at least 15 headache days (including at	Female: 78.6%	Female: 86.4%	Migraine Disability     Assessment (MIDAS)
University of Washington	least 8 migraine days) per month in the preceding 3 months. Additional inclusion	Home	Home	
Osher Center for Integrative Medicine Small Research Project	tive tive	10 minutes/day, at least 3 days/week	10 minutes/day, at least 3 days/week	<ul><li>Pain intensity/severity (12 wk)</li><li>Monthly headache days</li></ul>
Grant	<b>Exclusion:</b> "Excluded participants were those with cognitive impairment, severe psychiatric comorbidities (including active suicidal or homicidal ideation and/or psychosis), hearing/seeing difficulties,	"Respiratory rate associated with the lowest LF/HF ratio was chosen as the participant's optimal respiratory rate. Then calming music with	Waitlist control group	<ul> <li>Pain catastrophizing (12 wk)</li> <li>Concerns About Pain (CAP) scale</li> </ul>
	epileptic or non-epileptic seizures, and prisoners."	ascending tones (to cue inhalation) and descending tones (to cue exhalation) at the participant specific optimal respiratory rate was uploaded into the participant's		<ul> <li>Adverse events (12 wk)</li> <li>% of participants with nausea or dizziness</li> </ul>
		biofeedback-VR device. The Oculus Go headset was placed on the participant's headwith the option to choose between 2 VR environments, a beach or hilltop settingThe participant was then guided through a trial biofeedback- VR session During the 10-minute session, participants were asked to "try to improve" the appearance of their feedbacked HRV tracing so		Non-eligible: PHQ-8; Perceived Stress Scale; Insomnia (PROMIS); total acute medication use per month (prescription and over- the-counter)

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		that it resembled a sine wave-like curve, the "reward" reflecting synchronous entrainment of respiration and HRV."		
Chuan, 2023 <sup>71</sup>	Inclusion: "treating oncologist or palliative care physician diagnosed	N=19	N=20	Primary: feasibility, acceptability, recruitment
Some concerns	symptoms of neuropathic pain caused by cancer or interventions for their cancer,	Age, mean (SD): 56 (8)	Age, mean (SD): 63 (11)	rates, and risk of cybersickness
3 months	independent in most activities of daily living with an Eastern Cooperative	Female: 58%	Female: 70%	Pain-related functioning (1
Cancer Therapy Centre, Liverpool Hospital, Sydney,	Oncology Group Performance Status score ≤ 2"	Clinic	Clinic	BPI-Interference
Australia	<b>Exclusion:</b> "Patients with psychological	3 x 30-min sessions within a 4-week period	3 x 30-min sessions within a 4-week period	Pain intensity/severity (1 mo, 3 mo)
Tour de Cure Cancer Foundation, HCF Health Foundation. and the	therapy or medications were excluded."			BPI-Intensity
NSW Health Department Agency for Clinical Innovation	ency	reality-delivered software programme that taught pain self- efficacy to patients using progressive muscle relaxation and guided pain visualisation techniquesFor example, a computer-generated, anatomically	instead asked to view a selection of short documentaries and videos specifically filmed in a virtual reality format for viewing through a virtual reality headset. These publicly available videos were selected from the dedicated virtual reality channel	Adverse events (1 mo) • Counts of participants with dizziness, nausea, and eyestrain during any session
		correct human body highlighted the deltoid and biceps muscles of the proximal arm, asking the patient to localise tension before guiding the patient in a scripted relaxation	on YouTube. In their 30-minute session, patients could choose from any of the following: a documentary on jaguars in Brazil, a documentary on the Apollo 11 moon landing, an	<ul> <li>Quality of life (1 mo, 3 mo)</li> <li>QLQ-C30 (only global quality subscale)</li> </ul>
		exercise. In the pain visualisation	animated cartoon in a snow	Opioid use (1 mo, 3 mo)
		therapy, an angry, fiery ball symbolised the patient's neuropathic pain, evoking imagery of burning	environment and a car review "	Average MME in the previous week
		and shooting."		Non-eligible: feasibility, acceptability, recruitment rates, tolerability

	la charles (Frankssien, Oritania	h-4	<b>0</b>	Duine Outran
Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias				Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Darnall, 2020 <sup>72</sup>	Inclusion: " aged 18-75 years with self-reported chronic nonmalignant low	N=35	N=39	Primary: Defense and Veterans Pain Rating Scale
High	back pain or fibromyalgia, with an average pain intensity >4 over the past	NR	NR	(DVPRS)
22 days	months."	Female: 26%	Female: 13%	Pain-related functioning (21 days)
Community health system, United States	Exclusion: NR	Home	Home	<ul> <li>DVPRS-Stress, Mood, Sleep, &amp; Activity domains</li> </ul>
AppliedVR Inc.		21-day program with 4-8 treatment sessions from 1-15 minutes.	21-day program with 4-8 treatment sessions from 1-15 minutes.	Pain intensity/severity (21 days)
Boungida 2022 <sup>73,121</sup>		"Treatment consisted of a variety of sessions to support participants in learning self-management skills based on evidence-based CBT principles as well as biofeedback and mindfulness strategies used in pain management. The program was designed to improve self- regulation of cognitive, emotional, and physiological responses to stress and pain and comprised 3 main content categories: skills rooted in pain CBT relaxation training[and] mindfulness"	"The audio program consisted of the majority of the same narrative content contained in the VR program, with changes made to the descriptive titles for each session approximately one-third of the VR program could not be included verbatim in the audio. Rather, the audio session topical content was closely matched to the corresponding VR session for that day and adapted to eliminate any references to visual content that would be confusing to the listener"	<ul> <li>DVPRS-Pain Rating Scale</li> <li>Pain catastrophizing (21 days)         <ul> <li>PCS (no follow-up data, only model statistics)</li> </ul> </li> <li>Adverse events (22 days)</li> <li>Pain global change (22 days)         <ul> <li>PGIC</li> </ul> </li> <li>Non-eligible: Pain Self-Efficacy Questionnaire, Patient satisfaction with VR</li> </ul>
Some concerns	diagnosis of MBC, be over 18 years, be able to physically wear and tolerate the	N=20 Age mean (SD): 52.7 (13.2)	N=18 Age mean (SD): 51.28 (9.32)	Primary: EQ-5D-5L
	VR headset, and have experienced		, ge, mean (02). 01.20 (0.02)	days, 9 days)
4 weeks	the week prior to enrolment"	Women: 100%	Women: 100%	BPI-short form (11 items)
Community health system, New Zealand	<b>Exclusion</b> : "any visual, hearing, or cognitive impairments that would limit their ability to take part in the study or if	Home	Home	Adverse events (9 days)
	anon ability to take part in the study, of it			Quality of the (7 days)

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Breast Cancer Foundation New Zealand (Grant #3719356)	they could not read, speak, or write in English."	>10 minutes/day, 1 week Ripple, 1 week washout, 1 week Happy Place	>10 minutes/day, 1 week Happy Place, 1 week washout, 1 week Ripple	<ul> <li>EuroQoL-5D (only transformed scores)</li> </ul>
		Randomization was to order of VR interventions.: "Group 1 used Ripple, then Happy Place (R:HP), and Group 2 experienced Happy Place before Ripple (HP:R). "Happy Placeis a commercially available VR application in which participants experience a tranquil, animated camping scene. Participants experience changes to the weather and time of day and can interact with optional tasks, guided relaxation, and soothing music. Ripple is a collection of three short 360° [and] are as follows: 1) a beach where the participant can write words in the sand or the sky; 2) a waterfall where the participant can stack stones; and 3) a mountain range where the participant can jump between different locations amongst mountaintops and lakes."	Happy Place, then Ripple (HP:R). There was a one-week washout period to minimise carryover effects between the two interventions"	Non-eligible: FACIT-Fatigue, DASS (Depression, Anxiety and Stress Scales), Acceptability & satisfaction questions/rating
Wankhade, 2022 <sup>74</sup>	Inclusion: "Patients between the age group of 40-60 yearsand having stage 2 or stage 3 primary or idiopathic frozen	N=25	N=25	Primary: not specified
nıyı)	shoulder."		אזא	wk)
2 weeks	Exclusion: "Patients with any post-	NR	NR	NRS
Data Meghe Institute of Medical	operative nistory of shoulder joint, fractures, subluxations or dislocations,	Clinic	Clinic	Pain intensity/severity (2 wk)
Sciences, Musculoskeletal OPD of Acharya, Vinoba Bhave Rural Hospital, Sawangi (Meghe), Wardha, India	diabetes, rheumatoid arthritis etc."	15-20 minute daily sessions for 2 weeks	15-20 minute daily sessions for 2 weeks	<ul> <li>Shoulder Pain and Disability Index (SPADI) Scale</li> </ul>
		"patients were treated with		Physical performance (2 wk)
		Oculus-guided physical therapy in		Shoulder flexion



Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Pandomized	Comparator(s):	Primary Outcome
Risk of Bias				Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		addition to Maitland's mobilizationHand Physics Lab on Oculus Quest is a program that allows participants to use their hands and fingers to interact with a virtual environment as well as other goods and experiences. Various shoulder movements such as shoulder internal and external rotations can be performed with the help of this games. Shoulder extensions flexion activities can also be carried out with the help of virtual reality games. This various gaming on virtual reality is useful for improving range of motion of joint."	"conventional therapy which included Maitland's mobilization"	<ul> <li>Shoulder extension</li> <li>Shoulder abduction</li> <li>Shoulder adduction</li> <li>Shoulder internal</li> <li>Shoulder external</li> </ul>
AR Interventions				
Ambrosino, 2020 <sup>75</sup> Some concerns	<b>Inclusion:</b> "40 consecutive inpatients 18–35 years of age, diagnosed with RA according to the 1987 American College	N= 20 Age, mean (SD): 27.05 (5.71)	N=20 Age, mean (SD): 27.85 (3.41)	Primary: "Our study is aimed to assess the effectiveness of home exergaming with a
12 weeks	referring to our Intensive Orthopedic and Rheumatologic	Female: 65%	Female: 60%	nonimmersive videogame system as an additional
Intensive Orthopedic and Rheumatologic Rehabilitation	Rehabilitation Unit were enrolled. All subjects had been treated with a "biologic" agent (22 adalimumab, 10 golimumab, 8 adaparcent) for at least 12	Home, Clinic	Clinic	rehabilitative tool in young RA patients, following a 4- week program of in hospital multidisciplinary
Italy	months before admission."	50 mins (10 minutes per game) once daily during acute rehab (4 weeks), then at home x 8 weeks	Same as intervention group for 4 weeks, then "habitual activity" for 8 weeks	rehabilitation."
"No funding was received"	<b>Exclusion:</b> " malignancy, intolerance to exercise, unstable medical conditions, pregnancy, any condition that could compromise the patient's ability to comply with and/or perform study-related activities."	"Participants were asked to play the five preselected Wii-Fit games (running, skiing, balloons shooting, bike slalom, balls moving through labyrinth) for 10 minutes per game, once/daily, throughout the period of hospitalization (Group A and B) and at home (Group A only). Videogames required to perform a	5 games during acute rehab (4 wk only)	<ul> <li>Health Assessment Questionnaire (HAQ) measures function &amp; fatigue</li> <li>Non-eligible: Disease Activity Score (DAS-28); Global Health</li> </ul>

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		wide range of exercises for upper and lower arms, including shoulder flexion/extension, abduction/adduction, internal/external rotation, circumduction, elbow flexion/extension, forearm pronation/supination, hand digit motion, weight shift back and from side-to-side, and knee and ankle flexion/extension."		VAS; ESR; swollen & tender joint counts; FACIT-fatigue
Ditchburn, 2020 <sup>76</sup>	Inclusion: "aged 65 years or over, able to walk unassisted ( <i>ie</i> , did not use,	N=27	N=27	Primary: Pain & postural control/sway
High	or require, any walking aids) for at least 0.5 of a mile and having musculoskeletal	Age, mean (SD): 71.78 (6.1)	Age, mean (SD): 69.78 (4.48)	Pain intensity/severity (6 wk)
6 weeks	12 weeks duration."	Female: 81.5%	Female: 65%	• NRS
Teesside University's physiotherapy laboratory, United	Exclusion: "diagnosis (or suspicion) of any systemic conditions that may cause	Clinic	Clinic	Adverse events (6 wk)
Kingdom Teesside University doctoral	pain in two or more joints, of more than 12 weeks duration (such as cancer, rheumatic or neurological disease, or condition), self-report of current condition or self-report of history of any condition or injury which would contra-indicate participation in the exercises under study"	40 min sessions twice weekly for 6 weeks.	40 min sessions twice weekly, for 6 weeks.	<ul> <li>Physical performance (6 wk)</li> <li>Postural sway with eyes open &amp; closed</li> </ul>
scholarship		5 games from the IREX® system: volleyball, sharkbait, formula racing, snowboard, and birds & balls. "Each IREX® exergame was played for 2 minutes and was repeated three times within a sessionIn both groups participants were given rest periods of 10 to 30 s, or longer, if required, between exergames, or [traditional] exercise sets."	"All exercises were completed on a one-to-one basis, with the first author supervising the sessions (and exercising with the [traditional exercise group])Those in [this] group performed exercises that were matched to the IREX® exergames for movement patterns required, physiological demands, sequence, duration and mode of exercise, by adopting open and closed kinetic chain movements, in the same range and loading, across both groupsexercise was conducted in sets of 2 minutes	Non-eligible: Multi Affect and Pain Survey (MAPS); acceptability measure (UTAUT); Flow State Scale; Rating of Perceived Exertion; Subjective Mental Effort Questionnaire; HR

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Fligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
<b>9</b> • • • •		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
			duration and was repeated three times within a session. In both groups participants were given rest periods of 10 to 30 s, or longer, if required, between exergames, or [traditional] exercise sets."	
Gouveia e Silva, 2020 <sup>77</sup>	<b>Inclusion:</b> "individuals with a diagnosis of [post-polio syndrome] established by	N=19	N=20	Primary: Motor Function Measure-32 (MFM-32)
Some concerns	the consensus of Halstead and Rossi; 40–75 years of age, muscle strength degree >=3 in shoulders and elbows:	Age, mean (SD): 54.94 (9.34)	Age, mean (SD): 55.58 (8.08)	Pain intensity (7 wk, 11 wk)
11 weeks	motor function impairment (Motor Function Measure (MFM)-32 <=81), and	Female: 52.5%	Female: 55%	• VAS
Instituto Giorgio Nicoli, Sao	who were not performing rehabilitation or	Clinic	Clinic	Adverse events (11 wk)
Paulo, Brazil Coordination for Improvement of Higher Education Personnel—	Exclusion: "Individuals with clinically assessed shoulder subluxation by	50 min sessions twice weekly x 7 weeks, totaling 14 sessions	50 min sessions twice weekly x 7 weeks, totaling 14 sessions	<ul> <li>Count of events such as upper limb pain, dizziness, nausea, and vomiting</li> </ul>
Brazil (CAPES)	paipation (>=2 fingers), upper limb deformities that made it difficult to perform the interventions, and people who were not available to perform the 14 intervention sessions"	"[Interactive video game group] participants were positioned in front of a 32" TV placed 1.2m away and attached to the wall, 1.5m from the groundParticipants were then provided with two opportunities to practice for each game. Each game was performed with the help of the researcher who corrected the movements and posture of participants through guidance and verbal commands, instructing them to carry out each movement correctly, to reach the goal of the game. Each game was played for*10 minutes. Players reproduced the movements of each sport."	"[Active Exercises Group] performed similar movements required for playing the four videogames of the IVG The AEG intervention included upper limb active exercises involving shoulder, elbow, and trunk, in blocks of 8 minutes with a 2-minute rest interval between the exercises (to avoid muscle fatigue)."	<ul> <li>Physical performance (7 wk, 11 wk)</li> <li>Box and Block</li> <li>Functional Reach Assessment</li> <li>Non-eligible: MFM-32; Functional Independence Measure (FIM); Fatigue Severity Scale; acceptability questions</li> </ul>

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	, Other Non Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Karahan, 2016 <sup>78</sup>	<b>Inclusion:</b> "aged 18–65, lack of regular	N=28	N=29	Primary: Not clearly specified
Some concerns	months."	Age, mean (SD): 36.1 (12.4)	Age, mean (SD): 36.6 (11.3)	activity via VAS, change in BASFI score were listed first
8 weeks	<b>Exclusion:</b> "the presence of cardiopulmonary dysfunction that hinders acrobic eversion such as acute	Female: 14%	Female: 21%	Pain-related functioning (8
Physical Medicine and Rehabilitation Outpatient Clinic of	congestive heart failure, unstable angina pectoris, third-stage cardiac block, etc.;	Clinic	Clinic	<ul> <li>Bath Ankylosing Spondylitis Functional Index (BASFI)</li> </ul>
Beyhekim State Hospital, Turkey	regular exercise habits during the previous six months; the presence of	30 minutes/day, 5 days a week for 8 weeks (40 sessions in total)	N/A\	
NR	central or peripheral neurological disease: the presence of issues		No exercises or other treatments	• VAS
	hindering standing, such as previous surgery on the lower extremities; the presence of a diagnosed serious psychiatric disorder; the presence of a serious visual disorder; the presence of a serious hearing disorder."	""Kinect Adventures," "Kinect Sports" and "Kinect Sports Season Two" video game programs, which include soccer, table tennis, skiing, tennis, golfing, volleyball, and bowling simulations"		<b>Quality of life (8 wk)</b> • Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
				Non-eligible: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Lewis, 2021 <sup>79</sup>	Inclusion: "Met the Budapest clinical diagnostic criteria for CRPS affecting one	N=23	N=22	Primary: body perception disturbance, pain intensity
High	upper limb; aged 18 or over"	Age, mean (SD): 52 (11)	Age, mean (SD): 52 (14.5)	rating scale, and perceptual statement ratings
6 weeks	<b>Exclusion:</b> "had no co-morbidity that might influence CRPS symptoms, <i>ie</i> , state, disbate, and fibramulatia."	Female: 65%	Female: 64%	Pain intensity/severity (1 wk,
Clinics at The Royal National Hospital for Rheumatic Disease,	stroke, diabetes, and informyalgia.	Clinic	Clinic	• NRS
Royal United Hospitals Bath NHS Foundation Trust, Bath and Walton Center NHS Foundation Trust, CRPS UK network registry, United Kingdom		5 sessions comprising 4 weekly intervention sessions and a final follow-up session 2 weeks later	5 sessions comprising 4 weekly intervention sessions and a final follow-up session 2 weeks later	Non-eligible: Body perception disturbance, perceptual statement ratings
5		"participants sat with each arm placed into one of the two apertures	"The procedure and duration (approx. 1 min) for non-	

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator(s):	Primary Outcome
Risk of Bias		Participants Randomized	Participants Randomized	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
National Institute for Health Research		of the MIRAGE system so that both hands rested palm down on a flat surface within the system In response to the specific description given by each participant, changes were made in real time to aspects of shape, size and/or colour of the hand, based on how they wished their hand to look, i.e., their desired hand appearance. Participants rated their satisfaction of hand appearance whilst looking at the hand imagethe image was further altered tobetter match the participant's desired hand appearance. Once they were satisfied, participants viewed the resultant image for 1 min. No visual changes were made to the unaffected hand"	manipulation was exactly the same as that described in i) manipulated condition by the operator appearing to click the computer keys with the exception that the image was not actually visually altered, although the participant believed it to have been The hand image was viewed for 1 min and followed by post-intervention data collection."	
Rothangel, 2018 <sup>80</sup>	Inclusion: "adult patients who had a unilateral lower limb amputation and	N=26	Mirror Therapy	Primary: Average pain intensity during preceding
Some concerns	reported an average intensity of PLP of 3 or more on the 11-point NRS and	Age, mean (SD): 59.7 (16.1)	N=25	week on 11-pt NRS
6 months	minimally one episode of PLP per weekNo restrictions were made	Clinic, home	Age, mean (SD): 62.5 (11.4)	Pain-related functioning (10 wk, 6 mo)
Cologne University; 6 rehabilitation clinics, 2 private	sensation or the time since amputationeligible patients needed to	10 sessions (each 30-minutes) during first 4-weeks delivered by	Clinic, home	• PDI
practices and 1 hospital, Germany	communicative skills and motor functions	therapist, self-delivered exercises using iPad at home for 6 weeks	10 sessions (30-minute each) during first 4-weeks, delivered by	Pain intensity/severity (10 wk, 6 mo)
"State of North Rhine-Westphalia	instructions and understand and fill out	"During the first four weeks	therapist, self-delivered MT at home afterwards	• NKS
(NRW, Germany) and the	questionnaires.	[participants] performed exercises		Quality of life (10 wk, 6 mo)
NRW Ziel2 Programme as a part	Exclusion: "comorbidity such as	the intact limb in front of the mirror:	First 4-weeks same as iPad group,	EuroQoL-5D
of the European Regional Development Fund (grant no. 005-GW02-035)"	the intact limb, severe mental disorders ( <i>eg</i> , PTSD), living >50 km away from a	observation of different positions, basic motor exercises, exercises using sensory stimuli, motor	perform self-delivered MT as much as they wished at home. No training materials were provided."	Pain global change (10 wk, 6 mo)

Author, Year	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Risk of Bias		•	·	Eligible Outcomes &
Follow-Up Duration		Demographics	Demographics	Measures Reported (Time Points)
Site(s)		Setting	Setting	Other Non-Eligible Outcomes
Funding Source		Frequency; Duration	Frequency; Duration	Reported
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
	participating center and having received more than 6 sessions of mirror therapy	exercises using various objects and mental practice of phantom limb	Sensomotor exercises	<ul> <li>Global Perceived Effect (GPE) on pain</li> </ul>
	during the previous 3 months."	exercises). Patients were instructed to also perform the exercises with	N=24	Non-eligible: Frequency and
		soon as they perceived voluntary,	Age, mean (SD): 61 (15.2)	duration of phantom limb pain, neuropathic pain
		phantom limb. During the last session, patients were given a tablet	Clinic, home	symptom inventory (NPSI), patient-specific functional scale (1-3), disturbance in
		and a set of training materials. They received detailed verbal and written instructions on how to use the teletreatment Patients were encouraged to use the teletreatment as often as they wished."	10 sessions (30-minute each) during first 4-weeks, delivered by therapist. Self-delivered exercise as often as they wished.	sleep, disturbance in mood, pain-specific self-efficacy
			"Patients received the same amount and frequency of sensomotor exercises performed with the intact limb as those in [other] groups during the first four weeks but without using a mirror. Instead, patients were instructed to look at their intact limb only during all exercises and not to perform	
			exercises with their phantom limb. After these four weeks, patients were encouraged to perform self- delivered sensomotor exercises with the intact limb at home, without handing out training materials."	

Abbreviations. AR=augmented reality; BPI=Brief Pain Inventory; CBT=cognitive behavioral therapy; CRPS=Chronic Regional Pain Syndrome; DVPRS=Defense and Veterans Pain Rating Scale; EQ-5D-5L=European Quality of Life scale; ESR=erythrocyte sedimentation rate; FACIT=Functional Assessment of Chronic Illness Therapy scale; HR=heart rate; HRV=heart rate variability; LF/HF=low frequency to high frequency; MFM-32=Motor Function Measure-32; MME=morphine milligram equivalent; mo=month; MT=mirror therapy; NR=not reported; NRS=Numeric Rating Scale; PCS=Pain Catastrophizing Scale; PDI=Pain Disability Index; PHQ-8=Patient Health Questionnaire-8; QLQ-C30=EORTC Core Quality of Life questionnaire; RA=rheumatoid arthritis; S=seconds; SD=standard deviation; USA=United States of America; VR=virtual reality; wk=week.
Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Pain-Related Functio	ning or Interference			
Ambrosino, 2020 <sup>75</sup> AR Some concerns	HAQ-function & fatigue	1.8 (0.21) 12 wk: 1.1 (NR), -0.7*	1.75 (0.25) 12 wk: 1.6 (NR), -0.15*	Diff ∆*: 12 wk: -0.55
Cuneo, 2023 <sup>70</sup> VR High	MIDAS	100.36 (72.76) 12 wk: 72.64 (46.91), -27.72	77.55 (64.7) 12 wk: 59.5 (46.4), -18.05	Diff ∆*: 12 wk:-9.67
Chuan, 2023 <sup>71</sup> VR Some concerns	BPI-Interference	4.7 (2.4) 1 mo: 3.7 (2.4), -1.0* 3 mo: 2.8 (2.7), -1.9*	4.1 (2.7) 1 mo: 4.1 (2.9), 0.0* 3 mo: 3.8 (3.7), -0.3*	Diff ∆*: 1 mo: -1.0 3 mo: -1.6
Darnall, 2020 <sup>72</sup> VR High	DVPRS - Stress	5.6 (2.8) 21 days: 2.8 (NR), -2.67 (3.02)	5.1 (2.6) 21 days: 3.4 (NR), -1.67 (1.92)	Diff ∆*: 21 days: -1.0
	DVPRS - Mood	5.5 (2.7) 21 days: 2.8 (NR), -2.61 (2.79)	4.8 (2.4) 21 days: 3.6 (NR), -1.58 (2.08)	Diff ∆*: 21 days: -1.03
	DVPRS - Sleep	5.5 (2.6) 21 days: 3.2 (NR), -2.25 (2.58)	5.2 (2.4) 21 days: 3.8 (NR), -1.33 (2.09)	Diff ∆*: 21 days: -0.92
	DVPRS - Activity	4.9 (2.1) 21 days: 3.1 (NR), -1.95 (2.35)	4.8 (2.2) 21 days: 4.2 (NR), -0.62 (2.33)	Diff ∆*: 21 days: -1.33
Karahan, 2016 <sup>78</sup> AR Some concerns	BASFI	3.7 (1.5) 8 wk: 2.9 (1.3), -0.8*	3.9 (1.6) 8 wk: 3.9 (1.7), 0.0*	Diff ∆*: 8 wk: -0.8
Reynolds, 2022 <sup>73</sup> VR Some concerns	BPI-short form (11 items)	37.7 (95% CI 31.2, 44.2) 7 days: 35.2 (28.7, 42.0), - 2.5* 9 days: 33.8 (27.3, 40.3), - 3.9*	42.1 (95% CI 35.5, 48.6) 7 days: 40.1 (33.4, 46.6), - 2.0* 9 days: 33.9 (27.3, 40.5), - 8.2*	Diff ∆*: 7 days: -0.5 9 days: 4.3
Rothgangel, 2018 <sup>80</sup> AR Some concerns	PDI	30.5 (16.5) 10 wk:21.5 (13.9), -9.0* 6 mo: 20.6 (14.4), -9.9*	23.6 (18.2) 10 wk: 9.5 (10.9), -14.1* 6 mo: 10.1 (16.9), -13.5	Diff ∆: 10 wk: 5.1 6 mo: 3.6
			32.0 (20.1) 10 wk: 19.1 (16.9), -12.9 6 mo: 21.2 (20.0), -10.8	Diff ∆: 10 wk: 3.6 6 mo: 0.9
Wankhade, 2022 <sup>74</sup> VR High	SPADI	NR 2 wk: NR, 30.68 (15.07)	NR 2 wk: NR, 14.4 (2.93)	Diff ∆*: 2 wk:16.28
Pain Intensity or Seve	erity			
Cuneo, 2023 <sup>70</sup> VR High	Headache days/month	23.71 (5.58) 12 wk: 15.64 (7.91), -8.07	25.41 12 wk:17.77 (9.45), -7.64	Diff ∆*: 12 wk: -0.43

## Appendix Table I2. Detailed Results for KQ1 Other Conditions Studies



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Chuan, 2023 <sup>71</sup> VR Some concerns	BPI-Intensity	4.9 (1.1) 1 mo: 4.5 (1.6), -0.4* 3 mo: 4.1 (2.1), -0.8*	4.4 (1.9) 1 mo: 4.5 (2.2), 0.1* 3 mo: 3.8 (2.7), -0.6*	Diff ∆*: 1 mo: -0.5 3 mo: -0.2
Ditchburn, 2020 <sup>76</sup> AR	NRS (current)	2.96 (1.87) 6 wk: 2.07 (2.11), -0.89*	3.33 (2.82) 6 wk: 3.48 (3.03), 0.15*	Diff ∆*: 6 wk: 1.04
High	NRS (past 30 days)	5.52 (2.24) 6 wk: 5.04 (2.21), -0.48*	6.0 (2.34) 6 wk: 5.85 (2.43), -0.15*	Diff ∆*: 6 wk: -0.33
Darnall, 2020 <sup>72</sup> VR High	DVPRS	4.7 (1.7) 21 days: 3.2 (NR), -1.5*	4.5 (1.8) 21 days: 3.8 (NR), -0.7	Diff ∆*: 21 days: -0.8
Gouveia e Silva, 2020 <sup>77</sup> AR Some concerns	VAS	6.22 (2.98) 7 wk: 2.0 (2.47), -4.22 (2.82) 11 wk: 2.33 (2.22), -3.89, (2.93)	6.89 (1.59) 7 wk: 2.68 (1.53), -4.21 (1.87) 11 wk: 3.05 (1.47), -3.84 (1.83)	Diff ∆: 7 wk: -0.01 11 wk: -0.05
Karahan, 2016 <sup>78</sup> AR Some concerns	VAS	4.9 (2.0) 8 wk: 3.6 (1.7), -1.3*	5.1 (2.2) 8 wk: 5 (2.4), -0.1*	Diff ∆*: 8 wk: -1.2
Lewis, 2021 <sup>79</sup> AR High	NRS	5.7 (3.3) 6 wk: 5.15 (3.1), -0.55*	5.45 (3.4) 6 wk: 5.33 (3.4), -0.12*	Diff ∆*: 6 wk: -0.43
Rothgangel, 2018 <sup>80</sup> AR Some concerns	NRS	5.9 (1.9) 10 wk: 4.6 (1.9), -1.3* 6 mo: 4.1 (2.6), -1.8*	Non-AR mirror therapy: 5.4 (2.4) 10 wk: 3.6 (3.1), -1.8* 6 mo: 2.7 (2.8), -2.7*	Diff ∆: 10 wk: 0.5 6 mo: 0.9
			Control: 5.8 (2.1) 10 wk: 4.1 (2.6), -1.7* 6 mo: 4.5 (2.8), -1.3*	Diff ∆: 10 wk: 0.4 6 mo: -0.5
Wankhade, 2022 <sup>74</sup> VR High	NRS	NR 2 wk: NR, 3.56 (0.5)	NR 2 wk: NR, 2.52 (0.5)	Diff ∆*: 2 wk: 1.04
Adverse Events				
Cuneo, 2023 <sup>70</sup> VR High	% with nausea, dizziness (VR only)	Nausea: 28.6% Dizziness: 21.4%	AE not assessed	Diff ∆: NC
Chuan, 2023 <sup>71</sup> VR Some concerns	% with nausea, dizziness, eyestrain during any VR session	Nausea: 4/19 (21%) Dizziness: 4/19 (21%) Eyestrain: 4/19 (21%)	Nausea: 5/20 (25%) Dizziness: 4/20 (20%) Eyestrain: 8/20 (40%)	Diff ∆*: Nausea: 4% Dizziness: 1% Eyestrain: -19%
	Free text response on tolerability survey	NR	"For one control patient, the side-effect (severe headache) was severe enough to withdrawand two control patients were unable to tolerate the headset and did not	Diff ∆: NC



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
			complete one of their virtual reality sessions."	
Ditchburn, 2020 <sup>76</sup> AR High	AE, motion sickness	No events	No events	Diff ∆*: 0
Darnall, 2020 <sup>72</sup> VR High	Frequency of motion sickness or nausea while using VR (only for VR group	Never: 19/25 (76%) Sometimes: 5/25 (20%) Often: 1 (4%)	AE not assessed	Diff ∆: NC
Reynolds, 2022 <sup>73</sup> VR Some concerns	Free-text questions on acceptability, suggestions for change	"some participants reported adverse effects in using the VR headsets including feeling 'claustrophobic' and 'I got a bit dizzy/nauseous'."	AE not assessed	Diff ∆: NC
Gouveia e Silva, 2020 <sup>77</sup> AR Some concerns	% with late upper limb pain after first session	15%	10%	Diff ∆*: 5%
Pain Catastrophizing				
Cuneo, 2023 <sup>70</sup> VR High	CAP	16.07 (5.36) 12 wk: 13.21 (5.67), -2.86	11.86 (3.55) 12 wk: 11.36 (4.64), -0.5	Diff ∆*: 12 wk: -2.36
Pain Global Change				
Darnall, 2020 <sup>72</sup> VR High	PGIC	21/25 (84%) pain improved, 4/25 (16%) no change, 0/25 worsening pain	18/29 (62%) pain improved, 10/29 (34%) no change, 1/29 (3%) worsening pain	Diff ∆*: Improved: 24% Worsened: -3%
Rothgangel, 2018 <sup>80</sup> AR Some concerns	GPE on pain	10 wk: 1.1 (1.0) 6 mo: 1.4 (1.1)	non-AR mirror therapy 10 wk: 1.4 (1.5) 6 mo: 1.2 (1.8)	Diff ∆*: 10 wk: -0.3 6 mo: 0.2
			Control 10 wk: 1.0 (1.2) 6 mo: 0.8 (1.3)	Diff ∆*: 10 wk: 0.1 6 mo: 0.6
Quality of Life				
Chuan, 2023 <sup>71</sup> VR Some concerns	QLQ-C30 global quality subscale	62 (25) 1 mo: 57 (18), -5* 3 mo: 54 (25), -8*	55 (20) 1 mo: 57 (18), 2* 3 mo: 56 (24), 1*	Diff ∆*: 1 mo: -7 3 mo: -9
Karahan, 2016 <sup>78</sup> AR Some concerns	ASQOL (0-18)	9.5 (6.1) 8 wk: 6.8 (4.3), -2.7*	10.2 (6.0) 8 wk: 10.3 (6.4), 0.1	Diff ∆*: 8 wk: -2.8
Rothgangel, 2018 <sup>80</sup> AR Some concerns	EuroQoL-5D	0.6 (0.3) 10 wk: 0.7 (0.2), 0.1* 6 mo: 0.8 (0.2), 0.2*	Traditional mirror therapy 0.6 (0.3) 10 wk: 0.8 (0.3), 0.2*	Diff ∆*: 10 wk: -0.1 6 mo: 0.1



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
			6 mo: 0.7 (0.3), 0.1*	
			Control	Diff ∆*:
			0.4 (0.3)	10 wk: -0.2
			10 wk: 0.7 (0.3), 0.3*	6 mo: -0.1
			6 mo: 0.7 (0.3), 0.3*	
Opioid Use				
Chuan, 2023 <sup>71</sup>	Average MME in the	Means NR	Means NR	Diff $\Delta$ : NC
VR	previous week	Median (IQR	Median (IQR	
Some concerns		baseline 0 (0-23	Baseline 0 (0-24	
		1 mo0 (0-19	1 mo0 (0-38	
		3 mo0 (0-15	3 mo0 (0-51	
Physical Performance	ce in the second se			
Ditchburn, 2020 <sup>76</sup>	Postural sway with	5.45 (2.06)	4.44 (1.4)	Diff ∆*:
AR	eyes open – AP SD	6 wk: 4.64 (2.03), -0.81*	6 wk: 3.92 (1.66), -0.52*	6 wk: -0.29
High	Postural sway with	25.92 (6.25)	21.42 (5.89)	Diff ∆*:
	eyes open – AP range	6 wk: 21.25 (6.79), -4.67*	6 wk: 18.02 (7.54), -3.4*	6 wk: -1.27
	Postural sway with	3.15 (1.89)	2.13 (0.83)	Diff ∆*:
	eyes open – ML SD	6 wk: 2.56 (1.52), -0.59*	6 wk: 1.84 (0.59), -0.29*	6 wk: -0.3
	Postural sway with	17.82 (10.24)	12.42 (4.46)	Diff ∆*:
	eyes open – ML range	6 wk: 13.97 (7.72), -3.85*	6 wk: 10.17 (3.78), -2.25*	6 wk: -1.6
	Postural sway with	32.69 (10.73)	29.47 (6.72)	Diff ∆*:
	eyes open – Center of pressure velocity	6 wk: 32.38 (9.58), -0.31	6 wk: 31.48 (10.43), 2.01	6 wk: -2.32
Gouveia e Silva,	Functional Reach	31.1 (3.38)	30.8 (3.10)	Diff $\Delta$ :
2020 <sup>77</sup> AR	Assessment	7 wk: 34.4 (3.45), 2.28 (2.08)	7 wk: 32.1 (3.47), 1.26 (1.10)	7 wk: 1.02 11 wk: 0.83
Some concerns		11 wk: 34.1 (3.23), 1.94 (2.04)	11 wk: 31.9 (3.57), 1.11 (1.15)	
	Box and Block test	101 (10.9)	88.2 (13.2)	Diff $\Delta$ :
		7 wk: 111 (15.7), 9.89 (8.96)	7 wk: 92.7 (11.9), 4.58	7 wk: 5.31
		11 wk: 109 (13.95), 8.11 (7.51)	(4.09) 11 wk: 91.4 (11.7), 3.21	11 wk: 4.90
			(3.51)	

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparison
Wankhade, 2022 <sup>74</sup>	Shoulder flexion ROM	NR	NR	Diff ∆*:
VR		2 wk: NR, 29.6 (8.88)	2 wk: NR, 23.4 (8.0)	2 wk: 6.2
High	Shoulder extension	NR	NR	Diff $\Delta$ *:
		2 wk: NR, 9.92 (3.12)	2 wk: NR, 6.8 (3.78)	2 wk: 3.12
	Shoulder abduction	NR	NR	Diff $\Delta$ *:
		2 wk: NR, 34.0 (10.1)	2 wk: NR, 20.2 (10.04)	2 wk: 13.8
	Shoulder adduction	NR	NR	Diff $\Delta$ *:
		2 wk: NR, 9.48 (1.89)	2 wk: NR, 6.4 (3.06)	2 wk: 3.08
	Shoulder internal	NR	NR	Diff ∆*:
		2 wk: NR, 11.8 (2.84)	2 wk: NR, 7.4 (2.92)	2 wk: 4.4
	Shoulder external	NR	NR	Diff ∆*:
		2 wk: NR, 12.84 (2.86)	2 wk: NR, 11.0 (3.22)	2 wk: 1.84

Notes. \* Calculated by review team.

Abbreviations. AR=augmented reality; ASQOL=Ankylosing Spondylitis Quality of Life; BASFI=Bath Ankylosing Spondylitis Functional Index; BPI=Brief Pain Inventory; CAP=Concerns About Pain; CI=confidence interval; Diff ∆= difference in change scores; DVPRS=Defense and Veteran Pain Rating Scale; EuroQoL-5D= European Quality of Life 5 Dimensions; GPE=Global Perceived Effect; HAQ=Health Assessment Questionnaire; IQR=interquartile range; MIDAS=Migraine Disability Assessment; MME=morphine milligram equivalents; mo=month; NR=not reported; NRS=Numeric Rating Scale; oMEDD=oral morphine equivalent daily dose; PCS=Pain Catastrophizing Scale; PDI=Pain Disability Index; PGIC=Patient Global Impression of Change; QLQ-C30=Quality of Life Questionnaire-C30; ROM=range of motion; SD=standard deviation; SPADI=Shoulder Pain and Disability Index; VAS=Visual Analog Scale; VR=virtual reality; wk=week.

## **APPENDIX J. POST-SURGICAL PAIN**

### Appendix Table J1. Detailed Characteristics for Included Trials on Post-Operative Studies

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator: Participants Randomized	Primary Outcome
Follow-Up Duration Country Sito(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
Eichler, 2019 <sup>84</sup>	Inclusion: "[T]otal hip or knee replacement was	N=56	N=55	Primary: 6-minute walk test
High	performed following idiopathic, posttraumatic, or congenital osteoarthritis,	Age, mean (SD): 53.5 (7.0)	Age, mean (SD): 56.8 (5.7)	Pain related functioning or interference (3 mo)
3 months	between 18-65 years, and additional criteria	Female: 54.2%	Female: 48.7%	<ul><li>WOMAC</li><li>Five Times Chair Rise Test</li></ul>
3 Sites (unspecified)	(eg, High Definition Multimedia Interface	Home	Home	Physical performance (3 mo) <ul> <li>TUG</li> </ul>
German Pension Insurance Berlin-Brandenburg (grant number 10-40.07.05.07.007); Deutsche Forschungsgemeinschaft; and Open Access Publishing Fund of	[HDMI]-compatible screen, minimum 2.5-meter space in front of the screen, and internet access)"	3 x per week; 3 months (following 3 weeks of inpatient rehabilitation) " home-based telerehabilitation	NR; 3 weeks inpatient followed by no specific therapy "Patients in the control group did not	<ul> <li>Stair Ascend Test</li> <li>Quality of life (3 mo)</li> <li>SF-36-physical</li> <li>SF-36-mental</li> </ul>
University of Potsdam	Exclusion: "Patients not expected to achieve functional safety in walking with full load by the end of the rehabilitation were excluded. For those patients, it was assumed that they would not be able to perform exercises with adequate load or the assessments at the study site. Insufficient verbal and written German-language skills also led to exclusion."	program based on the MeineReha system, which consisted of a home component as well as a working portal for the therapist in the clinicThe exercises to build up strength and improve postural control were chosen by the supervising therapistThe training intensity was individualized in terms of the choice of exercises, the number of sets and repetitions, and the duration of the breaks, which could all be adjusted by the therapist options for the patient and the therapist to communicate: (1) the patient could record and send audio messages to their therapistand the therapist was able to listen to it	receive any study-specific therapy after their inpatient rehabilitation. The follow- up was carried out identically to the [intervention group] three months after randomization. The patients of both groups were also offered the usual aftercare"	

Author, Year	Inclusion/Exclusion	Intervention:	Comparator:	Primary Outcome
Risk of Bias	Criteria	Participants Randomized	Participants Randomized	
Follow-Up Duration				Eligible Outcomes & Measures
Country		Demographics	Demographics	Reported (Time Points)
Site(s)		•	• •	
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		whenever their schedule gave them		
		time to do it; (2) the therapist could		
		individualized text messages which		
		the patient was shown whenever they		
		started the system; and (3) the		
		patient and the therapist were able to		
		make appointments for live video		
		conferences, which they were		
		basis During the training the		
		exercises were demonstrated on		
		screen by an avatar The patient		
		performed the exercises		
		simultaneously and was detected by		
		means of a Kinect sensorThe		
		systemsent them real-time visual		
		segments were colored green for		
		correct movements and red in the case		
		of incorrect movements For training		
		supervision, the therapist was given		
		access to the frequency of the training		
		as well as the exercise evaluations."		
Fuchs, 2022 <sup>82</sup>	Inclusion: "(1) Patients diagnosed with	N=30	N=25	Primary: VAS
High	osteoarthritis, either	Age mean (SD)	Age mean (SD):	Pain related functioning or
i ligit	uni/double/triple	70 (7)	70 (7)	interference (6 mo)
C m anth a	compartmental	70(7)	70(7)	
6 months	osteoarthritis, and found	F 1 00 00/	F 1 F0 0%	• WOMAC
	suitable for surgery. All	remale: 63.3%	remale: 52.0%	
Kaplan Medical Center, Rehovot	were included in the study.			
	(2) Patients undergoing	Clinic/facility	Clinic/facility	
"This research did not receive	unilateral TKA."			
any specific grant from funding		1 session per day; 1-2 days post-	1 session per day; 1-2 days post-	
agencies in the public,		operatively	operatively	

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator: Participants Randomized	Primary Outcome
Follow-Up Duration Country Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
commercial or not-for-profit sectors."	Exclusion: "(1) Patients undergoing revision of TKA; (2) Ligament injury or periprosthetic fracture occurring during TKA; (3) Unstable vital signs; (4) Vision loss, hearing loss, or functional illiteracy."	"The VR intervention included a movie that was picked by the patient from several options, either a nature film or a music film. The patient watched the VR film during the CPM physiotherapy."	"The CPM was used as a tool to match the physiotherapy conditions for all patients and to measure a possible change in the range of motion."	
Janhunen, 2023 <sup>85</sup>	<b>Inclusion</b> : "(1) first primary unilateral TKR, (2)	N=25	N=27	Primary: Oxford knee score 12-item questionnaire, TUG
Some Concerns	mechanical axis of the limb in varus, (3) posterior stabilising or cruciate-	Age, mean (SD): 66.9 (3.1)	Age, mean (SD): 66.4 (4.5)	Pain intensity (2, 4 mo)
4 months	retaining prosthesis and (4) normal vision with or	Women: 64.0%	Women: 63.0%	<ul> <li>VAS</li> <li>Physical performance (4 mo)</li> </ul>
Turku University of Applied	without eyeglasses"			• SPPB
Jyväskylä	Exclusion: "[F]ractures,	Home	Home	<ul> <li>Active and passive knee flexion and extension, using universal goniometer</li> </ul>
Päivikki and Sakari Sohlberg Foundation; the Business	other biomechanical disruptions in the affected lower limb within 1 year	4-5 exergames (variable duration and sets) played several times a day; 16 wks	Multiple exercises 2-5 times a day; 16 wks	<ul> <li>Muscle force flexion and extension, assessed with Metitur Good Strength dynamometer in Jyväskylä (Newtor INI) and a Con Tray</li> </ul>
5794/31/2016, 5941/31/2016, 6057/31/2016); Finnish partner companies (SE Innovations Oy [Senior Some Oy], Suunto Oy, Physiotools Oy, GoodLife Technology Oy, Lingsoft Oy, eSeteli Palveluverkko Oy, PN Turku Oy, Ade Animations Design & Effects Oy, Adesante Oy, 4FeetUnder, Intechso and Realmax Oy)	before surgery, a diagnosed memory disorder, cognitive impairment or a neurological condition."	"[P]rotocol included 11 gamesThe player controls the games using movements similar to the standard postoperative home exercise programExergames were categorized according to exercise target: knee extension and flexion, knee flexion or squatting, weight shifting from side to side, stretching, and functional exergamesThe knee extension-flexion games (the Cave Game and Intruders) and stretching game (the Cannon) were played in a sitting position, whereas the other games (the Rowing Game, Pick Up,	"[P]rotocol included 11–12 exercisesThe control group underwent a standard postoperative home exercise programThe research physiotherapist instructed the control group participants to follow this standard program several times a day for 16 weeks starting after discharge from the hospital. Similar to the exergame group, guidance was provided at the exercise laboratory baseline visit immediately after randomization. Face-to-face individual guidance was provided for 5 to 10 minutes by the same research	Multijoint dynamometer (Newton- meter [Nm]) in Turku from the operated

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator: Participants Randomized	Primary Outcome
Follow-Up Duration Country Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		Squat Pong, Bubble Runner, Hat Trick, Brick Breaker, Hiking, and Toy Golf) were played in a standing position."	physiotherapist who had conducted the baseline assessment."	
Jin, 2018 <sup>83</sup>	Inclusion:	N=33	N=33	Primary: WOMAC, VAS, ROM
High	"1) Patients diagnosed as OA according to The Guidelines for Diagnosis and Treatment of	Age, mean (SD): 66.45 (3.49)	Age, mean (SD): 66.30 (4.41)	Other non-eligible outcomes reported (1, 3, 6 mo)
6 months	Osteoarthritis issued by the Chinese Rheumatology	Female: 54.55%	Female: 60.61%	• HSS
	Patients undergoing unilateral TKA for the first	Clinic/facility	Clinic/facility	
	time"	30 minutes, 3 times per day; NR	30 repetitions, 3 times per day; NR	
	Exclusion:			
	"1) Overweight (BMI ≥ 30 kg/m <sup>2</sup> 2); 2) Severe osteoporosis; 3) Ligament injury or periprosthetic fracture occurring during TKA; 3) Unstable vital signs, complications of incision healing, or clot formation in leg veins; 4) Vision loss, hearing loss, or functional illiteracy.	" patients exercised by performing foot dorsiflexion and plantar flexion beginning the first day after TKA. Exercises targeting quadriceps muscle strength occurred from the second day after TKA. Passive exercises on knee flexion began after the drainage tube was removed. Exercises were assisted with psychological intervention and pain management education In addition, VR (Mide Technology Inc., Cangzhou, China) intervention was applied in the experimental group beginning the second day after TKA. Patients were asked to row a boat using knee flexion (interaction of VR) in an immersive virtual environment"	"patients exercised by performing foot dorsiflexion and plantar flexion beginning the first day after TKA. Exercises targeting quadriceps muscle strength occurred from the second day after TKA. Passive exercises on knee flexion began after the drainage tube was removed. Exercises were assisted with psychological intervention and pain management educationPatients in the control group were asked to flex their knees passively using their arms until pain tolerance was reached. They held that position for 20 seconds followed by relaxing for 40 seconds."	
Piqueras, 2013 <sup>86</sup>	Inclusion: "[S]uccessful primary TKA surgery: post-	N=90	N= N=91	Primary outcome NR
High	TKA active range of motion: flexion 80° and	Age, mean (SD):	Age, mean (SD):	Pain intensity (2 wk, 3 mo)

Author, Year	Inclusion/Exclusion Criteria	Intervention:	Comparator:	Primary Outcome
Follow-Up Duration Country Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
	extension –10°, without	NR	NR	• VAS
3 months	signs of stiffness; ability to			Physical performance (2 wk, 3 mo)
	walking aid; ability to read	Women: 83%	Women: 62.5%	• TUG
An acute-care university general hospital, Barcelona	and understand Spanish; ability to understand and accept the trial procedures	Home/Clinic or health care facility	Home/Clinic or health care facility	<ul> <li>Quadriceps muscle strength, measured in kg (NMMT dynamometer)</li> </ul>
Partially financed by Telefónica Research and Development.	and to sign an informed consent form in	1 hour sessions; 10 days	1 hour sessions; 10 days	<ul> <li>Hamstring muscle strength, measured in kilograms (NMMT dynamometer)</li> </ul>
	accordance with national legislation."	"The IVT is an interactive virtual software-hardware platform that facilitates the development of remote	"In all cases, functional rehabilitation started the day after TKA. All participants were instructed by a	<ul> <li>Active Knee extension, measured in degrees with a goniometer</li> <li>Active Knee flexion, measured in</li> </ul>
	Exclusion: "[S]ensory, cognitive and/or praxic impairment; concomitant medical conditions that may influence the rehabilitation process; discharge to destination other than home; patients with any local or systemic complication (e.g. surgical wound infection, suspicion of deep vein thrombosis) in the 3-month follow-up period were also excluded."	rehabilitation therapy for multiple diseases[The] patient receives the information needed to perform the exercises and the therapist can remotely monitor the patient's performance. For the purpose of this trial, the IVT system was designed for lower limb motor recovery in patients undergoing TKA[]Wireless sensors (WAGYRO) including a 3-axis accelerometer and two self-powered gyroscopes [] connected to the patient and allow calculation of their movement trajectories. [I]nteractive software with a 3D avatar that demonstrates the exercises to be undertaken, while patients reproduce the movements[]Web portal for the therapist: receives data and records them for evaluation, with the option to modify the therapy as the rehabilitation evolves[]The therapist supervised patients remotely on a daily basis from the hospital to check that they were performing the therapy, adjusted the prescribed therapy as appropriate, and	physical therapist in weight bearing to tolerance with an assistive device and underwent inpatient care. (mean length of stay 6.2 days) and outpatient intervention (outpatient physical therapy or IVT) for the first 3 weeks after surgery. Inpatient care consisted of assisted walking within 24 h, knee range of motion exercises and preparing for the return home. After hospital discharge, conventional physical therapy consisted of a 2-week face-to-face rehabilitation programme (progressive exercise and instruction including knee range of motion, gait training, and instructions in negotiating stairs and community-related obstacles). Any signs of adverse knee joint responses ( <i>eg</i> , increased swelling or pain) resulted in a lowering of the intensity, frequency and duration of the exercises or elimination of a rehabilitation component."	degrees with a goniometer

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator: Participants Randomized	Primary Outcome
Follow-Up Duration Country Site(s)		Demographics	Demographics	Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		contacted the patient via telephone as necessary."		
Prvu Bettger, 2020 <sup>87</sup>	Inclusion: "Patients who had an in-	N=153	N=153	Primary outcome: Total healthcare costs 12 weeks after discharge
Some concerns	person clinic visit at least	Age, mean (SD):	Age, mean (SD):	
12 weeks	10 days prior to TKA. Patients who were ≥18	65.4 (7.7)	65.1 (9.2)	Pain related functioning or interference (6, 12 wk)
Two academic medical centers	scheduled for TKA for the treatment of nontraumatic	Female: 59.6%	Female: 65.4%	<ul> <li>KOOS</li> <li>Pain intensity (12 wk)</li> </ul>
and 2 independent private practices	conditions, and who had a Risk Assessment and	Home/Clinic or health care facility	Home/Clinic or health care facility	<ul> <li>NRS</li> <li>Adverse events (12 wk)</li> </ul>
Reflexion Health, "the	Prediction Tool (RAPT) score of $\geq 6$ (indicating expected discharge to	NR; NR	NR; NR	<ul> <li>Number of falls, patient-reported</li> <li>Physical performance (6 wk)</li> </ul>
manufacturer of the VERA	home after surgical	"VERA is a cloud-based virtual	"Patients in the usual care group	<ul> <li>Knee Extension (degrees)</li> </ul>
	hospitalization) were eligible."	telehealth system that functions with use of 3-dimensional (3D) tracking	followed their care team's recommendations for all preoperative	<ul><li>Knee Flexion (degrees)</li><li>10-meter gait speed</li></ul>
		motion, an avatar (digitally simulated	rehabilitative care."	Quality of life (12 wk)
	were scheduled to undergo	coach) to demonstrate and guide		<ul> <li>PROMIS physical function</li> </ul>
	bilateral or staged bilateral	activity, visual and audible instructions		PROMIS mental health
	nursing home prior to	quality, and a virtual video connection		Other non-eligible outcomes reported
	surgery, or who were	for synchronous telehealth visits with		<ul> <li>Healthcare costs, total and by different services</li> </ul>
	unable or unwilling to provide informed consent "	physical therapist. Individualized		<ul> <li>Hospital readmissions, patient-</li> </ul>
		prescribed therapy regimens were		reported
		through the clinician interface prior to surgery		
		The VERA system tracked activity,		
		performance, exercise quality, and adherence: the telebealth therapist		
		monitored the patient's progress		
		asynchronously. Patients had a video visit with their telehealth therapist in		

Author, Year	Inclusion/Exclusion	Intervention:	Comparator:	Primary Outcome
Risk of Bias	Criteria	Participants Randomized	Participants Randomized	
Follow-Up Duration				Fligible Outcomes & Measures
Country		Domographico	Domographico	Reported (Time Points)
Country		Demographics	Demographics	Reported (Time Forms)
Site(s)				
Funding source		Setting	Setting	Other Non-Eligible Outcomes
				Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention	Detailed Comparator Characteristics	
		Characteristics	Betalled Semparator Sharacteristics	
		the week after bespital discharge and		
		weekly thereafter to review progress		
		and to revise the therapy regimen		
		accordingly. The telehealth therapist		
		provided remote clinician oversight to		
		the patients for the duration of the		
		intervention and communicated		
		progress to each clinical site ahead of		
		the patients' 2 and 6-week		
		postoperative visits. Patients and the		
		telehealth therapist mutually agreed		
		when therapy goals were met for		
		discharge from virtual P1."		
Shim, 2023 <sup>88</sup>	Inclusion:	N=28	N=28	Primary: 4-m gait speed
	"Participants aged ≥ 50			
Some concerns	years who underwent TKA	Age, mean (SD):	Age, mean (SD):	Pain related functioning or
	and were discharged	68 6 (5 8)	73.0 (4.6)	interference (3, 12, 24 wk)
24 weeks	home."	00.0 (0.0)	10.0 (4.0)	• WOMAC
24 weeks		NV 00.4%	75.00/	Boin intensity (2, 12, 24 wk)
	Exclusion: "[P]articipants	Women: 82.1%	Women: 75.0%	Fail intensity (5, 12, 24 wk)
Two academic medical centers,	with a history of			• NRS
Seoul	osteotomy, severe	Home	Home	Physical performance (3, 12, 24 wk)
	neurological deficits,			<ul> <li>Berg balance scale</li> </ul>
Korea Health Technology R&D	infection in the	30 min. dailv: 12 wks	3-5 sets of exercises (10 repetitions	• ROM
Project through the Korea Health	affected knee, inability to	"[AR] group performed brochure-based	each); 12 wks	Ouadricens strength
Industry Development Institute;	perform exercises due to	exercises in the early phase In the		
Ministry of Health Welfare,	severe comorbidities, or	advanced phase, exercise was	"Both groups performed the same	
Republic of Korea (grant no.:	inability to participate in the	performed using an AR-based digital	exercises for the same duration but the	Quality of life (3, 12, 24 wk)
HR19C0781).	rehabilitation program for	healthcare system At levels 1–4,	types of instructions provided at home	<ul> <li>EuroQoL-5D-5L</li> </ul>
	other reasons."	participants performed range of motion	differedParticipants in the	
		and isometric strengthening of lower	[conventional rehab] group performed	
		extremities while lying down or sitting	brochure-based home exercises,	
		in a chair. At levels 5–9, participants	according to the standard rehabilitation	
		performed a program designed to train	protocol for patients after TKA In the	
		stretching and isotonic strengthening	early phase, an exercise program	
		or lower extremities while standing with	consisting of ankle pumping, ROM, and	
		support. At levels 10–12, participants	isometric/isotonic exercise was	

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator: Participants Randomized	Primary Outcome
Follow-Up Duration Country Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		performed a program designed to train stretching and isotonic strengthening, including lunges and squats, while standing without support The exercises were displayed on the screen (avatar plus written summaries). Participantswere provided with real-time feedback on the screen The exercise performance and motion accuracy were recorded online and reviewed by a physician. Participants were provided detailed feedback on their performance at the outpatient clinic visits."	performed in a sitting or lying position. In addition, gait training using a walker and stair up-and-down training were performed. In the advanced phase, participants performed cane/self-gait training and strengthening exercise, such as squats and lunges."	

Abbreviations. AR=augmented reality; BMI=body mass index; CPM=continuous passive motion; h=hour; HSS=hospital for special surgery knee score; IRENA=multimodal intensified aftercare; IVT=interactive virtual telerehabilitation; NMMT=Nicholas manual muscle tester; KOOS=knee injury and osteoarthritis outcome score; NR=not reported; NRS=numerical rating scale; PROMIS=patient-reported outcomes measurement information system; PT=physical therapy; RAPT=risk assessment and prediction tool; ROM=range of motion; SPPB=short physical performance battery; SD=standard deviation; SF-36=short form health survey-36; TKA=total knee arthroplasty; TKR=total knee replacement; TUG=timed up and go test; VAS=visual analogue scale; VERA=virtual exercise rehabilitation assistant; VR=virtual reality; WOMAC=Western Ontario and McMaster Universities Arthritis Index.

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparison
Pain-Related Fu	nctioning or Interferer	nce		
Eichler, 2019 <sup>84</sup> AR Hiah	WOMAC (3 mo)	26.4 (18.5) 11.5 (12.7), -14.9 (13.6)	24.8 (16.4) 13.9 (14.3), -10.9 (13.5)	Diff $\Delta^*$ : -4.0 Stand Diff $\Delta^*$ -0.3*
Fuchs, 2022 <sup>82</sup> VR High	WOMAC (6 mo)	36.4 (15.1) 57.2 (27.3), 20.8	34.5 (17.0) 54.2 (25.4), 19.7	Diff $\Delta$ : 1.1*
Janhunen, 2023 <sup>85</sup> AR Some concerns	OKS	26.7 (6.7) 2 mo: 33.4 (6.3), 6.7 4 mo: 38.6 (6.1), 12.1 (7.0*)	26.9 (6.5) 2 mo: 30.3 (5.5), 3.4 4 mo: 36.7 (6.7), 9.8 (7.0*)	Diff $\Delta^*$ : 2 mo: 3.3 4 mo: 2.3 Stand. Diff $\Delta^*$ :
Jin, 2018 <sup>83</sup> VR High	WOMAC	45.03 (5.1) 1 mo: 32.0 (5.2), -13.0 3 mo: 25.8 (4.2), -19.2 6 mo: 21.6 (4.2), -23.5	44.18 (5.73) 1 mo: 35.1 (5.2), -9.1 3 mo: 29.7 (5.6), -14.5 6 mo: 26.3 (3.9), -17.9	4 mo: 0.33, p=0.27 Diff ∆*: 1 mo: -3.9 3 mo: -4.7 6 mo: -5.6
Prvu Bettger, 2020 <sup>87</sup> AR Some concerns	KOOS	37.0 (12.0) 6 wk: 61.0 (11.5), 24.0 12 wk: 69.6 (12.1), 32.6	36.0 (13.0) 6 wk: 61.8 (13.5), 25.8 12 wk: 67.2 (14.3), 31.2	Diff ∆*: 6 wk: -1.8 12 wk: 1.4
Shim, 2023 <sup>88</sup> AR Some concerns	WOMAC	83.1 (13.0) 3 wk: 66.1 (12.5), -17 12 wk: 46.5 (9.1), -36.6 24 wk: 40.1 (7.0), -43.0	81.1 (14.4) 3 wk: 62.2 (15.0), -18.9 12 wk: 45.3 (15.0), -35.8 24 wk: 40.9 (16.0), -40.2	Diff ∆*: 3 wk: 1.9 12 wk: -0.8 24 wk: -2.8
Pain Intensity				
Fuchs, 20 VR High	VAS (2 days)	Means NR Median (IQR): Before treatment: 6 (5-8), NC After treatment: 4 (1-7), NC	Means NR Median (IQR): Before treatment: 6 (6-8), NC After treatment: 5 (2-7), NC	Diff ∆: NC
Janhunen, 2023 <sup>85</sup> AR Some concerns	VAS	57.1 (18.3) 2 mo: 30.5 (21.0), -26.6 4 mo: 20.8 (20.3), -36.3 (24.4*)	54.2 (21.6) 2 mo: 28.7 (20.0), -25.5 4 mo: 27.0 (27.5), -26.7 (24.7*)	Diff Δ*: 2 mo: -1.1 4 mo: -9.1 Stand. Diff Δ*:
				4 mo: -0.39, p=0.18
Jin, 2018 <sup>83</sup> VR High	VAS	7.4 (1.14) 3 days: 6.5 (0.9), -0.9 5 days: 5.4 (0.8), -2.0 7 days: 3.9 (0.6), -3.5	7.4 (1.3) 3 days: 6.8 (1.1), -0.6 5 days: 6.0 (0.9), -1.5 7 days: 4.4 (0.8), -3.0	Diff ∆*: 1 mo: -0.3 3 mo: -0.5 6 mo: -0.5

## Appendix Table J2. Detailed Results for Post-Operative Studies

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparison
Piqueras, 2013 <sup>86</sup> AR High	VAS	3.8 (2.0) 2 wk: 3.1*, -0.7 (1.4) 3 mo: 2.0*, -1.8 (2.5)	4.3 (1.9) 2 wk: 3.7*, -0.6 (1.9) 3 mo: 2.0*, -2.3 (2.0)	Diff ∆*: 2 wk: -0.1 3 mo: 0.5
				Stand. Diff ∆*: 2 wk: -0.1, p=0.80 3-mo: 0.2, p=0.28
Prvu Bettger, 2020 <sup>87</sup> AR Some concerns	NRS (12 wk)	5.2 (2.1) 2.7 (2.0), -2.5	5.7 (2.0) 3.0 (2.6), -2.7	Diff ∆: 0.2*
Shim, 2023 <sup>88</sup> AR Some concerns	NRS	5.7 (2.1) 3 wk: 5.1 (2.0), -0.6 12 wk: 2.8 (1.5), -2.9 24 wk: 2.5 (1.6), -3.2	5.5 (2.2) 3 wk: 4.7 (2.0), -0.8 12 wk: 3.3 (2.1), -2.2 24 wk: 2.3 (2.1), -3.2	Diff ∆*: 3 wk: 0.2 12 wk: -0.7 24 wk: 0
Adverse Events				
Prvu Bettger, 2020 <sup>87</sup> AR Some concerns	Number of falls, patient-reported (12 wk)	19.4%	14.6%	Diff ∆: 4.8%*
Physical Perform	nance			
Eichler, 2019 <sup>84</sup> AR	6-minute walk test (m) (3 mo)	440.6 (78.2) 530.4 (79), 88.3 (57.7)	433.3 (80.2) 513 (70.6), 79.6 (48.7)	Diff ∆: 8.7*
High	TUG (s) (3 mo)	9.3 (1.8) 7.5 (1.2), –1.9 (1.5)	9.0 (2.4) 7.5 (1.6), -1.5 (2.2)	Diff ∆: -0.4*
	Stair Ascend Test (3 mo)	8.7 (2.7) 6.2 (1.2), –2.5 (2.4)	8.6 (4) 6.1 (1.5), –2.5 (3.0)	Diff ∆: 0*
Janhunen, 2023 <sup>85</sup> AR	TUG (s)	9.4 (3.6) 2 mo: 8.2 (1.5), -1.2 4 mo: 7.6 (1.5), -1.8	8.3 (1.7) 2 mo: 8.7 (1.6), 0.4 4 mo: 7.7 (1.2), -0.6	Diff ∆*: 2 mo: -1.6 4 mo: -1.2, p=0.04
Some concerns	Active and passive knee flexion (4 mo)	107 (18) 106*, -1.0 (15.2*)	107 (13) 100*, -7.0 (14.0*)	Diff ∆*: 6.0, p=0.17
	Active and passive knee extension (4 mo)	7.3 (7.7) 6.8*, -0.5 (7.0*)	6.6 (4.1) 6.7*, 0.1 (7.1*)	Diff ∆*: -0.6, p=0.76
	Muscle force flexion (4 mo)	0.6 (0.3) 0.7*, 0.1 (0.4*)	0.6 (0.2) 0.7*, 0.1 (0.1*)	Diff ∆*: 0.0, p=0.88
	Muscle force extension (4 mo)	1.2 (0.5) 1.1*, -0.1 (0.2*)	1.1 (0.4) 1.0*, −0.1 (0.3*)	Diff ∆*: 0.0, p=0.85
	SPPB (4 mo)	9.5 (1.5) 10.6*, 1.1 (1.5*)	9.6 (1.5) 10.4*, 0.8 (1.6*)	Diff ∆*: 0.3, p=0.51
Jin, 2018 <sup>83</sup> VR High	ROM (°) (14 days)	43.6 (3.4) 93.7 (6.6), 50.2	42.9 (3.6) 86.4 (5.0), 43.5	Diff ∆*: 6.7, p=0.0



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparator Baseline Mean (SD) Follow-Up Mean (SD), Mean Change (SD)	Comparison
Prvu Bettger, 2020 <sup>87</sup> AR Some concerns	10-m gait speed (s) (6 wk)	1 (0.3) 1 (0.3), 0	1 (0.3) 1 (0.3), 0	Diff ∆: 0*
Shim, 2023 <sup>88</sup> AR Some concerns	4-m gait speed	0.4 (0.2) 3 wk: 0.5 (0.2), 0.1 12 wk:0.8 (0.2), 0.4 24 wk: 0.9 (0.2),0.5	0.5 (0.3) 3 wk: 0.6 (0.3), 0.1 12 wk: 0.9 (0.1), 0.4 24 wk: 1.0 (0.3), 0.4	Diff ∆*: 3 wk: 0 12 wk: -0.1 24 wk: 0.1
	Berg balance scale	29.8 (11.9) 3 wk: 34.7 (15.3), 4.9 12 wk: 45.8 (11.9), 16.0 24 wk: 49.3 (8.5), 19.5	29.7 (10.3) 3 wk: 37.6 (14.2), 7.9 12 wk: 48.8 (11.3), 19.1 24 wk: 47.9 (11.5), 18.2	Diff ∆*: 3 wk: -3 12 wk: -3.1 24 wk: 1.3
	ROM	79.0 (22.6) 3 wk: 96.6 (21.1), 17.6 12 wk: 117.9 (11.8), 38.9 24 wk: 120.6 (12.9), 41.6	82.0 (12.6) 3 wk: 106.0 (13.6), 24.0 12 wk: 118.8 (12.8), 36.8 24 wk: 122.3 (12.0), 40.3	Diff ∆*: 3 wk: -6.4 12 wk: 2.1 24 wk: 1.3
	Quadriceps strength	NR 3 wk: 107.1 (35.2), NR 12 wk: 138.4 (29.7), NR 24 wk: 149.2 (37.6), NR	NR 3 wk: 98.1 (43.8), NR 12 wk: 131.1 (39.7), NR 24 wk: 146.5 (41.1), NR	Diff ∆: 3 wk: NR 12 wk: NR 24 wk: NR
	Hamstring strength	NR 3 wk: 91.0 (34.1), NR 12 wk: 153.1 (34.2), NR 24 wk: 174.1 (42.0), NR	NR 3 wk: 103.2 (45.3), NR 12 wk: 146.9 (55.1), NR 24 wk: 157.7 (45.1), NR	Diff ∆: 3 wk: NR 12 wk: NR 24 wk: NR
Quality of Life Eichler, 2019 <sup>84</sup> AR	SF-36 physical component score	33.8 (7.6) 44.6 (9.9), 10.7 (10.4)	33.3 (7.9) 44.4 (8.3), 11.1 (7.2)	Diff ∆: -0.4*
High	(3 mo) SF-36 mental component score (3 mo)	54.8 (10.6) 52.4 (10.6), –2.5 (12.4)	53.9 (11.8) 54.1 (9.8), 0.1 (8.5)	Diff ∆: -2.6*
Prvu Bettger, 2020 <sup>87</sup> AR	PROMIS physical function (12 wk)	12.5 (2.4) 15.3 (2.4), 2.8	12.3 (2.5) 14.8 (2.8), 2.5	Diff ∆: 0.3*
Some concerns	PROMIS mental health (12 wk)	15 (2.8) 16.6 (2.5), 1.6	14.9 (3.2) 16.1 (3.2), 1.2	Diff ∆: 0.4*
Shim, 2023 <sup>88</sup> AR Some concerns	EuroQoL-5D-5L	0.4 (0.2) 3 wk: 0.6 (0.1), 0.2 12 wk: 0.8 (0.1), 0.3 24 wk: 0.8 (0.1), 0.4	0.5 (0.2) 3 wk: 0.6 (0.1), 0.1 12 wk: 0.7 (0.1), 0.3 24 wk: 0.8 (0.1), 0.3	Diff ∆*: 3 wk: 0.02 12 wk: 0.1 24 wk: 0.1

Notes. \* Calculated by review team.

Abbreviations. AR=augmented reality; Diff ∆=between group difference (Intervention-Comparator) in mean change; KOOS=knee injury and osteoarthritis outcome score; NC=not calculable; NR=not reported; NRS=numerical rating scale; OKS=Oxford Knee Score; PROMIS=patient-reported outcomes measurement information system; ROM=range of motion; SD=standard deviation; SF36=36-item Short-Form Health Survey; SPPB=short physical performance battery; Stand Diff ∆=standardized between group differences over SD; TUG=timed up and go test; VAS=visual analogue scale; VR=virtual reality; WOMAC=Western Ontario and McMaster Universities Arthritis Index.



# **APPENDIX K. KQ2 OTHER CONDITIONS**

## Appendix Table K1. Detailed Characteristics for Included Trials on KQ2 Other Conditions

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s) Funding Source		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
VR Intervention				
Abd-Elsayed, 2021 <sup>91</sup>	Inclusion: "All adult patients aged 18 to 65 treated from April 2019 to April 2020 for acute or chronic workplace injuries and	N=36		Primary: Average pain relief, measured through the VAS (0- 10)
Critical	were on workers' compensation were retrospectively identified for inclusion All	Age, mean (range): 45 (20-65)		
12 weeks	patients were referred to and overseen by a prescribing physician and referred to the	Female: 56%		<ul> <li>Pain intensity/severity</li> <li>VAS</li> </ul>
Harvard MedTech Vx Pain Relief Program	Harvard MedTech Vx Pain Relief Program by orthopedic specialists, pain specialists,	Home		Opioid use
N/A	primary care physicians, and occupational health providers. All types of workplace injuries were considered"	At least 1 to 2 times daily for 45 min each, over 90 days (~12 weeks)		Self-reported opioid use
	<b>Exclusion:</b> "patients were excluded if their attorney required them to discontinue therapy. Patients were also excluded if they attended less than five in-person behavioral therapy sessions with their behavioral health clinician, as this would indicate possible poor compliance with the Harvard MedTech Vx Pain Relief Program."	"During headset use, patients selected specialized categories, or experiences, pre-loaded onto the headset to target either the knowledge of pain, meditation techniques, escape from pain, or distraction from pain. The choice to view a specific category of VRT was based on weekly phone calls between the physician and patient. For the tailored behavioral therapy component of the program, patients and clinicians discussed their progress with headset use (all outcomes re-reassessed) and the goals of therapy for 30–60 min each week and set three specific goals for the patients care. The goals could be		Non-eligible: Anxiety awareness and level of immersion in therapy, patients' perception of set goals being achieved, sleep improvement, average time thinking about pain

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
running Source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		related to pain reduction, sleep improvement, behavioral health, or social well-being. Any adjustments in therapy were also made at this meeting (as previously discussed). The patient's clinician directed the program, ensured compliance, and also provided further education on how to generalize the skills acquired by the virtual reality headset."		
Bahat, 2020 <sup>90</sup>	<b>Inclusion:</b> "fighter and helicopter pilots from the Israeli Air Force with acute,	N=22	N=23	Primary: NDI, mean velocity
Some concerns	subacute, or chronic neck pain; with or without referral to the upper limbs; and with an average neck pain intensity	Age, mean (SD): 30 (5.8)	Age, mean (SD): 28 (5.1)	Pain-related functioning (4 wk, 7 mo)
7 months	(during the past week) of at least 20% [on a Visual Analog Scale (VAS)/100 mm]."	Female: 5%	Female: 13%	• NDI
Israeli Air Force	Exclusion: "Participants were excluded if	Home	Usual care	<ul><li>Pain intensity (4 wk, 7 mo)</li><li>VAS</li></ul>
IDF-Medical Corps' research grant	they reported suffering from neurological disorders, systemic disease, history of spinal surgery, or any disorders that may have limited the ability to complete the study's procedure."	5 min/session (1 exercise each for 1- 2 mins, 1 min break between modules), 4 sessions per week (total 20 min/wk) for 4 weeks "The individualized VR training software programs were installed on personal laptops for independent use by the subjects During the interactive VR sessions, the subject's head was visualized as an animated image of a pilot flying a small airplaneThe subject's head movements controlled interactions within the virtual environment and the various tasks stimulated different therapeutic aims. The VR software	NR "both groups (control and intervention) continued physical therapy, if receiving any, and this was the control intervention."	<ul> <li>Quality of life (7 mo)</li> <li>EQ5D-VAS general health</li> <li>Physical performance (7 mo)</li> <li>Isometric strength flexion/extension</li> <li>Global peak velocity</li> <li>Global mean velocity</li> <li>Global time to peak velocity</li> <li>Global accuracy</li> <li>Global # of velocity peaks</li> </ul>

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s)		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
Funding Source		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		included three modules aimed at stimulating: 1) increased ROM, 2) faster motion with a quick response, and 3) increased neck motion accuracy"		
AR Interventions				
Rodriguez-Hernandez, 2021 <sup>92,96,122</sup>	Inclusion: "attended the hospital rehabilitation unit who had been	N=23	N=23	Primary: EQ-5D-5L
High	diagnosed with strokeage: 18 to 85 years maximum evolution time of six	Age, mean (SD): 62.6 (13.5)	Age, mean (SD): 63.6 (12.2)	Quality of life (15 wk)
15 weeks	involvementdependence in activities of daily living (Stroke Impact Scale: version	Female: 21.7%	Female: 15%	Physical performance (3 wk
University General Hospital of Talavera de la Reina, Spain	3.0) life expectancy greater than six months (absence of life-threatening diagnoses such as end-stage	Clinic	Clinic	<ul> <li>Fugl-Meyer Assessment –</li> </ul>
University of Castilla La Mancha (grant # 2020-GRIN-29192)	diagnoses such as end-stage cancer)absence of other serious and disabling pathologies."	150 mins per daily session, 5 consecutive days per week x 3 weeks	150 min per daily session, 5 consecutive days per week x 3 weeks	<ul> <li>Upper Extremity</li> <li>Action Research Arm Test (ARAT)</li> </ul>
	Exclusion: "presence of other neurological diagnoses, severe hemineglect, psychiatric pathologies"	"conventional upper and lower limb strength and motor training (100 min; guided by the hospital's physiotherapy and occupational therapy team with the use of virtual reality devices (50 min)Motor training with virtual reality devices consisted of several systems: First, the Hand-Tutor© glove (Figure 1a) for hand rehabilitation and 3DTutor© for upper extremities. Both systems are based on intensive and repetitive practice through movement and feedback instructions provided by the software with virtual environments and task that stimulate movements	"The conventional intervention protocol consisted of receiving manual therapy techniques (massage); passive and active assisted mobilization of the upper and lower limbs; walking in parallel, on slope and stairs; exercises with and without resistance with balls, elastic bands, and dumbbells in therapeutic cage and trellises; active- assisted mobility exercises of the upper limb and fingers in a sitting position; moving objects horizontally on a table; elevation and superposition of objects in vertical plane; biomechanical tasks that simulate flexion-extension and	Non-eligible: Modified Ashworth Scale; Stroke Impact Scale

Author, Year Risk of Bias	Inclusion/Exclusion Criteria	Intervention: Participants Randomized	Comparator(s): Participants Randomized	Primary Outcome
Follow-Up Duration Site(s) Funding Source		Demographics	Demographics	Eligible Outcomes & Measures Reported (Time Points)
		Setting	Setting	Other Non-Eligible Outcomes Reported
		Frequency; Duration	Frequency; Duration	
		Detailed Intervention Characteristics	Detailed Comparator Characteristics	
		that stroke survivors require for daily life."	abduction-adduction of the shoulder and flexion-extension of the wrist and fingers."	
Taveggia, 2016 <sup>94</sup>	Inclusion: " aged 18 to 80 years oldpatients in the acute phase of stroke	N=27	N=27	Primary: Functional Independence Measure (FIM),
Some concerns	(between 0.5 and 12 months post- onset)self-reported functional	Age, mean (SD): 73 (10)	Age, mean (SD): 68 (13)	clinician-reported measure of functional ability; Motricity Index (MI) for motor strength
12 weeks	after stroke first stroke episode; no history of peripheral nerve injury or	Female: 66.7%	Female: 48.1%	
3 hospitals (2 owned by Habilita), Italy	musculoskeletal disease (e.g., arthritis, musculotendinous injury or bone fracture) in the affected upper extremity: no	Clinic	Clinic	Pain intensity/severity (6 wk, 12 wk) • VAS
NR	contracture of the affected wrist or fingers (Modified Ashworth <3); and no history of any invasive procedure (botulinum toxin	1 hr/day, 5 days per week, for 6 weeks	1 hr/day, 5 days per week, for 6 weeks	Adverse events (6 wk)
	type A) for the treatment of spasticity for at least 6 months prior to the start of this study."	Armeo Spring device "allows the reinforcement and facilitation of movement by means of a visual feed- back with a three-dimensional virtual	"traditional rehabilitationsuch as passive and active assisted mobilization of the upper limbs traditional training based on the	Physical performance (6 wk, 12 wk) • Motricity Index (MI)
	Exclusion: "unstable medical disorders, aphasia, or cognitive problems (MMSE≤21)."	asked to perform various tasksIn the first session the device was adjusted for patient's arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station. Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment"	facilitation, postural control and proprioception exercises, verticalization and gait training)."	Non-eligible: FIM; Modified Ashworth Scale for Grading Spasticity (MAS)

Abbreviations. AR=augmented reality; EQ-5D-5L=European Quality of Life scale; EQ5D-VAS=European Quality of Life-Visual Analog Scale; mm=millimeters; MMSE=Mini Mental State Examination; NDI=Neck Disability Index; NR=not reported; SD=standard deviation; VAS=Visual Analog Scale; VR=virtual reality.

## Appendix Table K2. Detailed Results for KQ2 Other Conditions Studies

Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Man (SD) Follow-Up Mean (SD), Mean Change	Comparison
Pain-Related Fur	nctioning or Interfe	rence		
Bahat, 2020 <sup>90</sup> VR Some concerns	NDI	17.6 (8.9) 4 wk median (IQR): 10 (6, 26) 7 mo median (IQR): 9 (6, 18)	17.9 (10.4) 4 wk median (IQR): 16 (8, 20) 7 mo median (IQR): 18 (6, 26)	Diff ∆: NC
Pain Intensity				
Abd-Elsayed, 2021 <sup>91</sup> VR Critical	VAS	Baseline pre: 6.0 (NR) Baseline post: 5.4 (NR) 12 wk pre: 3.8 (NR) 12 wk post: 3.1 (NR)	NR	NA
Bahat, 2020 <sup>90</sup> VR Some concerns	VAS	36.4 (22.9) 4 wk: 25.7 (24.0), -10.7* 7 mo: 23.0 (22.2), -13.4*	49.5 (21.1) 4 wk: 26.9 (22.3), -22.6* 7 mo: 24.5 (22.3), -25.0	Diff ∆*: 4 wk: 11.9 7 mo: 11.6
Taveggia, 2016 <sup>94</sup> AR Some concerns	VAS	4.5 (1.5) 6 wk:1.7 (1.2), -2.8 (1.4) 12 wk: 1.0 (1.1), -3.5 (1.3)	4.2 (2.0) 6 wk: 2.5 (1.6), -1.7 (1.8) 12 wk: 2.6 (1.6), -1.6 (1.8)	Diff ∆*: 6 wk: -1.1 12 wk: -1.9
Adverse Events				
Taveggia, 2016 <sup>94</sup> AR Some concerns	Participants who experienced an AE	No AE	No AE	Diff ∆*: 0
Quality of Life				
Rodriguez- Hernandez, 2021 <sup>92</sup> AR High	EuroQoL -5DL - Mobility	n (%) No problems: 0 Mild/moderate problems: 5 (22) Severe/extreme problems: 18 (78) 15 wk: No problems: 9 (39)	n (%) No problems: 0 Mild/moderate problems: 12 (60) Severe/extreme problems: 8 (40) 15 wk: No problems: 0	
		Mild/moderate problems: 14 (61)	Mild/moderate problems: 18 (90)	
	EuroQoL -5DL - Selfcare	n (%) No problems: 0 Mild/moderate problems: 5 (22) Severe/extreme problems: 18 (78)	n (%) No problems: 0 Mild/moderate problems: 12 (60) Severe/extreme problems: 8 (40)	
		15 wk: No problems: 15 (65) Mild/moderate problems: 8 (35) Severe/extreme problems: 0	15 wk: No problems: 5 (25) Mild/moderate problems: 15 (75) Severe/extreme problems: 0	
	EuroQoL -5DL – Daily activities	n (%) No problems: 0 Mild/moderate problems: 5 (22) Severe/extreme problems: 18 (78)	n (%) No problems: 0 Mild/moderate problems: 4 (20) Severe/extreme problems: 16 (80)	-
		15 wk:	15 wk:	



Author, Year VR or AR Risk of Bias	Effect Measure	Intervention Baseline Mean (SD) Follow-Up Mean (SD), Mean Change	Comparator Baseline Man (SD) Follow-Up Mean (SD), Mean Change	Comparison
		No problems: 8 (35)	No problems: 0	
		Mild/moderate problems: 15 (65)	Mild/moderate problems: 20 (100)	
		Severe/extreme problems: 0	Severe/extreme problems: 0	
	EuroQoL -5DL	n (%)	n (%)	
	– Pain/	No problems: 13 (56)	No problems: 10 (50)	
	disconnon	Mild/moderate problems: 6 (26)	Mild/moderate problems: 9 (45)	
		Severe/extreme problems: 4 (17)	Severe/extreme problems: 1 (5)	
		15 wk:	15 wk:	
		No problems: 4 (17)	No problems: 0	
		Mild/moderate problems: 19 (83)	Mild/moderate problems: 19 (95)	
		Severe/extreme problems: 0	Severe/extreme problems: 1 (5)	
	EuroQoL -5DL	n (%)	n (%)	
	– Anxiety/	No problems: 0 (0)	No problems: 0	
	depression	Mild/moderate problems: 18	Mild/moderate problems: 17 (85)	
		(78.3) Severe/extreme problems: 5 (22)	Severe/extreme problems: 3 (15)	
			15 wk:	
		15 wk:	No problems: 0	
		No problems: 7 (30)	Mild/moderate problems: 13 (65)	
		Mild/moderate problems: 15 (65)	Severe/extreme problems: 7 (35)	
		Severe/extreme problems: 1 (4)		
Opioid Use				
Abd-Elsayed,	Self-reported	Cessation: 38%	NR	NA
2021*	opioid use	Decrease: 31%		
VR		Increase: 6%		
		No Change: 25%		
Physical Perform	ance			
Rodriguez-	Fugl-Meyer	23.3 (6.9)	22.7(5.4)	Diff ∆*:
2021 <sup>93,96</sup>	Upper Extremity	3 WK: 57.7 (4.7), 34.4"	3 WK: 47.0 (6.1), 24.3	3 WK: 10.1
AR		15 wk. 50.0 (5.9), 55.5	15 wk. 49.3 (0.3), 20.0	15 WK: 8.9
High	Action	13.2 (11.7)	11.5 (10.6)	Diff ∆*:
	Test	3 wk: 46.0 (9.0), 32.8*	3 wk: 29.3 (10.5), 17.8*	3 wk: 15.0
		15 WK: 46.0 (9.0), 32.8	15 WK: 29.7 (10.6) 17.4	15 WK: 15.4
l aveggia, 2016 <sup>94</sup>	Motricity Index	37.0 (19.3)	39.2 (15.6)	Diff ∆*:
	(111)	6 wk: 54.7 (22.2), 17.7 (20.8)	6 wk: 50.6 (16.4), 11.4 (16.0)	6 wk: 6.3
Some concerns		12 WK: 80.5 (24.1): 43.5 (21.7)	12 WK: 50.3 (16.6), 5.6 (16.1)	12 wk: 17.9
Sarig Bahat.	Flexion	137 (32.2)	128.5 (43.7)	Diff ∆*:
2020 <sup>90</sup>		7 mo: 152.5 (41.9), 15.5*	7 mo: 140.9 (38.8), 12.4*	7 mo: 3.1
VIN Some concerns	Extension	190.1 (51.3)	157.6 (50.9)	Diff ∆*:
Come concerns		7 mo: 209.6 (68.5), 19.5*	7 mo: 177.6 (59.1), 20*	7 mo: -0.5

Notes. \*Calculated by review team.

*Abbreviations*. AR=augmented reality; Diff ∆=difference in change scores; EuroQoL-5D=European Quality of Life 5 Dimensions; IQR=interquartile range; mo=month; NC=not calculable; NDI=Neck Disability Index; NR=not reported; ROM=range of motion; SD=standard deviation; VAS=Visual Analog Scale; VR=virtual reality; wk=week.



# **APPENDIX L. PEER REVIEW COMMENTS AND RESPONSES**

Comment #	Reviewer #	Comment	Author Response
Are the objec	tives, scope, a	nd methods for this review clearly described?	
1	2	Yes	Thank you.
2	3	Yes	Thank you.
3	4	Yes	Thank you.
4	6	Yes	Thank you.
5	7	Yes	Thank you.
6	13	Yes	Thank you.
Is there any i	ndication of bia	s in our synthesis of the evidence?	
7	2	No	Thank you.
8	3	No	Thank you.
9	4	No	Thank you.
10	6	No	Thank you.
11	7	No	Thank you.
12	13	No	Thank you.
Are there any	published or u	npublished studies that we may have overlooked?	
13	2	No	Thank you.
14	3	Yes - Garcia et al., 2021 (doi:10.2196/26292); Garcia et al., 2022a (doi: 10.1016/j.jpain.2021.12.002); Garcia et al., 2022b (doi:10.2196/37480); Maddox et al., 2023 (doi: 10.1016/j.mcpdig.2023.09.003 Perhaps outside of the scope of the review, but interesting study on VR Cybersickness: https://doi.org/10.3389/frobt.2020.00004	The 3 articles by Garcia et al. report results of the RelieVRx trial for low back pain and are already included in the report (see Results on Chronic Low Back Pain, <i>eg</i> , Table 2). The fourth article by Maddox et al. was published in December 2023, about 6 months after our search date. We added a reference to this newly published study in Appendix C (Ongoing Studies) and also refer to it in the Discussion (Evidence Gaps & Future Research).
			We appreciate reviewer's suggestion of the article on etiology of gender differences in VR Cybersickness. Although it is not eligible (as it is not evaluating effects of XR interventions for an eligible pain condition), it provides important information about evaluation of VR side effects

2

Comment #	Reviewer #	Comment	Author Response
			and potentially how to mitigate some of these in future interventions. We have added the results from this reference to the Discussion (Evidence Gaps & Future Research).
15	4	No	Thank you.
16	6	No	Thank you.
17	7	No	Thank you.
18	13	No	Thank you.

#### Additional suggestions or comments can be provided below.

19

Overall this is every good and I'm sure a reflection of what is available given the rigor of the review. A couple of comments for consideration. I would ensure that citations are used in the intro to support claims made (think I only saw 1 in the exec summary and number of statements made that should have been cited). I would also consider not making a positive statement about possible benefit and then in the same sentence seemingly de-qualifying it with "but there was limited info on adverse events." I understand this was a significant miss across studies, but it would also be helpful to be clear about the potential good that was seen. The Executive Summary usually does not contain citations, to help keep the content concise and to avoid complications with reference management (*eg*, references in the Discussion may then precede those for the eligible studies, which may not be individually named in the Summary). The Executive Summary content is a high-level summary of statements and findings in the full report, where all appropriate citations are included. We have also carefully reviewed the Introduction and Discussion sections of the main report for adequate citation of references.

We organized the Key Findings using the same structure as the Results sections in the main report. Thus, we briefly summarize the evidence addressing various XR interventions and the findings for different outcomes for each pain condition. Within this structure, the findings for adverse events are generally in close proximity to the benefits of each intervention type (per pain condition). Additionally, we emphasize the lack of evidence on adverse events across all the pain conditions and interventions in the Key Findings because this is an important consideration for clinicians and patients when selecting treatments: side effects are often the reason that treatments are declined or stopped. In the rest of the Executive Summary, as well as in the main report, the findings for each outcome (per intervention and comparator pairing for each pain condition) are laid out in greater detail, and these sections are much more focused on the benefits. This was largely due to eligible studies infrequently reporting adverse events.

Comment #	Reviewer #	Comment	Author Response
20	3	Page IX, Lines 15-16 • How were the prioritized primary outcomes of interest determined (e.g., a priori, ad hoc)?	Prioritization of the primary outcomes for GRADE assessments was discussed with Operational Partners and Technical Expert Panel members, and additional information was collected via an online ranking exercise. We clarified in the Executive Summary the stage at which this prioritization occurred (p. viii) and have added more information about this process to the Methods section in the main report (p.11).
21	3	<ul> <li>Page X, Lines 35-37, 42-44</li> <li>In lines 35-36, when discussing the direction of the effects the authors state "AR physical activity v. any active comparator". <ul> <li>To me, this could leave the reader to assume the standardized mean difference (SMD) = MAR – MControl / SD of change.</li> <li>Thus, SMD =7 (-1.2,2) indicated that mean reduction in pain intensity is larger in comparator groups is than AR (before accounting for uncertainty).</li> </ul> </li> <li>Then in lines 42-44, the authors state that "AR physical activity may result in better pain-related functioning (eg, Diff Δ -0.4 on Roland-Morris Disability Questionnaire), when compared with usual care"</li> <li>To me, this now indicates that the standardized mean difference (SMD) = MControl – MAR / SD of change.</li> <li>To orient the reader, I think that the general equation posted in page 6 (line 12 = Diff Δ /standard deviation [SD] of change) should be expanded upon to orient the reader whether positive/negative effects size point estimates and confidence intervals reflect the AR/VR or control conditions.</li> </ul>	We have clarified the calculation of the Diff $\Delta$ (and standardized Diff $\Delta$ ) in both the Executive Summary (p. viii) and the main report Methods (p.11). The reviewer is correct in the direction of the comparison; however, improvement is reflected by lower scores for most of the outcome measures (including NRS, VAS, and Roland-Morris Disability). For outcome measures where lower scores reflect an improvement ( <i>eg</i> , less pain or less disability), the negative value for Diff $\Delta$ indicates a greater improvement in the XR intervention group. The reverse would be true for measures where higher scores are better but this was uncommon; we have described in greater detail when there are such findings in the main report. Additionally, the direction of comparison in pooled analyses are also indicated on the forest plots in the main report (when meta-analyses were conducted for that outcome).
22	3	Page XI, Lines 19-26 "Five trials evaluated XR interventions for chronic knee pain due to osteoarthritis, and all compared XR physical activity programs (1 VR, 4 AR) with conventional exercises and rehabilitation. The single trial on VR physical activity showed greater improvement in pain-related functioning and pain intensity in the VR group (eg, Diff $\Delta$ -5.1 on the Western Ontario and McMaster Universities Arthritis Index [WOMAC] and -1.1 on VAS 0-10 at 7 weeks). This trial did not address adverse events. The evidence is very uncertain on the effects	We have added a summary of AR study results to the Executive Summary (p. x).

Comment #	Reviewer #	Comment	Author Response
		of AR physical activity on pain-related functioning, pain intensity, and adverse events." • No mention of the AR studies or aggregate XR effects?	
23	3	Page 9, Lines 33-37 • Were studies inly specified if they had a specified population (e.g., chronic low back pain, fibromyalgia) versus chronic pain in general regardless of type? If studies were chosen with non- specific chronic pain populations, how please describe how the data from participants were handled in the study.	For KQ1 eligible studies, the included population could comprise individuals with an eligible condition with pain as a primary symptom ( <i>eg</i> , fibromyalgia), individuals with a mixture of these eligible conditions, and/or individuals with chronic pain symptoms directly assessed in the study ( <i>eg</i> , pain in 2 or more joints for at least 3 months). In the KQ1 Other Conditions subsection, we report results for those pain conditions (or other chronic pain) with only 1 identified eligible study (pp. 54-62). For example, this subsection includes 1 study evaluating AR intervention for participants with chronic pain in multiple joints, as well as 1 study examining VR intervention for individuals with either chronic low back pain or fibromyalgia. Since this latter study did not provide results broken down by each condition, we were not able to include its findings under the sections for low back pain and fibromyalgia, respectively. We clarified these groupings in the Results Overview (p. 2).
24	3	Page 11, Lines 17-19 • Please provide additional detail KQ1 to describe imputation methodology used to estimate missing standard deviations of change scores.	We added to the Methods a description of the imputation method we used, which was recommended by the Cochrane Handbook for Systematic Reviews (p. 11).
25	3	Page 12, Lines 11-52 • Why are n's in the flow diagram blank?	The literature flow diagram was not produced for the draft report. It has been completed for the final report.
26	3	Page 13, Lines 5-8 • It was stated that 70 eligible articles reported 59 primary studies. Given the very specific methodology (e.g., RCTs for KQ1), please explain how there more eligible articles than primary studies?	Eligible studies could have multiple articles reporting the findings and this is described in greater detail within each Results subsection. For example, the 5 articles reporting results for RelieVRx for chronic low back pain are described in the Results subsection on chronic low back pain (pp. 21-23) and also cited in Table 2 (pp. 17-19).
27	3	Page 16, Lines 17-18 • Table 2 is repeated twice: "Study characteristics and findings for VR interventions are summarized in Table 2Table 2."	This has been fixed.
28	3	Page 16, Lines 33-35	We rated RoB using the Cochrane RoB2 (for RCTs) or ROBINS-I (for observational studies). In the text and

Comment #	Reviewer #	Comment	Author Response
		<ul> <li>This may be beyond the scope of the review, but in the description of single studies comments such as below read as very vague without further details which were also not provided in the cited appendix (E):</li> <li>"The study was rated as high RoB due to concerns about randomization, adherence to the intervention, measurement of outcomes, and the selection of reported results".</li> </ul>	Appendix E, we summarize and provide detailed ratings for each domain addressed by these standardized assessments. Each domain is evaluated through several items, and the number of items may vary depending on the response to preceding items. As the RoB assessment involves answering a potentially large number of questions, we do not customarily report all the response to these items for each study rating. For example, the study cited here (Yilmaz Yelvar 2017) was rated high risk of bias for the domain of randomization because neither the randomization nor the allocation procedures were described, and there were substantial differences between intervention and control groups in baseline characteristics. Overall, the RoB assessment for Yilmaz Yelvar, 2017 involved 20 items.
29	3	Page 20, Lines 33-36 • Error with referencing software? "The evidence is also very uncertain on the effect of VR embodiment on pain-related functioning and pain intensity, compared with other VR experiences (very low COE; Error! Not a valid bookmark self-reference.)"	This has been fixed.
30	3	<ul> <li>Page 22, Lines 30-33</li> <li>The statement below reads as if many severe events were reported across conditions, and that no serious adverse events were reported across conditions. Please clarify.</li> <li>"Eccleston, 202225 reported a range of adverse events, finding for example that severe adverse events (symptoms leading to inability to perform daily or work activities) were relatively common: 50% of participants experiencing any severe events in the VR psychological skills group, 29% in VR control, and 36% in usual care. No serious adverse event was reported in any group."</li> </ul>	We have added the definition of "serious adverse events" (any event leading to death or serious deterioration in health) to clarify that these are actually more severe than the AE described as "severe" in these studies (p. 22).
31	3	<ul> <li>Page 23, Lines 8-10</li> <li>The AR for back pain section begins by introducing a comparison to active physical activity interventions then a comparison to usual care. Why is the VR for back pain not aligned with similar comparisons (in the previous section)?</li> </ul>	For eligible studies examining the same pain condition ( <i>eg</i> , for chronic low back pain or fibromyalgia), we grouped VR and AR interventions first by intervention type, and then within each intervention type, by comparators, when these were thought to be substantially different. Studies of VR interventions for low back pain evaluated different intervention types (embodiment and psychological skills).

Comment #	Reviewer #	Comment	Author Response
			Within each of these 2 intervention types, there were a range of comparators, which are described in greater detail in the VR results subsection. Similarly, the AR section is broken down first by intervention type (in this case, all AR studies evaluated physical activity interventions) and then by comparators. The VR and AR subsections are different because the studies evaluated different interventions and comparators.
32	3	<ul> <li>Page 41, Lines 23-26; Page 52, Lines 46-47</li> <li>When discussing the effects of VR v. non-VR physical activity on pain catastrophizing the authors state that all 3 studies used the Tampa Scale of Kinesiophobia. This is puzzling given the noted distinction between these construction in the empirical literature.</li> <li>o Sullivan et al. (2001) often cited definition describes pain catastrophizing as an 'exaggerated negative mental set brought to bear during actual or anticipated experience of pain'.</li> <li>o Influential papers by Kori et al. (1990) and Vlaeyen et al. (1995) define kinesiophobia (or fear of movement) as "an excessive, irrational, and debilitating fear of physical movement and activity resulting from a feeling of vulnerability to painful injury or re-injury".</li> <li>The influential Fear-Avoidance Model for Chronic Pain identifies pain catastrophizing as an important predictor of precursor factor in pain-related fear and avoidance. Studies often report a fair to moderate correlation between these two constructs. I am curious to the rationale of the authors decisions.</li> </ul>	We agree that kinesiophobia and pain catastrophizing are distinct, though related, concepts that are variably correlated. Our goal was to evaluate the impact of XR interventions on negative perceptions (of potential pain triggers) that contribute to poor outcomes particularly fear of movement, pain catastrophizing, or both. To ensure we accurately represent the full scope of XR effects on pain- related outcomes, we intended to be inclusive in selecting eligible outcomes. We have revised the description of this outcome to "pain catastrophizing and kinesiophobia" and have clarified the naming of specific findings regarding these concepts throughout the Results.
33 I	3	Page 44, Lines 43-44 • Typo: "Villafaina, 201957) used 0-100 scale and showed greater improvement in the AR group immediately post- intervention at 6 months (Diff $\Delta$ -11.1)."	This has been fixed.
34	3	Page 55, Lines 26-28 • Typo: "Pain-related functioning was assessed with BPI- Interference at baseline, 1 month and 3 months, showing slightly greater reduction in the VR psychological skills group (Diff $\Delta$ -1.0 at 1 month and -1.6 at 3 monhts).	This has been fixed.

Comment #	Reviewer #	Comment	Author Response
35	3	Page 66, Lines 25-27 • Formatting error: "Prvu-Bettger, 202085 found very similar improvements in both groups at 3 months, using NRS (Diff $\Delta$ 0.2). and using the VAS assessed at baseline, 2 and 4 months."	This has been fixed.
36	3	<ul> <li>Page 72, Lines 32-33; Page 73, Lines 24-26</li> <li>The authors state that "VR psychological skills may have some benefit for chronic low back pain, but this was not compared with an active treatment." I found this to be an inaccurate statement. Specifically, in the Darnall et al. (2020) paper the authors cite, they comparison group is an audio only version of the same psychological skills intervention. To me, this can be interpreted as an active control group, albeit non-XR (as noted on page 73, lines 21-24). Furthermore, in a follow-up RCT by the same group (see Appendix L for recommendation), they compared 3D VR to sham VR (2D) versions of the same program.</li> <li>The authors claim "For XR physical activity and psychological skills interventions, a proposed mechanism for enhanced benefits is increased patient engagement, so it would be important to compare to the non-XR versions, and also directly compare measures of engagement and adherence." Again, in the Darnall trial, the authors report the number of VR sessions completed by the intervention group compared to the audio-only (non-XR) control group. This can be taken as a measure of adherence in interpreting these findings.</li> </ul>	The Darnall 2020 study included individuals with self- reported low back pain or fibromyalgia, but did not provide results separately for each condition. This study also did not report the number of individuals with each condition by treatment arm. We were thus unable to include this study's results in either the low back pain or fibromyalgia section. Of the 7 studies evaluating an XR psychological skill intervention (for any condition), the Darnall 2020 study was also the only one to use an active comparator. We have revised the Discussion paragraph describing the importance of comparing XR interventions with analogous non-XR treatments, to highlight that this is a particular gap for XR psychological skills interventions (XR physical activity interventions typically were compared with non-XR physical activity). In this paragraph, we also added a sentence highlighting there was 1 study ( <i>ie</i> , Darnall 2020) that did this for VR psychological skills (p. 74).
37	3	Page 74, Lines 34-35 • Given the limited reporting of adverse events noted by the authors, any specific recommendations for reporting adverse events, measuring, or comparing adverse effect across interventions in VR trials?	We have added recommendations for evaluation and reporting of adverse events to the Discussion (pp. 74-75).
38	4	First and foremost, the report is very exhaustive and comprehensive. It takes a lot of effort to put this kind of analyses together and present them in a meaningful and compelling manner. The report is both educative and forward looking, addressing the research and evidence gap and future directions for research. The structure of the report is another aspect to be appreciated: providing an overview, detailed	Thank you. We agree that technology literacy and acceptance are distinct, and it is likely that both are key components of patients' experience (and uptake) of XR interventions. These factors also likely impact commonly proposed XR mechanisms of action, such as increased patient

Comment #	Reviewer #	Comment	Author Response
		analyses, and following it up with the Appendices that provide the information for the curious ones.	engagement with exercise. As with other proposed XR mechanisms of action, however, the relationship of XR to patient engagement appears understudied, and evaluation of
		With that being said loud and clear, I have to raise an important aspect. While XR in its different avatars as VR and AR has been around for a while, but the wide spread adoption is not really at the same level as a cell phone or laptop. This (the lack of widespread adoption) could lead to a "digital divide" in the population experiencing pain, not necessarily due to economic background, but due to technology acceptance.	relevant mechanistic indicators was beyond the scope of this review. We also agree that a systematic review of technology acceptance and its influence on XR outcomes would be useful – although our experience with the current review suggests that there are likely few studies that have rigorously addressed technology literacy and acceptance using a randomized design. We have revised the Discussion to highlight the need for improved understanding of these factors (n. 74)
		In this context, I should say I am disappointed about Appendix D on Risk of Bias Assessments in the sense that the biases listed are mostly on the processes used for study design and outcome ana analyses. There is no report (in Appendix D) that can throw light whether the conducted studies have identified the technology literacy level nor the technology acceptance level. Did the studies collect data and report for:	
		<ol> <li>What was the level of the participants' knowledge and comfort in using XR: high/medium/low/poor?</li> </ol>	
		2. What was the level of technology acceptance in using XR: high/medium/low/poor?	
		3. Do the studies attempt to correlate the outcomes with respect to the answers for (1) and (2)?	
		To me, the answers to the above questions are really important, perhaps even more important than the outcome of XR interventions for chronic pain. Simply because, the outcomes *might* heavily depend on answers for (1) and (2). Unlike other psychotherapy interventions where the level of technology might be less intrusive or "low". The only factor in the report that I could see closely related is the tracking of "adverse events" pertaining to motion / VR sickness - which in my opinion is not really the same as (1) and (2).	
		Another disappointment was that these factors (1) and (2) are NOT highlighted in the "EVIDENCE GAPS & FUTURE RESEARCH" section (Page 72, from Line 53). Of course, there is a passing mention of "barriers to technology adoption" in	

Comment #	Reviewer #	Comment	Author Response
		Page 74, Line 27. But this is mentioned only with respect to older adults - for future research.	
		To make my view clear, the point I want to convey is that reluctance to "accept" a technology - as a means for intervention - can *potentially* have a significant impact on the outcomes - and this needs to be studied along with other factors. The acceptance - or lack of it - of technology need not be due to economic or literacy factors alone, in my view. Another important thing is that this "acceptance" could change during the study period: one could be highly enthusiastic initially and might get bored quickly, and vice versa. A systematic study on technology acceptance and its impact on the outcomes is therefore needed.	
39	6	The draft review is a very nicely organized review that follows a clear and standard method to describe the current state of the evidence base. It provides a rationale for not including case studies and similar types of reports that are of the type that are commonly found in a relatively new intervention. It points out the VHA XR Network which is an important resource for readers of this review. It notes the important limitations in research quality that limits the ability to determine the effectiveness of these novel interventions. It describes possible mechanisms and gives guidance for improved research methods to help determine if these mechanism are present and to what degree XR could be a useful adjunct or alternative to more standard treatments. This is careful and helpful review. Its primary benefit is noting current limitation and providing guidance on what will improve the evidence base. Also appreciate the authors wish to be inclusive and the acknowledgement that it can be difficult to categorize XR, i.e., AR vs VR. These issues and the rationale were stated nicely. The appendices are also excellent resources for understanding the reviewed studies.	Thank you.
40	6	The authors are encouraged to be cautious in statements like "XR has great potential as part of a comprehensive plan for pain treatment." page 74, line 18. I share this enthusiasm but am also informed by the draft review which indicates that the current research does not provide reliable guidance on the	We have changed this sentence to state "considerable potential". Regarding the statements in the Conclusion, the use of "may" is consistent with the low CoE assessments for XR physical activity interventions for neck pain, which takes into consideration the methodological concerns noted in the

Comment #	Reviewer #	Comment	Author Response
		potential for XR. It may have great potential but the limitations in CoE that are the primary theme of this review do not support the word great. Similarly, stating that XR may be helpful for some conditions but not others, page 74, lines 36-38, should be restated with more care since the problems noted in Page 74, lines 34-35 suggest that such comparisons probably should not be made at this point.	beginning of the Conclusion. However, we have corrected the statement for low back pain to "the evidence is very uncertain," which is more consistent for the very low COE for low back pain (p. 76).
41	6	Pain Catastrophizing: For the most part, in the draft manuscript Pain Catastrophizing is used to refer to both catastrophizing and kinesiophobia. Table 2 Page 17 lines 22-24 has Outcomes column label Pain Catastrophizing & Kinesiophobia (both the TSK and FABQ can be considered measures of kinesiophobia. This table label is correct in that the two are related but not perfectly correlated and can have independent predictions and treatment indications. It would be helpful to note early in the main text that Pain Catastrophizing is being used as a general term to cover both related concepts as indicated in the Table 2.	We have further clarified the inclusion of these 2 related concepts and revised the report accordingly, as noted above in our response to comment #32.
42	6	The reviewed copy is a draft. Recommend further proofing to correct some typos, grammar and similar issues.	We have carefully copyedited the final draft.
43	13	This is an interesting and well-conducted review on an important topic. The limited evidence and paucity of robust studies on XR interventions for chronic pain is for me admittedly rather surprising and somewhat disappointing. Given what appear to be fundamental gaps related to the efficacy, effectiveness and adverse events associated with XR, I was also a bit surprised by some of the discussion about implementation as part of future research. Nonetheless, while some aspects related to implementation may be premature, I don't disagree that it is important to consider implementation, including user-centered design approaches and implementation context, while establishing the efficacy/effectiveness of XR interventions for chronic pain.	We agree that implementation of XR interventions for several pain conditions may be premature given the state of the evidence. However, implementation science frameworks may still be helpful by clarifying the role of XR as core intervention component vs. means of intervention delivery and engagement. Additionally, implementation science can help with evaluating real-world effectiveness and costs of XR interventions, when health systems (such as the VA) have begun to offer these interventions. We have revised the Discussion to reflect these points (pp.75-76).
44	13	Minor issues, mostly typos that may have already been identified Page vii, Key Findings section. Use of the phrase "effects on adverse events" is a bit awkward and potentially confusing. While perhaps technically correct, the issue is whether these interventions might cause or lead to adverse events, which	We have revised this phrase in the first Key Finding to "the evidence for adverse effects is very uncertain" (p. vi).

Comment #	Reviewer #	Comment	Author Response
		based on the findings of this review appear to be very uncertain or in many cases unreported and it would be helpful if this were more clearly stated, at least in presenting the key findings.	
45	13	Page x, line 49 would suggest rephrasing "but the evidence about adverse events is very uncertain"	We have revised this phrase to "the evidence for adverse effects is very uncertain" (p. x).
46	13	Page 16, line 18, Table 2 is repeated	This has been fixed.
47	13	Page 17, Table 2, line 49, for Kammler-Sucker outcomes it would be helpful to the reader if the two NRS measures had more distinct labels, e.g., pain-interference NRS and pain intensity NRS	We have clarified the labeling of NRS for these 2 outcomes in Table 2.
48	13	Page 20, line 35, flagging error and line 41 I believe the word environment is missing after immersive	This has been added.
49	13	Page 22, line 34, should be assessed rather than assess and lines 55-56 quality of life is repeated	These have been updated.
50	13	Page 24, line 32, word activity is missing after physical	This has been added.
51	13	Page 26, Table 6, line 61 typo for percentage in the second column (496%), perhaps 46% or 49%	This typo has been corrected.
52	13	Page 28, Table 6, line 33, word aged in second column (describing male university student sample) should be deleted	This has been fixed.
53	13	Page 34, several minor typos, line 18 missing period, line 23 missing word to after due and line 30 the word these can be deleted and the sentence start with "All showed"	These have been updated.
54	13	Page 53, line 28, capitalize VAS	This has been fixed.
55	13	Page 66, line 26 there appears to be in advertent period and extra space	This has been fixed.
56	13	Page 67, section on KQ2 Other Conditions, the citations are not suprascript	This has been fixed.